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Abstract 
A critical comorbidity of HIV infection is HIV-associated neurocognitive disorders 
(HAND). Although combined antiretroviral therapy (cART) is an effective treatment in 
blocking systemic viral replication, it is unsuccessful in reducing the incidence of HAND. 
HIV CNS damage, in the current cART era, can be associated to the presence of latently 
HIV-infected cells including microglia/macrophages and a small population of astrocytes. 
This Ph.D. thesis focuses on identifying, localizing, and quantifying viral reservoirs using 
an improved staining and microscopy technique. Although in low amount, our data 
confirmed that microglia/macrophages and a small population of astrocytes are still 
infected. These cells synthetize and secrete viral proteins generating a bystander damage 
in the CNS. Viral proteins are also involved in lipid dysregulation. We demonstrated by 
Mass Spectrometry Imaging (MSI) that in the brain of HIV-infected individuals with 
HAND lipids including sulfatide play a key role in bystander damage. Sulfatide is 
dysregulated in several neurocognitive diseases such as Alzheimer’s disease and 
Parkinson’s disease. Thus, we propose that sulfatide as a potential biomarker of 
neurocognitive disorders.  
We demonstrated that sulfatide secretion can be regulated by HIV proteins and we 
evaluated sulfatide effects in vitro, focusing on cell-to-cell communication and 
mitochondrial metabolism, all parameters altered in NeuroHIV. 
Therefore, this thesis provides specific tools and unique data to a better understanding the 
neuropathogenesis of HAND in the current cART-era and may lead to the identification of 
new molecular targets for preventing or curing HIV neurological decline.  
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Part I – Human Immunodeficiency Virus 
Epidemiology 
Human Immunodeficiency Virus (HIV) is a major public health concern with 37.9 million 
infected individuals worldwide in 2018. 1.7 million people were newly infected, and 
770,000 people died from AIDS-related illnesses (http://www.unaids.org/en/, 2019). In 
developed countries, 90% of individuals have access to combined antiretroviral therapy 
(cART) resulting in extended lifespan. Although clinically successful, cART is not a cure. 
Most ARTs are potent small molecules targeting entry, reverse transcriptase, protease 
maturation and integration steps of the HIV life cycle (Reeves and Piefer 2005), but not 
viral genome transcription and translation. Even though cART suppresses systemic virus 
replication, decreases the risk of transmission, and restores the immune competence, it 
cannot deplete circulating or tissue associated HIV reservoirs which remains one of the 
main obstacles for curing HIV infection (Vanhamel et al. 2019).  
 
HIV classification  
HIV was identified in 1983 (Barre-Sinoussi et al. 1983) and it was considered the causative 
agent of acquired immunodeficiency syndrome (AIDS), which was first diagnosed in 1981 
in the USA (Gottlieb et al. 1981). It is accepted that the origin of HIV occurred by a cross-
species adaptation, which started from simian immunodeficiency virus (SIV) infected 
monkeys and progressed to great apes and ultimately humans (Sharp and Hahn 2011). Two 
types of HIV have been identified, HIV-1 and HIV-2, with comparable structure, tropism 
and transmission pathophysiology. HIV-1 is more virulent, responsible of 95% infection 
worldwide. HIV-1 strains are subdivided into four groups: M, N, O, and P. The M group, 
or “Major” group, is the responsible for the global HIV epidemy. Within the group M, there 
are 9 genetically distinct and phylogenetically equidistant clades (A, B, C, D, F, G, H, J, 
and K) (Hemelaar 2012). From them, the clade C is globally dominant and responsible for 
approximately 50% of infections especially in South Africa and India (McCutchan 2006). 
On another hand, HIV-1 N group consists in a recombinant virus between two ancestral 
strains, one ancestor related to HIV-1 group M and one related to SIV chimpanzee strains 
found in Cameroon (Simon et al. 1998). This group is not so common in the global 
4 
 
population, and all the cases identified are from Cameroon (Mourez et al. 2013). The O 
group is present in the 1-2% of the population, especially in Cameroon and some European 
countries (Belgium, France and Spain) (Bush and Tebit 2015).  The last group is the P 
group that accounts for just 0.06% of infection in the global population (Vallari et al. 2011). 
In contrast to HIV-1, HIV-2 is mostly asymptomatic, and predominately found in West 
Africa. HIV-2 can be classified into nine groups (A to I), which derive from 9 different 
cross-species transmission involving SIV (Marlink 1996). The groups A and B are the most 
common in the population, and the other seven groups account for just one patient each 
(Visseaux et al. 2016). 
 
Time course of HIV infection 
HIV transmission is principally due to sharing of biological fluids including mucosal and 
blood (Shaw and Hunter 2012). The progression of HIV infection can be divided into 4 
phases: primary infection, acute infection, chronic or latent infection, and AIDS (Figure 
1.1) (Coffin and Swanstrom 2013). As indicated in Figure 1.1, prior to infection, the normal 
CD4+ T cell count is between 500 and 1500 cells/µl of blood. In the early stages of 
infection, plasma viremia increases and CD4+ T cell count in the blood decreases. The 
subsequent acute phase (weeks 2-9) is therefore characterized by high levels of viral RNA 
in the blood (>107 copies of viral RNA/ml) and spreading of infection to susceptible tissues 
and organs. In this phase, the adaptive immune response induces the production of 
antibodies against HIV proteins (Cohen et al. 2011, Tomaras and Haynes 2009) and the 
CD8+ cytotoxic T lymphocytes attach to productively infected CD4+ T lymphocytes 
contributing to the CD4 count decrease (Jones and Walker 2016). Typically, people show 
flu-like symptoms, such as fever, headache, and rash. The following phase corresponds to 
the clinical latency that can last 2-12 years (Lemp et al. 1990, Moss and Bacchetti 1989), 
but in cART virally suppressed individuals, this period can be extended for years 
(Nakagawa et al. 2013). During this phase, plasma viremia is low or undetectable due to 
cART (~50 copies of HIV RNA/ml plasma) but CD4+ T lymphocytes progressively decline 
due to chronic immune activation exhaustion and inflammation (Coffin and Swanstrom 
2013). The last phase, that does not directly involve infected individuals under effective 
cART, is defined by CD4+ T lymphocytes decline (<350 CD4+ T cells/µl of blood) and 
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high viremia levels (>106 copies of viral RNA/ml plasma) causing the loss of the immune 
control and leading to opportunistic infections and cancers (Cribbs et al. 2019, McNally 
2019, Shi et al. 2019). Therefore, the death of the HIV-infected population is mainly due 
to immunological disorders, opportunistic infections and aging related issues (Coffin and 
Swanstrom 2013).  
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Figure 1.1. Clinic time-line of HIV-infection, replication, and CD4 counts in humans, 
adapted from (Fauci and Desrosiers 1997) 
The black line represents the amount of CD4+ cells in the blood, the red line shows the 
amount of HIV RNA copies in the plasma of HIV-infected individuals. Early after primary 
infection, viral replication increases and CD4 count decreases. These parameters also 
characterize the acute phase of infection with high levels of viral RNA in the plasma (>107 
copies of viral RNA/ml) and decreased CD4+ T cells, but with spreading of infection in the 
tissues. On another hand, the long clinical latency phase is characterized by low or 
undetectable plasma viremia and by a progressive reduction of CD4+ T lymphocytes. In 
the last phase, CD4+ T lymphocytes continue to decline, and plasma viremia rapidly 
increases causing opportunistic infections and cancers, leading to death. 
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HIV life cycle 
HIV is a positive-sense single-stranded enveloped RNA virus. HIV is classified as a 
retrovirus and its RNA genome is structured in nine-open reding frames (ORF) (German 
Advisory Committee Blood 2016). Three major ORFs are retrovirus common: gag, pol and 
env; which encode for the polyprotein precursors of structural proteins. Specifically, gag 
encodes for a polyprotein cleaved to form 6 structural proteins: matrix protein p17, capsid 
proteins p24, p7 and p6, and two spacer peptides. The matrix protein p17 ensures capsid 
integrity, while p24, p7, p6 and the spacer peptides are essential for capsid assembly (Freed 
1998). The pol ORF encodes for reverse transcriptase, integrase, and protease, which 
provide critical enzymatic functions. Reverse transcriptase transcribes viral RNA into 
double stranded cDNA, integrase modulates the insertion of viral cDNA into the host cell 
genome, instead, HIV protease is involved in the final maturation of the released virions 
after budding (Tekeste et al. 2015). The env gene encodes for the envelop protein gp160 
which is proteolytical cleaved by furin to form gp120 and gp41, which are involved in the 
initial viral binding entry (Checkley et al. 2011). The other six ORFs of the HIV genome 
encode for regulatory and accessory proteins such as trans-activator of transcription protein 
(tat), regulator of expression of viral protein (rev), negative factor (nef), virion infectivity 
factor (vif), viral protein r (vpr) and viral protein u (vpu) (Karn and Stoltzfus 2012). Tat 
facilitates activation of viral transcription after integration, stabilizing the interaction 
between the RNA polymerase II and the viral integrated DNA, and phosphorylating the 
RNA polymerase II C-terminal domain inducing the elongation process. Rev and vpr 
regulate the transport. Nef, vif and vpu manipulate the host cell signaling and the immunity 
to attenuate immune surveillance (Freed and Mouland 2006, Turner and Summers 1999).  
The HIV infection is initiated by the Env-mediated adhesion viral particles binding to host 
attachment factors present on the surface of targeted cells (heparan sulfate proteoglycans 
for macrophages, α4β7 integrin for T cells, and dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin for dendritic cells), as well as by HIV envelop 
protein gp120 interacting with the CD4 receptor. Binding to CD4 induces a conformational 
change in gp120 that facilitates binding to co-receptor C-X-C chemokine receptor type 4 
(CXCR4) or C-C chemokine receptor 5 (CCR5) (Kwong et al. 1998). After gp120 binding 
to CD4 and co-receptor, the envelop protein gp41 is exposed into the host lymphocytes 
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membrane and inserts into the outer leaflet to facilitate the fusion process between the host 
cell and virus (Freed et al. 1992, Shugars et al. 1996).  
Once viral fusion with the host cell is completed, the HIV capsid containing two strands of 
viral RNA is deposited into the host cytoplasm to begin the process of reverse transcription 
(Campbell and Hope 2015). Reverse transcription is performed by reverse transcriptase 
that has two enzymatic activities, the DNA polymerase activity to copy either RNA or 
DNA template, and the RNase H that degrades RNA of the RNA–DNA duplex (Hu and 
Hughes 2012). Reverse transcription process induces the formation of double stranded 
DNA (dsDNA) with long terminal repeats (LTRs) sequences at the 5’ and 3’ ends. These 
repeats contain all the useful elements for gene expression (enhancer, promoter, 
transcription terminator, and polyadenylation signal), and they are also used as a substrate 
for HIV protein integrase which allow the HIV DNA insertion into the host cell genome 
(Klaver and Berkhout 1994). Specifically, the viral DNA made by reverse transcription 
within the cytoplasm is part of a large nucleoprotein complex, the pre-integration complex 
(PIC) (Bowerman et al. 1989), which allows crossing of the nuclear membrane through the 
nuclear pore complexes (NPCs). The nuclear import process is a crucial process in the 
establishment of infection and several viral proteins such as integrase, Vpr, Matrix, capsid, 
HIV-1 central DNA flap, and host importin proteins with host tRNAs are involved 
(Jayappa et al. 2012). In the nucleus, integrase catalyzes the reaction generating a hydroxyl 
nucleophile for DNA strand insertion in an LTR region adjacent to a cytosine-adenine (CA) 
dinucleotide sequence of the host genome (Roth et al. 1989). Later, the hydroxyl group 
cleaves the host cell DNA and become integrated following strand transfer and DNA repair 
(Engelman et al. 1991). The integration of HIV DNA into the host cell genome does not 
guarantee viral production. HIV integration is not random and preferentially occurs in host 
DNA areas with actively transcribed genes, gene-rich regions, intronic regions, and largely 
avoids promoter regions (Anderson E. M. and Maldarelli 2018). Therefore, the nuclear 
topography of HIV integration may impact HIV replication (Lusic et al. 2013). For 
instance, HIV pre-integrated complex preferentially targets those areas of open chromatin 
that are proximal to the nuclear pore, excluding the internal regions in the nucleus as well 
as the peripheral regions associated with the nuclear lamina. When HIV genome is 
transcribed by the host RNA polymerase II, the full-length (unspliced), singly spliced, and 
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multiply spliced RNAs are recognized by rev and transported to the cytoplasm by host 
exportin 1 (XPO1)-RanGTP nuclear export pathway (Dayton 2004, Mahboobi et al. 2015), 
where they can be translated in polyprotein precursors, regulatory and accessory proteins. 
Nevertheless, Gag and gag-pol polyproteins become localized to the cell membrane and 
the immature virion begins to bud from the cell surface to infect other cells (Sundquist and 
Krausslich 2012). This classical process of infection mediated by the virions is called "cell-
free spread" (Figure 1.2). Recent studies recognized a more efficient and predominant 
spreading process called "cell-to-cell spread" (Martin et al. 2010), in which intercellular 
structures such as gap junctions (GJs) and tunneling nanotubes (TNTs) transfer ions, small 
molecules, organelles, as well as pathogens, between the connected cells (Ariazi et al. 
2017, Bracq et al. 2018, Eugenin et al. 2009, Okafo et al. 2017). Part of this thesis also 
involved a detailed description of these communication systems in the contest of HIV 
spread (see Part II of General introduction).  
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Figure 1.2. HIV life cycle adapted from (Pau and George 2014) 
(1) Attachment. The HIV infection starts with the Env-mediated adhesion viral particles 
binding to host attachment factors present on the surface of targeted cells, as well as by 
HIV envelop protein gp120 interacting with the CD4 receptor and co-receptor (CXCR4 or 
CCR5), later gp41 inserts into the outer leaflet to facilitate the fusion between the HIV 
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envelop and the host plasma membranes. (2) Fusion. The viral genome, the pre-integration 
complex, and proteins from capsid such as p24 are released in the cytoplasm of the host 
cells. (3) Reverse transcription. It is performed by reverse transcriptase to convert HIV 
RNA into HIV dsDNA. (4) Integration. It is conducted by an intermediate PIC which 
includes reverse transcriptase and integrase to transport the HIV dsDNA into the nucleus 
to be integrated into the host genome. HIV begins to use the cell machinery to transcribe 
HIV mRNAs that are transported to the cytoplasm. (5) HIV protein production. This 
occurs in the cytoplasm, where HIV proteins are synthetized from viral mRNA. (6) 
Assembly. The new synthetized HIV proteins, as well as HIV RNA, accumulate and move 
to the host plasma membrane to generate immature virions. (7) Budding. Newly immature 
formed virions are released into the extracellular space. Protease induce the maturation of 
the virions to become infectious. 
The red box in the figure indicates the topic of this thesis: HIV-integrated DNA, HIV 
mRNA production and HIV protein synthesis. 
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Antiretroviral therapies  
The first anti-retroviral agent was introduced in 1987. Although, over 50% of patients 
treated with singular drug longer than 6 months develop the drug resistance (Larder et al. 
1989). Currently, HIV-infected individuals use combined antiretroviral therapy (cART), 
which transformed HIV from a deadly to a chronic disease. The first combined treatment, 
which block the virus replication at the multiple stages of the HIV life cycle, was 
introduced in 1996 (https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-
development). Combined ART treatment consists in a combination of anti-retroviral drugs 
with the purpose of reducing the viral load, delaying disease progression and prolonging 
patient survival. The first therapy combinations commonly prescribed include a 
“backbone” of 2 inhibitors of the HIV reverse transcriptase (nucleoside reverse 
transcriptase inhibitor NRTI) plus a non-nucleoside reverse transcriptase inhibitor 
(NNRTI), an integrase strand transfer inhibitors (INSTI) or a protease inhibitor (PI) 
boosted with cobicistat or ritonavir (https://aidsinfo.nih.gov/understanding-hiv-aids/fact-
sheets/21/53/what-to-start-choosing-an-hiv-regimen). Other new generated drugs include 
CCR5 antagonist, fusion inhibitor, and post-attachment inhibitor. The NRTIs are prodrugs 
that need to be activated into diphosphate or triphosphate metabolites. They inhibit the 
reverse transcriptase enzyme for the insertion of nucleotide analogue. NNRTs inactivate 
the reverse transcriptase enzyme inducing conformational change and they do not need 
intracellular phosphorylation to be active. The PIs block proteolytic activities necessary for 
the formation of mature infectious virions. The INSTIs work by preventing the integration 
of viral DNA into the host genome. In addition, the CCR5 antagonist and the fusion 
inhibitor obstruct the fusion process blocking the interaction of the HIV gp120 and the 
CCR5 receptor and avoiding conformational changes of gp41, respectively. The last class 
of drug is the post-attachment inhibitor or entry inhibitor that is a competitive inhibitor for 
the CD4 receptor. Together these drugs conform the cART targeting different steps of the 
viral replication, with the purpose of improving the CD4+ T cell count, prolonging patient 
survival, and reducing the risk of transmission. However, cART is not able to eradicate 
HIV. Moreover, cART need to be administrated regularly and constantly because viral 
rebound occurs rapidly after treatment discontinuation (https://aidsinfo.nih.gov/guidelin, 
https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-
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medicines). Even though cART blocks peripheral viral replication, cART does not prevent 
viral mRNA and protein expression. Thus, damage in the absence of viral production, is 
dependent on viral proteins. 
 
HIV latency 
Stable and productive HIV DNA integration is the most important aspect of HIV latency 
(Lafeuillade and Stevenson 2011). Thus, productively infected cells can become latently 
infected through viral silencing mechanisms that are still under investigation (Kim M. et 
al. 2014, Mok and Lever 2007). Several transcriptional and post-transcriptional molecular 
mechanisms have been proposed (Bruner et al. 2016, Hiener et al. 2017). Post-integration 
latency can be dependent on histone deacetylases (HDACs) (Margolis 2011) and methyl-
CpG-binding proteins which form complexes with HDACs (Bednarik et al. 1990) 
promoting chromatin condensation and HIV silencing. Other mechanisms involve the 
regulation of the essential Tat-cofactor P-TEFb (Kim Y. K. et al. 2011), NF-κB (nuclear 
factor κB) and NFAT (nuclear factor of activated T-cells) (Mbonye and Karn 2014) 
characterized by occlusion of transcription initiation or elongation complexes. For 
example, the elongation process requires P-TEFb that is recruited by Tat (Mbonye and 
Karn 2014). On another hand, a post-transcriptional mechanism involves microRNAs that 
regulate the levels of cyclin T1 protein, which is essential for T cell activation and viral 
replication (Chiang et al. 2012).  
Recent studies have proposed a new therapeutic approach based on the reactivation of 
latently-infected reservoirs by small molecules, called latency reversing agents (LRAs) that 
reactivate the virus stimulating the immune system with the goal of killing the viral 
reservoirs. This is called “shock and kill” strategy (Petravic et al. 2017, Schwartz et al. 
2017). The several LRAs proposed include drugs that induce NF-κB pathway activation, 
extra-terminal domain inhibitors enhancing the binding of the viral Tat protein to the HIV 
TAR element, and histone deacetylase inhibitors (HDACi-SAHA) that work as epigenetic 
modifiers, or a combination of them (Sadowski and Hashemi 2019). Moreover, current 
detection methods for viral reservoirs also use viral reactivators such as 
Phytohaemagglutinin (PHA) and phorbol myristate acetate (PMA) that block the binding 
of IκBα to NF-κB that can translocate to the nucleus and activate transcription (Chauhan 
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2015).  Although several groups focus primarily on LRAs or several stimulators to induce 
HIV reactivation, they are unable to reactivate all the integrated viruses, suggesting that 
there is a gap between the signals required for reactivation of some viruses, depending on 
where they are integrated, degree of epigenetic modulation and specific respond to different 
stimuli to induce reactivation.  
 
Viral reservoirs 
As discussed above, HIV remains incurable due to the early viral seeding and generation 
of latent-infected cells. Viral reservoirs are defined as a cell type in which a replication-
competent form of HIV persists. HIV reservoirs are long-lived infected cells due to their 
slow decay rate (t1/2=3.7 years) (Siliciano et al. 2003). Thus, the virus remains integrated 
in the host genome and it can be reactivated. The transient increase in plasma HIV RNA 
called blips, which are common in HIV patients under cART and there are typically related 
to viral rebound (Grennan et al. 2012). This stochastic reactivation of viral reservoirs is 
probably due to gaps in circulating concentration, toxicity or discontinuation of cART 
regimen. 
Currently, the best described viral reservoirs are resting CD4+ T lymphocytes including 
central memory T cells, transitional T cells, effector T cells, and naïve T cells (Stein et al. 
2016). However, other viral reservoirs are also described in circulation and in tissues such 
as peripheral blood monocytes, dendritic cells, macrophages (such as microglial), 
astrocytes and other myeloid cells (Castellano et al. 2017, Eugenin et al. 2011, Ganor et al. 
2019, Mitchell et al. 2019). The mechanism by which T cells survive and become latent 
has been investigated by the Siliciano group, creating a CD4 cell line transduced with the 
B cell Lymphoma 2 gene (Bcl-2) (Yang et al. 2009). Bcl-2 are pro-apoptotic members that 
regulate the mitochondrial outer membrane pore formation inducing apoptosis. Siliciano 
group showed that the Bcl-2 cell line survive infection and later are able to revert to the 
latent state, suggesting that Bcl-2 pathway can explain the survival mechanism of these 
viral reservoirs (Kim M. et al. 2014). However, there is no evidence that Bcl-2 can 
contribute to the latent stage since distinct cell types react differently after infection with 
HIV. Other mechanisms of cell survival are associated with other upregulated anti-
apoptotic proteins such as cFLIP and Mcl-1 or downregulated pro-apoptotic proteins such 
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as BAX and FADD (Timilsina and Gaur 2016), suggesting that blocking apoptosis 
contributes to viral reservoir survival. 
On another hand, data in our laboratory demonstrated that macrophage survival in response 
to HIV infection has a metabolic and an anti-apoptotic component. Latent macrophages 
show mitochondrial fusion, lipid accumulation, and reduced mitochondrial ATP 
production and use glutamine/glutamate as a primary energy source (Castellano et al. 
2019). Therefore, it’s necessary to enlighten on the importance of myeloid cells as viral 
reservoirs. Two critical cases are the “Berlin Patient” and the “Mississippi baby”, which 
can demonstrate the effective role of the myeloid cells in HIV infection. The first one 
achieved viral remission after a bone marrow transplant with stem cells from a donor who 
was homozygous for CCR5 delta32 used to cure acute myeloid leukemia (AML) (Hutter 
et al. 2009). In the case of the “Mississippi baby” after an early administration of ART (30 
hours after birth), plasma viremia was undetectable without cART, suggesting a crucial 
role of the myeloid reservoirs to viral persistence in the earliest stage of infection (Persaud 
et al. 2013). Several strategies have been proposed to study and target myeloid reservoirs, 
using the shock and kill mechanism with HDACi or protein kinase C activator, or using 
cell transplant and gene therapy to modify CCR5 in myeloid compartments (Mitchell et al. 
2019).  
 
Current methods to detect viral reservoirs 
The current methods to detect viral reservoirs are not able to precisely measure their size 
and the cell type involved. Currently, most viral reservoirs are detected in blood, but they 
are a poor representation of viral reservoirs in tissues. Quantitative Viral Outgrowth Assay 
(QVOA), Tat/rev Induced Limiting Dilution Assay (TILDA) and other Quantitative PCR 
assays for total HIV RNA or HIV DNA are frequently used to detect viral reservoirs. 
QVOA is a cultured based assay that identifies reservoir in circulating cells (Finzi et al. 
1997). TILDA is a PCR-based assay that measure the frequency of cells harboring HIV-
integrated genomes. Other PCR-based methods can also measure the frequency of cells 
harboring HIV-integrated and unintegrated DNA. QVOA is performed in the blood CD4+ 
T lymphocytes which are stimulated with phytohemagglutinin (PHA) in the presence of 
irradiated allogeneic peripheral blood mononuclear cells (PBMCs) that induces global T 
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cell activation of HIV-integrated genomes. The replication of the virus is detected by HIV-
p24 ELISA on the media of 2-3 week cultures combined with CD4+ lymphoblasts from 
HIV-negative donors (Finzi et al. 1997). Instead, TILDA measures the frequency of cells 
harboring viral genomes that produce tat/rev multiply-spliced HIV RNA upon maximal 
stimulation. It also needs isolation of the total CD4+ T lymphocytes that are stimulated with 
PMA and ionomycin for 12 hours to induce the maximal production of tat/rev RNA and 
later the qRT-PCR is used to quantify tat/rev transcripts. TILDA requires 10 ml of blood 
and can be completed in 2-3 days (Procopio et al. 2015). Other PCR-based techniques PCR 
assays such as digital droplet PCR for total HIV DNA/RNA or integrated HIV sequences 
(Alu or 2LTR) can be used to quantify HIV DNA or RNA in PBMCs, in purified CD4+ T 
cells or in plasma. They are expensive, use a large amount of starting materials and time 
consuming, as well as overestimate the size of the latent reservoirs (Eriksson et al. 2013).  
Overall, QVOA, TILDA, and other PCR-based techniques have enormous limitations such 
as timing, cost, accuracy, precision, sensitivity and use of a large volume of blood. 
Additionally, they detect just one component of viral cell cycle and are limited to only 
circulating viral reservoirs. Generally, they can misinterpret the data and incorrectly 
estimate the replication‐competent viruses within the circulating and tissue reservoirs 
(Churchill et al. 2016).  
Recently, Dr. Eugenin’s laboratory generated a highly sensitive and innovative protocol 
that is specific for viral DNA, viral RNA, several viral proteins and characterizes 
circulating and tissue-associated viral reservoirs in HIV-infected individuals (Prevedel et 
al. 2019). This technique is based on improved staining and confocal microscopy analysis. 
It determines the stage of the viral life cycle detecting, quantifying, and localizing 
concurrently HIV DNA, HIV mRNA, HIV proteins and host cell markers in vitro and in 
vivo (Prevedel et al. 2019). HIV reservoir identification and localization are necessary to 
study the mechanism of bystander damage and to find new molecular targets for HIV 
efficacious treatments. Our laboratory has developed techniques to identify viral reservoirs 
in urethral tissue (Ganor et al. 2019) and in other human tissues such as bone marrow (Real 
F. et al. in press). In this thesis, we present data about localization, identification, and 
quantification of viral reservoirs in brain and lymph nodes in Chapter 2.  
 
17 
 
Part II – HIV in CNS  
 
HIV CNS infection  
HIV-infection of the Central Nervous System (CNS) arises very early after primary 
infection (15 days). It is accepted that HIV transmigration into the brain occurs by the 
“Trojan Horse” mechanism (Hazleton et al. 2010). Briefly, circulating HIV-infected 
monocytes, specifically CD14+CD16+ intermediate monocytes, cross the Blood Brain 
Barrier (BBB) in response to chemotactic signals as such CCL2 and CXCL12 (Eugenin et 
al. 2006, Williams et al. 2012). The high sensitivity of HIV-infected cells to sense these 
chemokines is due to enhanced capacity of HIV-infected cells to sense physiological 
chemokine gradients such as CCL2 (Eugenin et al. 2006). During the process of 
transmigration of HIV-infected cells in response to CCL2, the BBB become compromised 
further contributing to local inflammation. In the CNS, migrated HIV-infected monocytes 
infect local resident cells such as microglia, perivascular macrophages and a small 
population of astrocytes (Williams et al. 2014). In particular, microglial cells and 
perivascular macrophages are the major productively infected cells by HIV (Cosenza et al. 
2002). On the contrary, astrocytes support a low viral replication. Astrocytes are CD4 
negative cells and they are infected by HIV using a mannose receptor that mediates vesicle 
endocytosis from the membrane that have to also avoid endolysosomal destruction, or via 
viral synapses using cell-to-cell contacts with infected lymphocytes (Do et al. 2014, 
Galloway et al. 2015, Liu Y. et al. 2004).  
During active CNS infection, formation of multinucleated giant cells and neuronal and glial 
cell death were common in infected individuals in the pre-ART-era. However, upon cART 
introduction, damage still occurs but is more controlled. 
 
Viral reservoirs within the CNS 
During the acute phase of HIV, infection of human microglia/macrophages and astrocytes 
results in inflammation due to the release of cytokines and chemokines, finishing in a 
massive apoptosis (Castellano et al. 2017). However, a small population of HIV-infected 
cells survive and become latently infected (Castellano et al. 2017, Eugenin and Berman 
2007, 2013, Eugenin et al. 2011, Orellana et al. 2014). Macrophages/microglia are the 
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primary CNS target of HIV (Wong and Yukl 2016). It was shown that uninfected 
macrophages derived from recently transmigrated monocytes die in few days (Bellingan et 
al. 1996), whereas microglia, perivascular, and alveolar macrophages have an long half-
life (months-years) (Lassmann and Hickey 1993). Latently HIV-infected macrophages are 
terminally differentiated and non-dividing cells that derive from circulating monocytes 
residing in all tissues. They are able to survive HIV infection principally due to metabolic 
alterations and apoptosis inhibition (Castellano et al. 2017, Castellano et al. 2019). In 
latently HIV-infected microglia/macrophages the pro- and anti-apoptotic pathways are 
blocked and Bim that is a highly pro-apoptotic negative regulator of Bcl-2 is upregulated 
and recruited into the mitochondria preventing apoptosis (Castellano et al. 2017). Thus, the 
mechanism of survival is different than CD4+ T cells mediated by Bcl-2 (Kim M. et al. 
2014).  
In macroglia/macrophage reservoirs, the mitochondria become larger and show lipid 
accumulation and produce less ATP for the compromised metabolic steps in the 
tricarboxylic acid (TCA) cycle preceding oxidative phosphorylation (OXPHOS). While 
HIV-infected macrophages use fatty acids and glucose as primary sources of energy as well 
as the uninfected cells, they also use glutamine/glutamate and alpha-ketoglutarate (αKG) 
as an alternative energy supply (Castellano et al. 2019).  Otherwise, latently HIV-infected 
astrocytes survival is principally due to cytochrome C mislocalization from the 
mitochondria to the cytoplasm and for the following alterations in inositol triphosphate 
(IP3), IP3 receptors and calcium that block the formation of the apoptosome (Figure 1.3) 
(Eugenin and Berman 2013). Despite the fact that only a small fraction of astrocytes 
become infected, they induce bystander apoptosis of neighboring cells through cell-to-cell 
mechanism (Eugenin and Berman 2007, Eugenin et al. 2011). Thus, macrophages and 
astrocytes have different survival mechanisms than CD4+ T cells. Moreover, HIV envelope 
sequencing studies from blood, brain and other non-brain tissues such as bone marrow, 
colon, lung and liver showed an HIV macrophage tropism with a different HIV 
compartmentalization and evolution within the blood and the tissues (Holman et al. 2010), 
suggesting that viral reservoirs are different in each compartment.  
Data showed in this thesis demonstrate the adaptation of glial networks to limited HIV 
infection. Briefly, we have shown that HIV-infected astrocytes prefer an alternative source 
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of energy independent from mitochondria such as pentose phosphate (see details in Chapter 
6). 
 
Novel mechanism of bystander CNS damage in the current cART-era 
HIV-associated neurocognitive disorders (HAND) are present in around 50% of HIV-
infected individuals of the post cART-era. CNS damage was identified in 90% of autopsied 
brains from HIV-infected patients displaying chronic neuroinflammation and 
neurocognitive impairment even after they received cART for many years (Lamers et al. 
2016). Moreover, HAND can be exacerbated by HIV-related infections, cART-related 
toxicities, cART discontinuation and comorbidities (alcohol and substance of abuse) (Byrd 
et al. 2011, Justice et al. 2010, Tedaldi et al. 2015). According to the severity of the clinical 
manifestations, HAND are divided in asymptomatic neurocognitive impairment (ANI), 
mild neurocognitive disorder (MND), and HIV-associated dementia (HAD) (Antinori et al. 
2007). In the post-cART era, the proportion of HIV-infected individuals with 
neurocognitive symptoms is the same of the pre-cART era, but the percentage of infected 
patients with HAD has decreased in favor of ANI and MND (Heaton et al. 2010, Saylor et 
al. 2016). The symptoms displayed in the milder forms of HAND include memory loss, 
problems in concentration, difficulty learning new tasks, diminished reflexes, personality 
changes, and mood swing. Instead, people diagnosed with HAD have severe memory and 
concentration problems, wild mood swings, symptoms of psychosis and loss of physical 
coordination (Eggers et al. 2017).  
Nowadays, the diagnosis and the monitoring of HAND is based on neuropsychometric 
performance tests, blood tests, CSF analysis, and neuroimaging (Clifford and Ances 2013). 
These techniques may provide metabolic and structural alteration in the blood and in the 
brain. However, techniques to identify viral reservoirs are lacking. In Chapter 2, we will 
describe a novel method to identify, localize, and quantify viral reservoirs in circulation 
and in tissues. In addition, in Chapter 4, we will show new potential biomarkers of HAND. 
Later, we will discuss the bystander effect of viral proteins and lipids.  
Our laboratory identified that viral reservoirs can promote a bystander damage into 
neighboring cells via GJs mediated mechanism. Gap junctions are expressed in most cell 
types of the nervous system, including astrocytes, neurons, oligodendrocytes, neuronal 
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stem cells, endothelial cells, and under inflammatory conditions in microglia/macrophages 
(Eugenin et al. 2012, Kielian 2008, Palacios-Prado et al. 2013, Vejar et al. 2019). Gap 
junctions are low-resistance bridges that perform electrical and metabolic functions, 
connecting the cytoplasm of adjacent cells and allowing the exchange of electrical signals 
and intracellular messengers, such as IP3, calcium, cyclic nucleotides, metabolites, 
neurotransmitters, and viral peptides (Yeager and Nicholson 1996). Gap junctions consist 
in connexin (Cx) dodecamer channels formed of two hexameric unopposed hemichannels 
(uHCs), one from each of the coupled cells (Harris A. L. 2001). Connexin-containing uHCs 
are defined homomeric when 6 monomers of Cx that compose it are the same, or 
heteromeric when the Cxs are different. Gap junctions can be docked by two identical 
(homotypic) or different (heterotypic) subunits of HCs. Homo- and hetero-combinations 
generate channels with different biophysical properties and permeability (Harris A. L. 
2007). Hemichannels and GJ channels have an internal pore of approximately 12 A° 
enabling the diffusion of molecules up of 1.2 kDa (Villanelo et al. 2017). The role of HCs 
and GJs in HIV infection has acquired an increased interest. Although uHCs exist 
physiologically in a closed state, HIV infection is one of the few cases where uHCs become 
opened enabling the release of pro-apoptotic and pro-inflammatory factors such as 
prostaglandin E2 (PGE2) and adenosine-triphosphate (ATP) in the extracellular space 
(Eugenin 2014). For instance, in HIV-infected astrocytes the opened Cx43 containing 
uHCs led the secretion of dickkopf-1 protein (DKK1) that is a soluble Wnt pathway 
inhibitor. It has been shown in neuron and astrocyte mixed cultures treated with DKK1 
resulted in a significant collapse of neuronal processes (Orellana et al. 2014). Thus, it can 
explain the synaptic compromise observed in HIV-infected individuals.  On another hand, 
GJs that are regulated in order to control synaptic function, after HIV infection they are 
permanently open and used by the virus to spread and maintain infection in the CNS. 
Specifically HIV reservoirs mediate bystander damage into the neighboring cells via 
Connexin-43 (Cx43) containing GJs and uHCs (Malik et al. 2017). To prove GJs crucial 
role in CNS damage, the Cx43-GJ blockers 18-α-glycerritenic acid (AGA) or octanol were 
used to treat HIV-infected astrocyte cultures resulting in decreased level of apoptosis in the 
neighboring HIV-uninfected cells (Eugenin and Berman 2007). In addition, bystander 
apoptosis was related to inositol trisphosphate and intracellular calcium (Figure 1.3) and to 
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endothelial apoptosis, dysregulation of lipoxygenase/cyclooxygenase, BK calcium 
channels, and ATP receptor activation within astrocytes (Eugenin and Berman 2013). 
Recently it was demonstrated that HIV Tat protein enhances Cx43 expression in primary 
human astrocytes to maintain communication between the few HIV-infected cells and 
surrounding uninfected cells suggesting a critical link between HIV proteins, commonly 
present in the brain of virally-suppressed infected individuals, and cell-to-cell 
communication (Malik et al. 2017). To conclude, we can remark that HIV reservoirs used 
a different way to survive to infection and to generate bystander effect on the neighboring 
uninfected cells. Several of these communication systems will be discussed in Chapter 6. 
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Figure 1.3. Proposed model of HIV-infected astrocytes for survival and bystander 
damage mediated by Cx43 containing GJs, from (Eugenin and Berman 2013) 
HIV-infected astrocyte survives to apoptosis for cytochrome c secretion in the cytoplasm 
that blocks the apoptosome formation and increases IP3 and intracellular calcium 
concentration. IP3 and calcium can diffuse into the neighboring cells through Cx43 
containing GJs and induce apoptosis.  
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Neuroimaging used to diagnose and monitor HAND in the current cART-era 
Neuroimaging includes the use of different techniques that directly or indirectly image 
metabolic, structural, and functional changes of the brain. They can be partially useful to 
generate a diagnosis and to monitor the clinical course of HAND (Clifford and Ances 
2013). The more common techniques for metabolic imaging are proton-magnetic 
resonance spectroscopy (H-MRS or MRS), positron emission tomography (PET), and 
single photon emission computer tomography (SPECT). H-MRS is a non-invasive 
technique that gives information on brain pathophysiology measuring signals from 
hydrogen atoms of specific brain metabolites, such as N-acetylaspartate (NAA), 
myoinositol (MI), choline (CHO), and glutamate-glutamine (GLX) (Van Zijl and Barker 
1997). N-acetylaspartate is a neuronal functional marker and it is synthesized as a result of 
the reaction between aspartate and acetyl coenzyme A (Baslow 2003). Myoinositol is an 
astrocyte marker associated with inflammation, astrocytosis and gliosis (Harris J. L. et al. 
2015). Choline is a cell membrane marker that specifically represents the membrane lipid 
turnover and reflects macrophage infiltration and inflammation (Lin et al. 2005).  
Glutamate (Glu) is the major excitatory neurotransmitter in the brain, stored as glutamine 
(Gln) in glial cells. Glutamate-glutamine balance cycling is essential for normal 
functioning of brain cells. Astrocytes are responsible for uptake of most extracellular 
glutamate via glutamate transporters GLT1 (or EAAT1) and GLAST (or EAAT2), in order 
to maintain Glu extracellular concentration and avoid excitotoxicity (Schousboe and 
Waagepetersen 2005). In MRS the magnet strength is not always sufficient to resolve Glu 
from Gln and in some cases they are combined as GLX (Ramadan et al. 2013). Moreover, 
some MRS data are expressed as a ratio of the specific metabolites compared to creatine 
(Cr) that is a reference marker (Vigneswaran et al. 2015). The most common MRS features 
in HIV seropositive population are increased levels of CHO and MI that suggest 
inflammation and microglial proliferation, and decreased levels of NAA and GLX that are 
related to neuronal-axonal injury or dysfunction (Mohamed M. A. et al. 2010). During HIV 
infection, MRS is also used to monitor changes in brain inflammation and neuronal 
integrity associated with cART effects. The biggest limit of MRS is that the results of the 
analysis are restricted to certain brain regions. During acute HIV infection, brain 
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metabolites have been measured in frontal grey and white matter, in the occipital grey 
matter, and in basal ganglia.  Elevated levels of CHO/CR in the basal ganglia and in the 
occipital grey matter of acute HIV cases (14 days after HIV infection) were detected 
compared to uninfected controls, as well as chronic HIV subjects. These values became 
normal after 6 months of cART (Sailasuta et al. 2012). Moreover, the levels of Cho/Cr, 
NAA/Cr, Glu/Cr and MI/Cr have been shown to be increased in frontal white matter, in 
parietal grey matter and in basal ganglia, but after cART initiation their excitotoxicity and 
neuronal injury effect were attenuated (Young et al. 2014). In addition, the relationship 
between HIV-cognitive impairment and brain metabolism was investigated in older HIV-
infected individuals under cART and it was shown that NAA and Glu were lower and 
correlated with worse performance on neuropsychological tests in MND or HAD 
individuals (Mohamed M. et al. 2018). Although, MRS can detect several brain metabolites 
only one study mentions the possibility to detect lipid molecules (Bairwa et al. 2016), 
without identifying either the class or their specific alteration.  
Other techniques that can be applied for metabolic investigation in HIV pathology are PET 
and SPECT. Positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) were used to study HIV patients with or without HAND. PET and 
SPECT are used to evaluate glucose metabolism or cerebral perfusion applying nuclear 
medicine tracers (18F-deoxyglucose - 99Tc-HMPAO) that specifically bind to a positron-
emitting radioisotope, such as 18fluorine (18F) or 11carbon (11C) (Sathekge et al. 2014). 
Decreased glucose metabolism in the frontal cortex detected by PET in HIV seropositive 
patients may reflect neuronal injury or dysfunction (Andersen et al. 2010). PET imaging is 
also used to assess dopamine (DA) function in HIV-infected patients, because HIV-
infected patients with HAND often present psychomotor slowing and parkinsonian 
symptoms. For this particular technique, (11C)-cocaine and (11C)-raclopride are used to 
measure presynaptic dopaminergic transporter and postsynaptic D2 dopaminergic receptor, 
respectively. These tracers demonstrated lower levels of dopamine transporters (DAT) that 
are associated with dopaminergic neuronal injury especially in HIV-positive patients with 
HAD (Wang et al. 2004) and worst neurocognitive performance (Chang et al. 2008). 
Likewise, SPECT is utilized to put in evidence the central dysfunction of the dopaminergic 
pathways in HIV infection and 123I-FP-CIT and 123I-IBZM are the trackers used for these 
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analyses (Scheller et al. 2010). Current studies are focusing on the development of 
radiotracers ((11C)PK11195, (11C)PBR18, (11C)DPA-713, and (11C)PBR28) specific for 
microglia in order to quantify and localize brain inflammation in HIV-infected patients 
(Chang and Shukla 2018, Hammoud et al. 2005). 
For the structural neuroimaging, two techniques have been applied to HAND investigation: 
volumetric analysis and diffusion tensor imaging. Structural neuroimaging involves brain 
tissue contrast that is based on differences in proton density and relaxation times amongst 
brain structures (Ashburner and Friston 2000, Good et al. 2001, Sanford et al. 2017). The 
measurement of cortical and subcortical grey matter and total and abnormal white matter 
(aWM) volumes showed that HAD and MND patients had smaller grey and white matter 
volumes and more aWM than neurocognitively unpaired patients (Alakkas et al. 2019). On 
the other hand, diffusion tensor imaging is an MRI-based neuroimaging technique used for 
the detection of microarchitectural changes. Using this technique, microstructural 
disruptions were localized especially in the frontal and motor white-matter regions of the 
HIV-infected individuals (Wright et al. 2012).  
Currently, functional neuroimaging techniques include magnetic resonance imaging (MRI) 
for blood oxygen level dependent imaging (BOLD) and perfusion.  BOLD fMRI signal 
investigates the ratio of oxygenated to deoxygenated hemoglobin in the microvasculature. 
Although, HIV regional injury can be associated with a partial dysfunction of the brain 
networks, BOLD task-activated fMRI and resting-state fMRI (rsfMRI) are used to evaluate 
functional networks (Fox and Raichle 2007). For instance, HIV seropositive patients 
showed a selective activation for networks involving attention, working memory, and 
hippocampal function (Chang et al. 2001), as well as risky choices (Connolly et al. 2014). 
On another hand, rsfMRI showed lesser connectivity within frontostriatal, salience, frontal, 
motor, and executive networks and within precuneus seed and prefrontal cortex in HAND 
population, suggesting a compromised brain activity (Ann et al. 2016, Chaganti et al. 
2017). Perfusion MRI is another functional method using arterial spin labeling (ASL) 
technique to measure the proton spins associated to endogenous oxyhemoglobin and 
deoxyhemoglobin for calculating the arterial function. Using ASL low levels of cerebral 
blood flow were demonstrated in HIV seropositive population that can be partially restored 
after cART (Ances et al. 2009).  
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Together all these neuroimaging techniques are useful to assess HAND onset and 
progression, but better markers in term of prediction and selectivity are required. Several 
of these neuroimaging techniques can also measure different species of lipids, but most of 
these data has been ignored. In this thesis, we study lipid metabolic alteration in the brain 
of HIV-infected patients and correlate them with neurocognitive impairments in order to 
find a specific biomarker that can be predictive of the risk to develop HAND. 
 
Brain volume changes and localized damage in HAND in the current cART-era 
Neuroimaging data have shown that volumetric changes involve the brain of HIV-infected 
patients virally suppressed with cART (Alakkas et al. 2019). By diffusion tensor imaging 
it was demonstrated that white matter deficits comprise dramatic thinning of the corpus 
callosum, reduction in blood flow to white matter, loss of structural integrity and volume 
in white matter structures such as the superior longitudinal fasciculus, superior corona 
radiata, and the internal capsule (Correa et al. 2015, Leite et al. 2013). A recent CHARTER 
study used structural MRI to determine reduced white matter volume in HIV-infected 
individuals with HAD and MND compared with HIV-infected patients who were 
neurocognitively normal, all of them were virally suppressed with cART (Alakkas et al. 
2019). Higher levels of abnormal white matter were associated with higher risk of HAND. 
Specifically, HIV-infected individuals of the post-cART era displayed synapto-dendritic 
damage (Ellis et al. 2007) with prominent atrophy in subcortical structures, such as caudate, 
putamen, amygdala, hippocampus, and thalamus, instead of neuronal loss often observed 
in pre-cART era (Ances et al. 2012, Harezlak et al. 2011). In addition, cortical thinning or 
regional volume loss affect parietal white matter, orbitofrontal cortex, cingulate cortex, 
primary motor and sensory cortices, frontal and temporal lobes suggesting worst cognitive 
performance (Sanford et al. 2017). One cross-sectional study performed using a volumetric 
analysis compared HIV-infected patients virally unsuppressed and suppressed to 
uninfected individuals showing that reduced brain volumes in the corpus callosum, 
amygdala, caudate, thalamus, and putamen volumes is independent of cART because both 
HIV positive groups displayed similar changes. As discussed before, volumetric reductions 
of subcortical regions happen despite cART, suggesting a faster morphometry change after 
seroconversion that is persistent also in the virologically suppressed cohorts (Ances et al. 
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2012). Thus, cART has no significant effects on these volume changes (Brier et al. 2015), 
and we propose it cannot prevent lipid dysregulation. Our idea for this thesis is to study 
lipid dysregulation and the future direction aim to better characterize the pathway involved 
for obtaining target molecules for a specific therapeutic approach.  
 
Potential biomarkers of HAND in the HIV-infected population 
Several blood and CSF biomarkers for HAND are under investigation in order to determine 
the risk of HIV-infected patients developing neurocognitive impairment. However, it is 
difficult to assess their unequivocal role because most of the performed studies are cross-
sectional or do not consider the evolution of cognitive impairment that in NeuroHIV is not 
linear (Bandera et al. 2019). The CSF/blood biomarkers for HAND may be divided into 
markers for neuronal injury, inflammation, and immune activation. Markers of neuronal 
injury previously investigated include β-Amyloid 1-42 (Petersen et al. 2016), the light 
subunit of the neurofilament protein (Yilmaz et al. 2017),  calcium binding protein B 
(S100B) (Du Pasquier et al. 2013, Guha et al. 2019), extracellular vesicles (Urbanelli et al. 
2019), and the Wnt pathway (Al-Harthi 2012), but none of these studies clearly explain the 
reason why they can be used as a biomarkers, especially in the virally suppressed patients 
with neurocognitive disorders. Although neuronal injury biomarkers have been long 
investigated, interest in inflammatory biomarkers has exponentially grown due to the 
persistent neuro inflammatory feature in cART suppressed individuals (Suh et al. 2014). 
Included among these biomarkers are: Monocyte Chemoattractant Protein-1 (CCL2) 
(Kamat et al. 2012), Tumor Necrosis Factor Alpha (TNF-α) (Oliveira et al. 2017), 
Interleukin-6 (IL-6) (Cassol et al. 2013), Interferon-γ-Inducible Protein (IP-10 or CXCL-
10) (Yuan et al. 2015), Interleukin-8 (IL-8 or CXCL-8) (Kamat et al. 2012, Yuan et al. 
2015), Interferon Alpha (IFN-α) (Anderson A. M. et al. 2017), Intercellular adhesion 
molecule-5 (ICAM5) (Yuan et al. 2017), Lipopolysaccharide (LPS) (Ancuta et al. 2008, 
Vassallo et al. 2013) and Growth Factors (Kallianpur et al. 2019, Yuan et al. 2015). 
Recently, our laboratory has identified ATP as a potential biomarker for HAND, affecting 
BBB function, stability, and neuroinflammation (Velasquez et al. 2019). Although several 
of these inflammatory factors may be directly or indirectly involved in HAND and 
increased in the blood and/or CSF of infected patients virally suppressed with cART and 
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with cognitive impairment, none of them explore the neuronal damage progression in 
HAND.  
To conclude, recent research focus in HAND biomarkers include immune activators such 
as neopterin (Valcour et al. 2013), soluble CD163 (Burdo et al. 2013), soluble CD14 
(Burdo et al. 2011) and Cathepsin B (Cantres-Rosario et al. 2013). 
Still, although all these markers are increased in HAND condition, their role in HAND 
pathophysiology is often ambiguous and still under investigation. Moreover, the large 
range of variabilities in infected and neurocognitive impaired populations obstruct the 
absolute validation of blood/CSF biomarkers. Additionally, all these biomarkers are late 
indicators of the CNS damage that need a total disruption of neurons to be released in the 
circulation and be detected, so they are not predictive. 
We demonstrated that sulfatide distributions in brain are perturbed in HIV-infected 
patients. Here, we explore the possibility that lipids, such as sulfatide, are potential 
biomarkers of HIV cognitive impairment.  
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Part III – Lipids in HAND 
 
General introduction of lipids  
Lipids are amphipathic biomolecules (Fahy et al. 2011). Lipids assist several important 
cellular functions, they are structural elements of the lipid bilayers, are sources of chemical 
energy, and are precursors for several second messengers (Glatz 2015). Lipids are 
classified into eight categories based on the ketoacyl groups and the isoprene groups: 
glycerophospholipids, fatty acyls, glycerolipids, sphingolipids, sterol lipids, prenol lipids, 
saccharolipids, and polyketides (Fahy et al. 2005). In order to simplify their metabolic 
characterization, we divided them in phospholipids, neutral lipids, and glycolipids.  
Phospholipids are the major class of lipids present in all cells and they can be divided into 
glycerophospholipids and sphingomyelins. Glycerophospholipids include 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, 
phosphatidic acid, phosphatidylglycerol, and cardiolipin. All of them have a structural 
function in the cellular membranes in which are asymmetrically distributed in the bilayer 
(Fadeel and Xue 2009). The major phospholipid component present in cell membranes is 
phosphatidylcholine, which represents the 40-50% of the total phospholipid pool. 
Moreover, phosphatidylcholine is a precursor of several signaling molecules such as 
phosphatidic acid, diacylglycerol, lysophosphatidylcholine, platelet-activating factor, and 
arachidonic acid (Billah and Anthes 1990). Phosphatidylethanolamine is the second most 
abundant phospholipid in the membrane representing the 20-30% of the total cell 
phospholipid. Its function is to stabilize the membrane proteins in the bilayer. 
Phosphatidylserine is a minor membrane phospholipid and it is involved in the early phases 
of apoptosis and in the production of anti-inflammatory mediators (Bratton and Henson 
2008, Vance and Steenbergen 2005). Phosphatidylinositol is also a minor lipid in 
mammalian cells, but it is involved in several signaling processes. It is the precursor of 
polyphosphoinositol lipids (PIP, PIP2, and PIP3) which regulate intracellular calcium 
signaling, gene transcription, RNA editing, nuclear export, and protein phosphorylation 
(Di Paolo and De Camilli 2006). Other classes of glycerophospholipids such as 
phosphatidic acid, phosphatidylglycerol, and cardiolipin are lower in abundance compared 
to phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and 
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phosphatidylserine. Specifically, phosphatidic acid is less than 1% abundant in the 
membrane but is a very important intermediate for the synthesis of membrane 
phospholipids and an important regulator of signal transduction, membrane trafficking, 
secretion, and cytoskeletal rearrangement (Jenkins and Frohman 2005). 
Phosphatidylglycerol is more express in the mitochondrial membranes and it is the 
precursor of cardiolipin which is necessary for normal electron transport and oxidative 
phosphorylation (Claypool 2009).  
Sphingomyelins are also important components of cell membranes and they amount at 10% 
of the total phospholipids. Specific sphingomyelin metabolites such as ceramide (Cer), 
sphingosine (Sph), sphingosine-1-phosphate (S1P), diacylglycerol (DAG) and 
gangliosides (GMs), are also involved in cell signaling (Merrill et al. 1997). Ceramide is a 
crucial metabolite for sphingolipid metabolism. It is involved in cellular apoptosis (Hannun 
and Obeid 1995), cell differentiation (Okazaki et al. 1990), and inflammatory responses 
(Masini et al. 2008). Sphingosine and S1P are cofactors of inflammatory signaling, SPH 
inhibits proliferation and promotes apoptosis, S1P mediates cell growth arrest and 
apoptosis inhibition (Hannun and Obeid 2008). DAG is a second messenger that supports 
the biosynthesis (and degradation) of glycerolipids regulating protein kinase C (PKC) 
activity (Bishop and Bell 1988). Gangliosides are predominantly localized in the outer 
leaflets of neuronal plasma membranes where they contribute to cell-cell recognition, 
adhesion, and signal transduction (Kolter 2012, Yu et al. 2011). 
Neutral lipids are comprised of sterols and glycerolipids. Sterols play a key role in the 
membrane integrity maintaining its microfluid state. The most abundant sterol in the 
cellular membranes is cholesterol (Dufourc 2008). Glycerolipids include triacylglycerols 
and steryl esters, and they are typically used as energy store (Athenstaedt and Daum 2006).  
Glycolipids are glycans with a lipidic portion that bind to monosaccharide or 
polysaccharide chains that is extended into the extracellular space. Glycolipids include 
glyceroglycolipids, lipopolysaccharides, glycosphingolipids, and glycosylphosphatidyl-
inositols. They have structural role for the cellular membrane and participate in immune 
responses to bacterial infections and cell-to-cell communication (Paulick and Bertozzi 
2008, Stoffel and Bosio 1997, Zajonc and Kronenberg 2009).  
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Lipids within the CNS 
Lipids such as cholesterol, fatty acids, sphingolipids, and glycerophospholipids are 
important structural components of the neuronal cells (Cermenati et al. 2015). 
Within CNS, cholesterol facilitates the extension of axons, promotes the neurons survival 
and the myelin formation (Bruce et al. 2017). On another hand, fatty acids determine 
membrane fluidity and plasticity of neuronal membranes, serving also as signaling 
molecules. They are classified in saturated fatty acids that are made by single bonds 
between neighbor carbons and unsaturated fatty acids that present one or more carbon–
carbon double-bonds. The neuronal membranes are mostly composed by polyunsaturated 
fatty acids (PUFAs), which are very abundant in the myelin sheath (Hooijmans and Kiliaan 
2008). Instead, glycerophospholipids and sphingolipids maintain structural integrity in 
neuronal membrane (Olsen and Faergeman 2017). Sphingolipids are also involved in 
synaptic transmission and neuronal differentiation.  
Altered lipid metabolism and changes in lipids concentration were presented in several 
neurodegenerative disorders, such as Alzheimer’s (AD) and Parkinson’s diseases (PD) 
(Hussain et al. 2013). The main changes in the brain of Parkinson’s and Alzheimer’s 
individuals were described in the altered levels of cholesterol and sphingolipids (Hussain 
et al. 2019), but also fatty acids and glycerophospholipid alterations contribute to the CNS 
structural compromise. For example, the high cholesterol in membrane causes 
incorporation of amyloid-β (Aβ) into the membrane in AD and accumulation of α-
synuclein in PD leading to neuronal death (Abramov et al. 2011, Galvagnion et al. 2015). 
On another hand, fatty acids accelerates AD progression by enhancing the production of 
amyloid beta (Aβ) (Amtul et al. 2011). It has also been demonstrated that in patients with 
AD, the expression of Cer, the precursor of sphingolipids, in membrane was increased, 
whereas the level of sphingomyelin was reduced as a result of sphingomyelinase activation 
(He et al. 2010) inducing synaptic loss and neuronal cell death in response to amyloid 
accumulation (Couttas et al. 2014). Altered levels of sphingolipids were also observed in 
the brains of Parkinson’s patients. Interestingly, oxidative stress results in the activation of 
neutral sphingomyelinase enzyme resulting in increased levels of Cer, leading to apoptosis 
in the substantia nigra (Posse de Chaves and Sipione 2010).  
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Moreover, glycerophospholipids, especially phosphatidylethanolamines, 
phosphatidylinositols, and phosphatidylcholines are significantly reduced in the neural 
membrane during the progression of AD (Gonzalez-Dominguez et al. 2014, Kosicek and 
Hecimovic 2013). This excessive degradation of glycerophospholipids may be due to 
stimulation of phospholipase A2 producing arachidonic acid (AA) that induces the release 
of inflammatory cytokines (Frisardi et al. 2011) 
 
Arachidonic Acid and Ceramide synthesis pathways 
Lipids are active compounds involved in important physiological and pathological 
processes. Disruption or imbalance in lipid composition or metabolism lead to various 
metabolic disorders including infections and neurodegenerative diseases (Lee et al. 2003). 
Although, any investigated biomarker will represent HAND onset and progression, few 
studies have investigated lipids as possible indicator of neurocognitive impairment in 
HAND. The dysregulation in lipid metabolism that occurs in the CNS and in the CSF/blood 
of HIV-infected population (Farooqui et al. 2007, Haughey et al. 2004) has never been 
considered as a direct or indirect cause of HAND.  
As previously discussed, phospholipids are the most abundant structural elements of the 
lipid bilayers, they support chemical energy and are precursors for inflammatory 
messengers such as AA and ceramides (van Meer et al. 2008). Arachidonic acid is an 
omega-6 (n-6) polyunsaturated fatty acid, esterified on the sn-2 acyl position of 
phospholipids such as phosphatidylethanolamine, phosphatidylcholine, and 
phosphatidylinositol (Yin et al. 2013). During CNS injury, microglial cells release 
cytokines/chemokines that activate the cytosolic calcium-dependent phospholipases A2 
(cPLA2) that catalyzes the hydrolytic release of AA from membrane phospholipids. 
Oxidation of AA produces pro-inflammatory eicosanoids, which are local hormones that 
can be further subdivided into prostaglandins, leukotrienes, prostacyclins, and 
thromboxanes (Figure 1.4) (Farooqui et al. 2007). Eicosanoids in the brain can be secreted 
by several classes of cells such as microglia, astrocytes, oligodendrocytes, neurons and 
endothelial cells (Bendani et al. 1995). They are proinflammatory lipid mediators with 
autocrine and paracrine activities. From AA, the cyclooxygenase (COX) pathway gives 
33 
 
rise to prostaglandins, prostacyclines and thromboxanes; alternatively, the lipoxygenase 
pathway generates leukotrienes and lipoxins (Figure 1.4) (Radmark and Samuelsson 2009).  
Another dysregulated lipidic pathway observed in the CNS of HIV-infected patients is the 
ceramide pathway. Ceramide is a crucial mediator of cell differentiation, proliferation, 
survival, and apoptosis (Andrieu-Abadie et al. 2001). It is a metabolic and structural 
precursor for many sphingolipids, such as sphingomyelin (SM), ceramide-1 phosphate 
(Cer1-P) and glucosylceramide. The de novo synthesis of ceramide originates in the 
endoplasmic reticulum (ER) through a series of condensation and reduction reactions. 
Specifically, serine palmitoyltransferase (SPT) catalyzes the initial step of the pathway 
converting the L-serine (L-ser) and the palmityl coenzyme A (PalmitylCoA) in 3-keto-
dihydrosphingosine (3KdhSph) that is translated in dihydrosphingosine (dhSph) by 3-keto-
dihydrosphingosine reductase (3KSR). (Dihydro)ceramide synthase (dihydroCS) removes 
sphingoid bases and produces dihydroceramide (dhCer), which is converted into Cer by 
dihydroceramide desaturase (DES). Next, Cer is transported via non-vesicular transport by 
ceramide transfer protein (CERT) and via vesicular transport by four-phosphate adaptor 
protein 2 (FAPP2) to the Golgi apparatus. There, Cer is modified to form SM, Cer1-P and 
glucosylceramide (GluCer). The latter is the precursor for complex glycosphingolipids 
(GSL). After Cer synthesis in the Golgi apparatus, SM and complex GSL are delivered to 
the plasma membrane by vesicular transport. Several sphingolipid metabolic enzymes are 
present at the plasma membrane to regulate the levels of SM, Cer, Sph and sphingosine-1-
phosphate (S1P). The latter is produced from Sph by sphingosine kinase (SK) and may also 
take part in the salvage pathway for generation of Cer. Coordination between S1P and 
Cer1-P is crucial for eicosanoid inflammatory mediator production such as prostaglandins 
(Hannun and Obeid 2008). During endocytosis, membrane sphingolipids are internalized 
and transported to the lysosome via endocytic vesicles, where acid sphingomyelinase 
(aSMase), acid ceramidase (aCDase), and glycosidase catalyze the hydrolysis (Figure 1.5) 
(Bartke and Hannun 2009).  
An important Cer related metabolite is sulfatide because it is the major lipidic component 
of the myelin sheet (~4%). It is synthetized in the Golgi apparatus of oligodendrocytes and 
Schwann cells. Sulfatide is a class of anionic sulfoglycolipids mainly found in the outer 
leaflet of the plasma membranes of cells (Honke 2013). Its presence is not exclusive to 
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oligodendrocytes and Schwann cells, where is located to the plasma membrane, it is also 
produced in neurons and astrocytes, where is located in intracellular compartments 
(Ishizuka 1997). The precursor of sulfatide is galactosylceramide, which undergoes 3-O-
sulfation of the galactose residue by the enzyme 3′-phosphoadenosine-5′-phosphosulfate: 
cerebroside sulfotransferase (CST). Galactosylceramide is synthesized in the ER from 
ceramides and UDP-galactose by the enzyme UDP-galactose: ceramide 
galactosyltransferase (CGT) and is then transported to the Golgi apparatus prior to sulfation 
to sulfatide. Sulfatide is specifically degraded by a sulfatase (arylsulfatase A) in the 
lysosome (Figure 1.5) (Eckhardt 2008).  
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Figure 1.4. Metabolic pathway of Arachidonic acid (AA) transformation into 
eicosanoid products 
After proinflammatory stimulus, AA can be cleaved by cytosolic phospholipase A2 
(cPLA2) from diacylglycerol or phospholipids that compose cellular membranes. Free AA 
can take part in the Cyclooxygenase (COX) and Leukotriene (LO) pathways. For the 
cyclooxygenase pathway, AA is converted into prostaglandin H2 (PGH2), which generates 
prostacyclin (TXA2) by prostacyclin synthase and thromboxane by thromboxane synthase. 
In addition, PGH2 is converted in prostaglandin D2 (PGD2) and prostaglandin F2 (PGF2) 
by PGD and PGE synthetases. On another hand, AA can be transformed in Arachidonate 
5-lipoxygenase (5-LO) by lipoxygenase. The same enzyme catalyzes the conversion of 5-
LO to leukotriene A4, which is conjugated with reduced glutathione to be transformed into 
leukotriene C4. Next, leukotriene C4 is converted into leukotriene D4 and leukotriene E4 
with subsequent production of glutamic acid. 
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Figure 1.5. Localization and metabolism of Ceramide 
Ceramide is generated either by hydrolysis of SM through SM-specific Phospholipase-C 
(PLC) termed Sphingomyelinases (SMases), by de novo synthesis through the enzyme 
ceramide synthase (CerS) in the endoplasmic reticulum (ER), through the acylation of 
sphingosine in the salvage pathway, by dephosphorylation of Cer1-P, and catabolism of 
glycosphingolipids.  
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Arachidonic Acid and Ceramide related metabolites as possible HAND indicators 
HIV-infection and subsequent treatment with cART is often associated with perturbations 
in lipid profiles (Archibald et al. 2014, Griffin et al. 1994, Padmapriyadarsini et al. 2017), 
but any studies have investigated their altered metabolism in the brain. For instance, HIV-
infected population show decreased levels of high density lipoprotein (HDL) cholesterol 
and increased levels of low density lipoprotein (LDL) cholesterol, total cholesterol (TC) 
and triglycerides in the blood (Archibald et al. 2014, Padmapriyadarsini et al. 2017). 
Interesting AA and Cer pathways have foreshadowed their direct or the indirect function 
in HAND but limited data are present in the literature. Some AA metabolites are 
upregulated in the HIV-infected CNS, which may be correlated with cognitive impairment. 
Prostaglandin E2 elevated levels in the CSF of HIV-positive individuals correlates with 
dementia (Griffin et al. 1994). However, the direct role of these inflammatory lipid 
mediators in the development and progression of HAND is still not completely understood.  
Relatively more investigations have been performed for Cer metabolites in the brain of 
HIV-infected patients. Levels of Cer and SM are significantly increased in brain tissues 
and CSF of HIV-infected patients with dementia compared to mild demented and HIV-
infected without cognitive disorder individuals (Haughey et al. 2004). The same group 
demonstrated elevated level of Cer and SM in hippocampal neuronal cultures after 
stimulation with Tat or gp120 which induces apoptosis (Haughey et al. 2004). This suggest 
a possible correlation between lipid secretion and HIV proteins.  In conclusion, our studies 
aim to demonstrate that lipid biomarkers associated with the cART can fill an important 
gap in the field of NeuroHIV. The screening of these structural and inflammatory lipids 
may have a potential use for diagnosis and follow-up of HIV aviremic population affected 
by HAND. Only a recent study by MRS showed increased lipids in HIV patients with CNS 
lesion versus asymptomatic HIV individuals and healthy controls (Bairwa et al. 2016). 
Whilst, they demonstrated increased lipid levels in HIV patients with CNS lesion 
suggesting a critical role of inflammatory lipid in HAND pathophysiology, the lipid species 
involved were not elucidated. To fully understand lipidomic and metabolic changes 
occurring due to advancing disease state, lipid classes and species need to be fully 
identified at the molecular level. Mass spectrometry has emerged as the leading technique 
for accurate, sensitive and detailed lipid analysis (Han and Gross 2003).  Advanced mass 
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spectrometry technologies such as matrix-assisted laser desorption/ionization (MALDI) 
are very useful tools for making available lipidic signature in several disease conditions 
including HAND. 
 
Mass Spectrometry Imaging 
Mass spectrometry imaging (MSI) is a powerful tool allowing molecule investigations 
without extraction, purification, separation, or labeling of biological samples (Chughtai 
and Heeren 2010). MSI was introduced in 1994 by Spengler B., Hubert M. and Kaufmann 
R. at the 42nd Annual Conference on Mass Spectrometry and continue to be used  to 
examine numerous analytes such as lipids (Jackson et al. 2014), proteins (Seeley and 
Caprioli 2008), peptides (Schober et al. 2012), metabolites (Bhandari et al. 2015), drugs 
(Mdanda et al. 2019) in different samples including mammalian tissues, plant tissues (Li 
B. et al. 2018), insects (Ly et al. 2019) and microbial cultures (Hoffmann and Dorrestein 
2015). Mass spectrometry imaging determines the molecule distribution present in 
biological samples by direct ionization from the tissue surface and without the requirement 
for chromatographic separation. The mass spectrometer ionizes and analyzes the molecules 
on the surface of the sample and generates a mass spectrum at each acquisition point (pixel 
in the resulting image) of the tissue section surface. Every mass spectrum is analyzed by 
computational software selecting individual mass-to-charge (m/z) values and calculating 
the intensity from each pixel. Signal intensities are later plotted to generate a heat map 
image showing the relative distribution of every molecule with specific m/z values 
(Buchberger et al. 2018). Matrix-assisted laser desorption/ionization (MALDI) is the most 
sensitive and used ionization technique for MSI (Leopold et al. 2018). For MALDI-MSI, 
fresh frozen samples are used, which are later sectioned (~12 μm thickness), thaw-mounted 
onto the microscope slides (e.g., indium tin oxide coated glass slides for MALDI-MSI 
lipidomics) and placed into a desiccator to dry in order to not compromise molecules 
distribution and structures. MALDI requires matrix or nanoparticles application to 
facilitate the production of charged ions. Commonly used matrices for lipids and small 
molecules include: 2,5-dihydroxybenzoic acid (DHB), 9-aminoacridine (9-AA), 1,5-
Diaminonaphthalene (DAN), and norharmane (NRM) (Goto-Inoue et al. 2011). The matrix 
is typically applied to the tissue by spraying method (Agar et al. 2007). The matrix absorbs 
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the energy of the UV laser resulting in thermal desorption and ionization of the co-crystal 
analytes in the gas phase where they are measured using by a mass analyzer (Karas and 
Kruger 2003). The tissue remains intact and the same section can be washed with methanol 
and used for histological examinations (Schwamborn and Caprioli 2010). The use of high-
mass resolution and high mass accuracy analyzers (such as the Orbitrap) provides specific 
and unequivocal information about the elemental composition of the desorbed ion from the 
tissue (Landgraf et al. 2009).  
Although MALDI-MS is used in lipidomics, proteomics, metabolomics, and glycomics, 
several reasons have encouraged the use of MSI for lipids. As discussed before, lipids are 
abundant molecules in the cells, especially in the membranes, and they can be easily 
ionized in order to generate abundant positive or negative ions during the MALDI process. 
Moreover, many (but not all) lipids have molecular weights below 1,000 Daltons, that is 
an optimal mass range for their diffusion into the matrix crystals and for sensitive operation 
of MALDI (Berry et al. 2011). Whether lipids can be detected in positive mode or negative 
mode depends upon the charge of the head group. Several types of lipids, such as 
phospholipids (Zaima et al. 2009), neutral lipids (Hayasaka et al. 2009), glycolipids (Goto-
Inoue et al. 2010), and fatty acids (Hayasaka et al. 2010) have been investigated by MSI. 
Multiple lipid species have been identified as potential markers for diseases including 
cancer (Paine et al. 2019), cardiovascular infarction (Menger et al. 2012), Alzheimer’s 
(Hong et al. 2016), and  hepatitis B (Park E. S. et al. 2014). 
For example, MALDI-MSI was applied to investigate specific host lipidic distribution as 
well as for accurate localization of Mycobacterium Tuberculosis in pulmonary granulomas. 
Using serial sections to perform MALDI-MSI assessed the spatial distribution of drugs for 
tuberculosis and mycobacterial glycolipids in lesion sections detected by acid-fast staining 
and microscopy. Thus, they obtained a perfect map of drugs colocalizing with specific 
metabolites and bacterial target populations (Blanc et al. 2018, Prideaux et al. 2015a, 
Prideaux et al. 2015b, Zimmerman et al. 2018). Using a similar approach, we have applied 
MALDI-MSI lipidomic analysis to investigate lipidic dysregulations that are very common 
in pathological conditions such as HAND. We identified in post-mortem brain tissues 
multiple structural lipids that maintain their distribution and abundance under HIV 
condition indicating little to no structural damage is occurring in these tissues. However, 
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we detected significant changes in sulfatide brain distribution and abundance compared to 
the control condition. Thus, we proposed sulfatide as a potential indicator of 
neurocognitive impairment. In the future, we want to expand our research to detect this 
specific lipid in the blood or in the CSF of HIV-infected patients and predict CNS damage.  
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Part IV - Aims of the study 
This Ph.D. thesis aims to test the hypothesis that “neurocognitive decline in HIV-infected 
population is mediated through CNS viral reservoirs by local lipid dysregulation”. To 
address this hypothesis, we generated a protocol to identify, localize, and quantify viral 
reservoirs in HIV-infected brain and lymph node tissues. We identified that the cells with 
HIV-integrated DNA are not totally silent and still producing viral proteins even in patients 
under efficient cART. In addition, viral proteins diffused to the neighboring uninfected 
cells. Therefore, viral reservoirs were shown to generate CNS damage using a bystander 
mechanism. Using MALDI-MSI, we aimed to identify whether altered lipid distribution in 
both grey and white matter could be involved in bystander damage. We identified sulfatide 
as a potential indicator for HAND pathogenesis. We also determined that HIV proteins can 
induce the secretion of sulfatide. Subsequently, we examined sulfatide effects by detecting 
key molecules involved in cell-to-cell communication such as Connexin43, Connexin36 
and Zonula Occludens-1. Additionally, we investigated the extracellular effects of sulfatide 
on cellular metabolism by performing proteomics analysis and cell mito stress Seahorse.  
Through the following aims, we intend to provide evidence for a new mechanism that can 
justify CNS viral reservoirs and lipid alternation connection with HAND.  
For the future, we will complete and expand our data to identify whether sulfatide and its 
biosynthetic pathways can be potential pharmaceutical targets to cure or prevent 
neurocognitive impairment in HIV-infected population that under cART show an 
undetectable viral replication.  
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Introduction 
HIV persists in the body of infected individuals despite effective c-ART due to the 
presence of viral reservoirs in different tissues (Balcom et al. 2019, Blankson et al. 2002). 
Viral reservoirs are characterized as a small population of cells with integrated HIV DNA 
into the host DNA that does not produce or produce low levels of virus. This process is 
called latency (Dahabieh et al. 2015). Upon cART interruption, virus rebounds and 
repopulates the body in few weeks (Sengupta and Siliciano 2018).  Currently, most viral 
reservoir studies are performed in blood due to the easy access. The current clinical limit 
of viral detection is 20-50 HIV RNA copies (Tan et al. 2018). However, recent advances 
in the field indicate that most viral reservoirs are present in different tissue compartments 
(Lamers et al. 2016). Several tissues have been proposed as anatomical compartments for 
viral reservoirs including gastrointestinal mucosa, the liver, the brain, the lymph nodes and 
the associated lymphatic tissues, and the genital tract (Svicher et al. 2014). Currently, there 
are two schools of thought about viral reservoir compartmentalization; one describes that 
there is no difference between viral strains and evolution in tissues versus the blood (Bozzi 
et al. 2019) and a second one that indicates that virus and viral reservoirs in different tissues 
can evolve in a different way than blood strains (De Scheerder et al. 2019). Most of these 
views are based on sequencing of HIV strains because there are no available techniques to 
detect viral reservoirs in tissues in a reliable manner. Also, all the techniques that detect 
and quantify viral reservoirs are based on the detection of only one component of the virus 
such as viral DNA, mRNA or proteins. These techniques to detect viral reservoirs are 
described in Table 1, overall, they involve the particular amplification of the viral reservoir 
population or viral component by inducing proliferation and selection by viral reactivation 
with phytohaemagglutinin (PHA) and phorbol myristate acetate (PMA). However, it is 
unclear whether these amplification systems overrepresent or only detect a partial size of 
the total viral reservoirs poll (Finzi et al. 1997, Massanella et al. 2018).  
Viral reservoirs are characterized by having a potentially productive HIV DNA 
integrated into the host DNA (Pinzone and O'Doherty 2018). Moreover, HIV DNA 
integration cannot assure viral replication because there are several mechanisms that could 
compromise HIV replication including mutations, wrong site or direction of integration, 
and epigenetic regulation (Abbas and Herbein 2012, Cary et al. 2016). If the HIV DNA 
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enables viral production, viral mRNA will be produced upon infection or reactivation. 
Viral mRNA expression results in viral protein production and subsequent viral particle 
assembly and release of mature virions. However, the ratio of HIV integration, viral RNA 
and protein production, are totally unknown in viral reservoirs. Several laboratories 
indicate that during effective cART, several HIV proteins are produced and several animal 
models overexpress them (Nesbit and Schwartz 2002). Furthermore, these viral proteins 
are secreted as soluble proteins and the proteins, not the virus, induce inflammation and 
bystander damage into the neighboring cells. However, there are no data in vivo that show 
this mechanism in latently HIV-infected individuals. Most of these models are accepted 
mechanisms but not based on strong data. The main problem to demonstrate that these 
models and bystander mechanisms of damage are present is due to the inability to correctly 
identify, localize, and quantify latent HIV reservoirs within infected individuals in the 
circulation and in the tissues. 
One of the major objectives of this thesis was to design, test, and validate a method 
to detect, localize, and quantify viral reservoirs in tissues and in circulation using a multi-
probe and antibody-based system visualized using microscopy. Our method enables the 
identification of HIV integrated DNA, HIV mRNA, and several viral proteins in a single 
test.  
 
Materials and Methods 
Sample Preparation 
Human brain and lymph node tissue blocks were obtained from the National NeuroAIDS 
Tissue Consortium (NNTC). The patient information are indicated in Table 2. Fixed and 
unfixed tissue blocks were cut in seven µm thick tissue serial sections using a Leica 
RM2235 microtome or Leica CM1850 cryostat (Buffalo Grove, IL) and thaw-mounted 
onto frosted glass microscope slides. After sectioning, unfixed tissues were fixed with PFA 
4% (15710-S, Electron Microscopy Science, Hatfield, PA) for 20 minutes and stored at 4 
ºC.  
For blood, an entire Leukopak was used to isolate PMBC using Ficoll-Paque (GE17-1440, 
GE Healthcare, Chicago, IL). Centrifugation of 30 minutes at 400 x g was required to 
obtain a clean buffy coat and an additional centrifugation of 10 minutes at ≥450 x g was 
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necessary for removing the ficoll from the white cells. The PMBC pellet obtained was 
sliced and fixed with PFA 4%.  
For all these analyses serial sections were essential to perform 3D reconstructions of large 
pieces of tissues with the main objective to quantify thousand-millions of cells in the 3D 
reconstructed samples. 
 
Protocol for Detecting Viral Reservoirs (fixed and fresh tissue blocks) 
Rehydration: 
1. Immerse slides into two separate xylene solutions, 5 minutes each. 
2. Immerse slides into two separate solutions containing 100% ethanol, 3 minutes 
each. 
3. Immerse slides into a solution containing 96% ethanol dissolved in ddH2O, 3 
minutes. 
4. Immerse slides into a solution containing 90% ethanol dissolved in ddH2O, 3 
minutes. 
5.  Immerse slides into a solution containing 70% ethanol dissolved in ddH2O, 3 
minutes.  
6.  Immerse slides into a solution containing 60% ethanol dissolved in ddH2O, 3 
minutes.  
7.  Immerse slides into a solution containing 50% ethanol dissolved in ddH2O, 3 
minutes.  
8.  Immerse slides into pure water for at least 3 minutes. 
5. Encircle the specimen with Dako Pen (cat # 52002). 
6. Immerse slides into a solution of pure water for 3 minutes. 
 
Pre-treatment: 
7. Place slides in humidity chamber. 
8. Dilute the needed amount of Proteinase K (0.01 mol/ml, K5201, Dako products-
Agilent Technologies, Santa Clara, CA),1:10 in TBS. 
9. Add 150 µl of diluted Proteinase K to each section and incubate for 10 minutes at 
room temperature. 
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11. Immerse slides into pure water for 3 minutes. 
12. Immerse slides in 96% ethanol for 20 seconds and air-dry the slides for 5 minutes. 
 
DNA probe Hybridization: 
13. Dilute probe stocks to 10 µM in TBS and add to the specific sections Nef-PNA 
Alexa 488 (Alexa488-GCAGCTTCCTCATTGATGG) and Alu-PNA Cy5 (Cy5- 
GCCTCCCAAAGTCGTGGGATTACAG) (PNA Bio, Thousand Oaks, CA).  
14. Place slides in a pre-warm humidity chamber. 
15. Incubate slides at 42 ºC for 30 minutes then at 55 ºC for 1 hour. 
Note: from this point try to work in the dark. 
 
DNA Probe Stringent wash: 
16. Preheat stringent wash working solution (PNA ISH kit, K520111-2, Dako products-
Agilent Technologies, Santa Clara, CA) diluted 1:60 to 55 ºC in a water-bath. 
17. Place slides in stringent wash solution for 25 minutes in an orbital shaker at 55 ºC. 
18. Equilibrate the slides to room temperature by immersion in TBS for 20 seconds. 
Note: Probe will be detected in the subsequent steps.  
 
Viral RNA Probe detection: 
21. Place slides in humidity chamber. 
22. Apply RNAscope probe (HIV RNAscope 2.5 HD Detection Reagent–RED Kit, 
322360, ACD). 
23. Incubate slides at 42 ºC for 30 minutes then at 55 ºC for 50 minutes. 
Note: the autofluorescence of the probe is used for accurate measure. 
 
RNA Probe Stringent wash: 
24. Preheat stringent wash working solution (PNA ISH kit, K520111-2, Dako products-
Agilent Technologies, Santa Clara, CA) diluted 1:60 to 55 ºC in a water-bath. 
25. Place slides in stringent wash solution for 15 minutes in an orbital shaker at 55 ºC. 
26. Equilibrate the slides to room temperature by immersion in TBS for 20 seconds. 
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Hybridize RNA (RNAscope 2.5 HD Detection Reagent–RED kit, 322360, ACD): 
26.  Add three drops of tube 1 and incubate for 30 minutes at 40 ºC. 
27.  Immerse slides in TBS for 5 minutes. 
28.  Add three drops of tube 2 and incubate for 15 minutes at 40 ºC. 
29.  Immerse slides in TBS for 5 minutes. 
30.  Add three drops of tube 3 and incubate for 30 minutes at 40 ºC. 
31.  Immerse slides in TBS for 5 minutes. 
32.  Add three drops of tube 4 and incubate for 15 minutes at 40 ºC. 
33.  Immerse slides in TBS for 5 minutes. 
34.  Add three drops of tube 5 and incubate for 30 minutes at room temperature. 
35.  Immerse slides in TBS for 5 minutes. 
36.  Add three drops of tube 6 and incubate for 15 minutes at room temperature. 
37.  Immerse slides in TBS for 5 minutes. 
36.  Add three drops of tube RED and incubate for 10 minutes at room temperature. 
37.  Immerse slides in TBS for 5 minutes. 
 
Immunofluorescence: 
38. Perform antigen retrieval incubating the section in antigen retrieval solution 
(S1700, Dako products-Agilent Technologies, Santa Clara, CA) at 80 ºC in water-bath for 
30 minutes. 
39. Permeabilize with Triton X-100 (X-100, Sigma-Aldrich, St. Luis, MO) 0.1% in 
TBS for 2 minutes. 
40.  Block unspecific binding sites of presence of Fc receptors using the blocking 
solution (1 ml 0.5 M EDTA pH 8.0 (15575-038, Thermo Fisher Scientific, Waltham, MA), 
100 μl gelatin from cold-water fish skin (G7765, Sigma-Aldrich, St. Luis, MO), 0.1 g 
bovine serum albumin (BSA immunoglobulin-free, A2058, Sigma-Aldrich, St. Luis, MO; 
or BSA fraction V,  BP1605, Thermo Fisher Scientific, Waltham, MA), 100 μl horse serum 
(H1138, Sigma-Aldrich, St. Luis, MO), 5% human serum (Corning, New York), and 9 ml 
ddH2O) to incubate the sections for at least 1 hour at room temperature or overnight at 4 
ºC.  
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41. Applied biotinylated primary antibodies for viral proteins (p24 GXT40774, Irvine, 
CA; integrase NIH 7374; Gp120 NIH 1476; tat NIH 705; Nef NIH 2949; Vpr NIH 3951) 
and cellular markers (Iba-1, anti-goat, dilution 1:200, ab5076, Cambridge, UK; and GFAP, 
anti-mouse, dilution 1:100, G3893, Sigma-Aldrich, St. Luis, MO) and incubate overnight 
at 4 ºC. 
42. Wash 3 times with TBS every 5 minute to eliminate the unbound antibodies. 
43. Add the secondary antibodies at the right dilution and incubate for at least 2 hours. 
44. Wash 3 times with TBS every 5 minute to eliminate the unbound antibodies. 
45. Mount slides with Prolong Diamond Antifade Mount Medium containing DAPI 
(P36930, Thermo Fisher Scientific, Waltham, MA).  
 
Analysis: 
To identify the probes and the antibodies a Nikon A1 confocal microscopy with spectral 
detection was used. Absorption and emission of each fluorophore were examined using 
spectral detection to narrow the wavelengths into 20-40 nm. These analyses were also 
performed using RNAscope due to the significant amount of red color present in uninfected 
samples. The fluorescent detection of RNAscope precipitate was only found in HIV 
infected samples. For further analysis, NIS Elements (Japan) and other proprietary software 
were used.  
 
Statistical Analysis  
All data were expressed as mean ± standard deviation (STD). Differences among groups 
were analyzed by the one-way analysis of variance (ANOVA test), using Bonferroni’s 
multiple comparison test for post-hoc analysis. The level of significance was accepted at 
p<0.05. Origin v9.0 software was used for all statistical analyses performed. 
 
Results 
Identification of viral reservoirs by staining and microscopy method. As described in 
Table 1, the current techniques to detect viral reservoirs are limited to circulating cells. 
Specifically, quantitative viral outgrowth assay (QVOA), Tat/rev induced limiting dilution 
assay (TILDA), and PCR based methods use large amount of blood and require 
49 
 
proliferation and reactivation by PHA and PMA, resulting in overestimation of the viral 
reservoirs. Using these techniques, the sensitivity is 0.02 copies per million cells (see 
details in Table 1). Moreover, all these methods detected only one component of the viral 
cell cycle (e.g. viral DNA, viral mRNA or viral proteins). Thus, the size of HIV reservoirs 
within infected individuals virally suppressed with cART is not well defined.  
 To develop a better system, we generated new methodologies for multi probe and 
antigen detection to identify, localize and quantify viral reservoirs as described in Figure 
2.1. Briefly, to detect multiple HIV and host markers, we sectioned large pieces of tissues 
(cm or inches) to detect a sufficient number of total cells, due to the presence of only one 
viral reservoir into millions of uninfected cells. In addition, to the large pieces, we also 
prepared serial sections to create a sufficient volume to perform 3D reconstructions if 
required.  
The main premise and specificity of our method is based on a redundant system of control 
probes and staining to assure proper viral reservoir detection.  Briefly, for the HIV-DNA 
probe to be considered as a positive signal it needs to colocalize with Alu-repeats probe. 
Alu repeats are abundant repetitive DNA sequences dispersed throughout the human 
genome (Batzer and Deininger 2002). Also, both HIV DNA and Alu repeats need to 
colocalize with DAPI. Any inconsistence of these colocalizations indicates un-specificity. 
However, minor inconsistences were observed (data not presented). For viral mRNA, 
signal does not colocalize with DAPI and Alu-repeats due to the different subcellular 
distribution. A similar selection for specificity was used for HIV viral proteins. An example 
of staining protocol is presented in Figure 2.1. Serial sections were used to perform the 
staining for HIV-integrated DNA (DNA Nef probe), HIV mRNA (RNA scope), Alu 
repeats (DNA probes), DAPI (nuclear staining), HIV proteins (p24, integrase, Gp120, Tat, 
Nef, or Vpr) and cellular markers (Iba-1 and GFAP). In addition, H&E and trichrome 
staining were also performed and repeated between the staining to evaluate the changes in 
morphology of serial tissue sections used to identify the viral reservoirs.  So far, we have 
identified myeloid and lymphoid viral reservoirs in bone marrow (Real F. et al. in press), 
vaginal, and urethral tissues (Ganor et al. 2019). Currently, we are expanding our 
identification of viral reservoirs into other human tissues and HIV/SIV animal models.  
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Identification, localization, and quantification of HIV reservoirs within the brain of 
HIV-infected individuals.  Based on the literature, two populations of CNS cells have 
been identified in the pre-cART to be HIV infected in vitro and in vivo, they are 
microglia/macrophages and a small population of astrocytes (Clayton et al. 2017, Li G. H. 
et al. 2016). Nevertheless, their contribution to CNS damage and to the pool of viral 
reservoirs is still controversial due to the lack of reliable data in the current cART era. 
Thus, we applied our protocol to large pieces of brain and lymph node tissue sections to 
detect viral components (HIV DNA, mRNA and viral proteins) in combination with 
staining for microglia/macrophages and astrocytes (positive cells for Iba-I and GFAP, 
respectively). 
Using cortical brain tissue sections obtained from uninfected and HIV-infected 
individuals under cART (see patient information in Table 2), we stained the tissues as 
described in Figure 2.1. In the patient samples analyzed we detected few cells with HIV-
Nef DNA colocalizing with DAPI and Alu-repeats. Our analysis identified that most of the 
HIV-integrated DNA (colocalizing with DAPI and Alu-repeats) was in Iba-1 and in a small 
percentage of GFAP positive cells. A representative example was given in Figure 2.2, 
where it is shown that one section of an image 6x6 covers approximately 1500 µm2. This 
area was multiplied by 6 fields to either side. Furthermore, this figure represents only 1 
tissue section of 12 serially analyzed (84 to 144 µm combined thickness, depending on the 
protocol). Thus, the analyzed area was large enough to detect the few infected cells in a 
pool of million uninfected cells.  
Interestingly, positive cells for HIV-DNA were always in clusters of 3-10 cells 
containing virus, suggesting a cooperative niche generated by HIV-infected cells within 
the brain. Most of these clusters were closely associated with blood vessels and areas rich 
in neuronal bodies. Unequivocally, HIV-integrated DNA had never been detected in Iba-1 
and GFAP negative cells such as endothelial cells or neurons. Thus, our results confirmed 
that our innovative strategies to detect viral reservoirs is extremely specific and 
demonstrates that the virus infects microglia/macrophages and a small population of 
astrocytes in the CNS. In conclusion, our data in vivo determines that HIV-reservoirs are 
present in a small population of CNS resident cells such as microglia/macrophages but also 
in a smaller population of astrocytes (see quantification in Figure 2.5). 
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The same specificity that we detected for HIV-integrated DNA was obtained for 
HIV mRNA (data not shown). Overall, minimal colocalization with DAPI and Alu-repeats 
was found because HIV mRNA is mainly localized in the cytoplasm.  Moreover, HIV 
mRNA staining was detected only in cells containing HIV-integrated DNA (see 
quantifications in Figure 2.5 B). However, only half of the cells having integrated DNA 
also expressed HIV mRNA. The mechanism of low expression of mRNA in HIV DNA 
positive cells could be explained by the use of cART that induced an effective viral control, 
or by the presence of abortive sequences of DNA, as well as by the lack of right reactivation 
mechanism or latency (Cary et al. 2016, Ishizaka et al. 2016, Kaiser et al. 2017, Pasternak 
and Berkhout 2018, van den Dries et al. 2017). Again, mRNA was only detected in cells 
that could support viral replication such as microglia/macrophages and a small population 
of astrocytes. No unspecific staining for HIV mRNA was observed in other cell types or 
uninfected tissues. An important note is the specificity of the spectral detection system to 
detect viral mRNA over traditional colorimetric systems promoted by several companies 
(RNAscope). Several laboratories reported unspecific HIV mRNA staining due to aging 
samples or precipitates related to salts or crystals. None of these artifacts were observed if 
the tissues were analyzed by fluorescence. A critical limitation of our approach is that 
currently we can only determine HIV mRNA for Nef. Therefore, it is unknown whether 
other viral mRNAs are produced. Future experiments will focus on developing probes and 
approaches to analyze additional viral mRNAs to complete these studies.   
 
A small population of the viral reservoirs express viral proteins in the current cART-
era. Using the same human tissue samples described above, we quantified the number of 
positive cells for Nef, Gp120, Integrase, Vpr, and Tat protein. As an example of the 
analysis, we focus this discussion on the data acquired for HIV Nef protein, but the results 
need to be expanded for all the proteins indicated (Figure 2.5 C). In cells containing HIV 
integrated DNA and expressing HIV Nef mRNA, only 2% of these cells expressed HIV-
Nef protein in tissues obtained from HIV infected individuals under cART (Figure. 2.5 B). 
As a positive control, HIV encephalitic (HIVE) brain tissue was used.  In HIVE conditions 
HIV-integrated DNA, perfectly correlated with expression of HIV Nef mRNA and Nef 
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protein expression as expected due to the high HIV replication rates observed in the brain 
of HIV-infected individuals without cART (Figure 2.5 B).  
However, HIV Nef protein did not fully colocalized with cells containing HIV-
integrated DNA, suggesting that viral proteins, including Nef, gp120, Integrase, Vpr, and 
Tat, diffuse or are secreted into neighboring uninfected cells (Fig. 2.5 B and C). The most 
abundant viral proteins secreted into neighboring uninfected cells were Nef, Gp120, Vpr 
and Tat (Figure 2.5 C). Secretion of Integrase protein was less than other proteins analyzed, 
but still significant as compared to cells containing HIV-integrated DNA (Figure 2.5 C).  
In contrast, in HIVE tissues a perfect correlation was observed between Nef, Gp120, 
Integrase, Vpr and Tat protein expression in cells containing HIV-integrated DNA and 
uninfected surrounding cells (Figure 2.5 C).  
Figure 2.3 and 2.4 show representative examples of human brain tissue sections 
stained for DAPI, Gp120 protein, HIV-Nef DNA and Iba-1. In Figure 2.3, we showed the 
staining for human brain tissue from a HIV-infected patient under cART, with a normal 
CD4 count and without systemic viral replication, where it was possible to observe that 
cells positive for HIV-Nef DNA (in green), for Alu repeats (data not shown) and Gp120 
protein (in red) corresponded to macroglia/macrophages (Iba-1 positive in white). 
However, most of the Gp120 signals did not colocalize with HIV-Nef DNA in 
microglia/macrophages, suggesting that Gp120 diffused from the HIV-integrated positive 
cells into the neighboring cells. No unspecific staining was detected in human brain tissue 
sections from uninfected individuals (Figure 2.4).  
 
Quantification and extrapolation of our results into the size of the viral reservoirs 
within the brain. In the field of viral reservoirs, several questions need to be addressed for 
the brain. 1) Are there infected cells within the brain in the current cART era? 2) Are there 
viral reservoirs within the brain? 3) Which are the cell types infected in vivo? And 4) Is the 
brain a significant anatomical compartment for viral reservoirs compared to other tissues? 
To address these questions, we extrapolated our data into the entire brain (Table 3) as 
compared to our data in lymph nodes (Table 4). Our data, described above, can give an 
answer for the first three questions. To address the last question, we calculated the volume 
of tissue analyzed versus the entire volume of the human brain (Figure 2.6). We repeated 
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the same analysis for the total human lymph nodes. Two important caviars of these 
extrapolation are present. First, cortex tissue was used, other brain structures (such as basal 
ganglia) have higher levels of HIV-infected cells, this means that the total number of viral 
reservoirs may be bigger. Second, we quantified the total number of reservoirs including 
all lobes of the cerebrum, the basal ganglia, the thalamus, the ventricles and the 
hippocampi, excluding the cerebellum and peripheral areas. 
Our analysis for brain used 8 serial sections of large brain areas obtained from 
uninfected and HIV infected individuals with different sizes as indicated in Figure 2.6 A. 
Overall, we estimated that the volume analyzed was 0.005152 cm3 (Figure 2.6 B).  The 
numbers of total Iba-1 positive cells (microglia/macrophages) containing HIV DNA was 
5170 ± 6689 cells in the volume analyzed. Also, the total number of GFAP positive cells 
(astrocytes) containing HIV DNA corresponded to 1645 ± 2128 cells in the volume 
analyzed; thus, combining the numbers of both populations, the total numbers of cells 
containing HIV DNA was 6580 ± 8514 in the volume analyzed (Figure 2.6 D).  
 If we consider that the total volume of the human brain in males is 1135 cm3 and 
female is 1003 cm3 including all lobes of the cerebrum, the basal ganglia, the thalamus, the 
ventricles and the hippocampi (Allen et al. 2002). Thus, the mean volume of the brain is 
1069.1 cm3 (Figure 2.6 D). Furthermore, overall quantifications of the numbers of cells in 
the entire brain indicate that the human brain contains approximately 1.1 trillion cells 
between neurons and glia (von Bartheld et al. 2016).  
To extrapolate our data into the entire brain several assumptions were used: first, a 
mean brain volume between male and female; second, a uniform distribution of viral 
reservoirs even that dopaminergic areas, not quantified in our analysis, that in general have 
higher numbers of HIV infected cells (Gaskill et al. 2014, Purohit et al. 2011); third, a 
constant ratio between glia/neurons/and other cell types to maintain similar percentages. 
Overall, the ratio between total brain volume and volume of the sample analyzed 
corresponded to 207511.6 fold. Thus, the total numbers of cells with HIV-integrated DNA, 
expressing viral mRNA and viral proteins can be calculated as described in Table 3.  
Analyzing the lymph nodes, we considered that the human body contains ~500 
lymph nodes and one lymph node, oval in shape, has a mean volume of 1.6 cm3 
(https://opentextbc.ca/anatomyandphysiology/chapter/21-1-anatomy-of-the-lymphatic-
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and-immune-systems/). Thus, the mean volume of the total lymph nodes in the human body 
is 785.4 cm3 and the ratio between total volume of all the lymph nodes and volume of the 
sample analyzed corresponded to 457692.3 fold. In addition, we evaluated that the 
lymphocytes in the total lymph nodes are approximately 0.5 trillion 
(https://assets.thermofisher.com/TFS-Assets/LSG/brochures/I_WEB.pdf). Thus, we 
extrapolated the numbers of lymphocytes with HIV-integrated DNA, expressing viral 
mRNA and Gp120 proteins for the total lymph nodes of the human body (Table 4). We 
calculated that the 7.8% of lymphocytes of the total cells in all the human lymph nodes 
presented HIV-integrated DNA, 4.6% presented HIV-integrated DNA and HIV mRNA, 
and the 0.6% were in addition positive for Gp120 (Table 4). Consistent with the brain 
quantification of viral reservoirs (Table 3), lymphocytes negative for HIV-integrated DNA 
and presenting Gp120 protein were higher (2%) compared to the lymphocytes positive for 
HIV-integrated DNA and Gp120 protein, confirming the bystander effect of HIV proteins 
also in lymph nodes. Comparing the brain with the 500 lymph nodes of the human body, 
the total number of microglia/macrophages and astrocytes with HIV-integrated DNA is 
1/62 of the total lymphocyte reservoirs with HIV-integrated DNA in the lymph nodes. 
However, lymph nodes may present higher levels of viral reservoirs compared to brain, as 
for this reason used as a control, it is necessary to consider that the lymphoid tissues are 
important sites of viral replication during active infection and are numerous (Huot et al. 
2018, Wong and Yukl 2016). Nevertheless, we showed that brain is a valid anatomic niche 
for viral reservoirs. 
In conclusion, our data demonstrated several points. First, our methodology cannot 
only detect viral reservoirs, but can identify cells with active replication and viral protein 
synthesis. Second, our method enables us to detect bystander protein secretion or diffusion 
into uninfected cells. Third, certainly, the brain contains HIV reservoirs. Fourth, these viral 
reservoirs are mostly microglia/macrophages and a small population of astrocytes. Fifth, 
the brain is a considerable viral reservoir compartment, compared to the lymph tissues.  
 
Discussion  
HIV, as well as other viruses, has evolved to persist within the host. HIV persistence 
involves the generation of viral reservoirs that remain undetectable in cellular and 
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anatomical sites (Denton et al. 2019). As discussed in the general introduction, most of the 
current techniques to detect viral reservoirs only detect one component of the viral cell 
cycle and require amplification or cell proliferation for efficient detection. Our method is 
extremely sensitive, reliable and specific for all the components analyzed.  We did not 
detect any signal in uninfected tissues and the negative and positive controls included in 
the methodology were reliable.  
 Overall, the numbers of detected viral reservoirs were lower than the described data 
in isolated microglia/macrophage and astrocytes (Castellano et al. 2017, Churchill et al. 
2009, Russell et al. 2017, Thompson et al. 2011). Thus, our data in vivo may be 
representative of the more realistic number of viral reservoirs present in HIV-infected 
individuals under effective cART, with low numbers of HIV-infected cells, with minimal 
viral mRNA and protein synthesis. Also, in the current cART era, not all the 
microglia/macrophages and astrocytes contain HIV. Thus, there is a selection mechanism 
that is not full known. 
 An important point to discuss is that for the first time, we can detect basal synthesis 
and release of several HIV proteins in tissue samples from HIV-infected individuals under 
effective cART, with normal CD4 counts and undetectable systemic replication. This result 
is unique and validates the multiple papers describing the toxic and inflammatory effects 
of viral proteins in tissue cultures and animal models without active HIV replication (Jaeger 
and Nath 2012, Kanmogne et al. 2002, Kovalevich and Langford 2012, Nath 2002). 
The clustering of the cells between microglia/macrophages and astrocytes denote a 
unique symbiosis between both cell types to keep viral reservoirs within the brain.  Viral 
reservoirs in the brain, but not in the lymph nodes, aggregate into cellular clusters. In the 
brain most clusters were close to the blood vessels. Contrary to the belief that viral 
reservoirs are only present in different kinds of CD4+ T cells, the identification of infected 
microglia/macrophages and astrocytes indicate that several cells may be infected with HIV. 
Recent data from our laboratory showing that specific macrophages of the urethral tissue 
and megakaryocytes can be infected with HIV (Ganor et al. 2019). Furthermore, data of 
human macrophages identified several mechanisms of survival that are not present in CD4+ 
T cells and require urgent examination to eliminate these cells.  
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 Our data provides a unique demonstration of the presence of viral reservoirs within 
the brain and their contribution to chronic inflammation and bystander damage is mediated 
by several HIV proteins. Our accurate process of localization and quantification is essential 
for the development of therapeutic strategies targeting specific areas of viral reservoirs and 
to treat HIV comorbidities such as the neurocognitive manifestations seen in HAND.  
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Table 1. Summary of the current techniques used to identify circulating associated 
viral reservoirs. Sample size indicates the amount of blood required; assay input reveals 
the cells used; amplification required means the necessity of clones to proliferate or 
sequences to be amplified before the assay; limits of detection indicates the lowest number 
of cells detectable.   
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Table 2. Clinical data of HIV-infected and uninfected patients. Tissues of the patients, 
provided by NNTC, used for this thesis. Data show the status of infection, the gender, the 
age, the possible cART administration during life, the last CD4 count (NP means not 
provided) and viral load of the patients analyzed plus the years following HIV diagnosis.  
Specifically, patients 1 to 5 were HIV-infected, instead, patients 6, 7, and 8 were HIV-
uninfected and used as controls. 
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Figure 2.1. Summary of the microscopy and staining protocols used to detect viral 
reservoirs. (A) Detection method. For our methodologies, blood or tissues can be used to 
detect circulating or tissue-associated viral reservoirs. Blood was prepared as described in 
the materials and methods section. Tissue sections can be unfixed or fixed with PFA 4% 
as explained in materials and methods section. The improved methods to detect viral 
reservoirs included hydration, antigen retrieval, RNA treatment, blocking and 
autofluorescence elimination that are well explained in the materials and methods section. 
The staining involved the use of 2 DNA probes, one for HIV DNA and one for Alu repeats; 
an RNA probe for HIV Nef mRNA; DAPI for the nuclear staining; and several antibodies 
for HIV and host cellular proteins. To amplify the small signals present in viral reservoirs, 
we take advantage of the biotin-streptavidin amplification system. The detection system 
required camera, software, automatic detection and algorism/spectral detection. This 
protocol was analyzed using Confocal-Stochastic Optical Resolution microscopy 
(STORM) with spectral detection capabilities. (B) Representative picture of 12 stained 
serial sections, reconstructed to generate a 3D map of the viral reservoirs. (C) 
Representative example of the protocol used to detect viral reservoirs. Serial sections were 
generated for a large piece of tissue and sections 1,11 and 12 were used to perform H&E 
and trichrome staining to assess histology and volume changes (62 µm of distance between 
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section 1 and 11). Serial sections 2, 7 and 10 were used to stain DAPI, HIV-integrated 
DNA, HIV mRNA, Alu repeats, and p24 protein to evaluate the correct 3D reconstruction 
of the tissue considering that the size of the cells is ~40 µm. Serial section 3 was stained 
for DAPI, HIV-integrated DNA, Iba-1 (microglia/macrophages marker), and GFAP 
(astrocytes marker). The other serial sections were stained for DAPI, HIV-integrated DNA, 
HIV mRNA, and HIV proteins such as Gp120, Integrase, Nef, Vpr, and Tat. Overall this 
experiment investigated 84 µm (in thickness) of tissue.  
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Figure 2.2. Representative example of staining for DAPI, HIV-Nef DNA, Iba-1 and 
GFAP in human brain tissue of HIV-infected patient under cART, with a normal 
CD4 count and without systemic viral replication. Shown is a positive field of 1500 µm2 
from a 6 by 6 picture, where it is possible to observe cells positive for HIV-Nef DNA (in 
green) and for Alu repeats (data not shown). These HIV-integrated DNA cells correspond 
to macroglia/macrophages (Iba-1 positive in red) and astrocytes (GFPA positive in white) 
that generate clusters as indicated by the arrows. Clusters are made by 3 to 10 cells located 
in the sample place. 
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Figure 2.3. Representative example of staining for DAPI, Gp120 protein, HIV-Nef 
DNA and Iba-1 in human brain tissue of HIV-infected patient under cART, with a 
normal CD4 count and without systemic viral replication. Shown is a positive field 
from a 6 by 6 picture, where it is possible to observe cells positive for HIV-Nef DNA (in 
green), for Alu repeats (data not shown) and Gp120 protein (in red). These HIV-integrated 
DNA and Gp120 protein positive cells correspond to macroglia/macrophages (Iba-1 
positive in white), as indicated by the white arrows. But most of the Gp120 signals do not 
colocalize with HIV-Nef DNA in microglia/macrophages, as indicated by the yellow 
arrows, suggesting that Gp120 can diffuse into the neighboring cells negative for HIV-
integrated DNA. 
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Figure 2.4. Human brain uninfected tissue showing no staining for HIV-Nef DNA and 
Gp120 protein. The staining is only positive for DAPI showing nuclear localization and 
Iba-1 indicating microglia/macrophages in the tissue. 
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Figure 2.5. Quantification of the viral reservoirs in brain tissue. (A) Identification of 
cell containing HIV-integrated DNA in human brain tissue sections. HIV-integrated DNA 
was not detected in any of the uninfected tissues analyzed. Between the HIV-infected brain 
tissue sections, we counted a total amount of 4-9x106-7 cells. From them, the HIV-integrated 
DNA positive cells represented 0.014% of the total volume analyzed. 0.011% of these cells 
were Iba-1 positive identifying microglia/macrophages and 0.003% were GFAP positive 
identifying them as astrocytes (* p<0.0001). (B) Identification of localized HIV-integrated 
Nef DNA, HIV Nef mRNA and Nef protein in uninfected, HIV-infected and HIV-
encephalitis conditions. HIV-integrated DNA, HIV-mRNA, and Nef protein were not 
detected in any of the uninfected tissues analyzed. Between the HIV-infected brain tissue 
sections we counted 600-1500 of HIV-integrated DNA positive cells that represent the 20% 
of the total cells, 8% of them were HIV mRNA positive and 2% were Nef protein positive. 
These small percentages are due to administration of cART during the life of the patients 
considered. HIV-encephalitis was used as a positive control for its correlation between 
HIV-integrated DNA, HIV mRNA and viral proteins. Moreover, Nef proteins were also 
located in the neighboring HIV-associated DNA negative cells, suggesting HIV protein 
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diffusion in both HIV and encephalitis conditions (* p<0.0001). (C) Identification of HIV 
proteins (Nef, Gp120, Integrase, Vpr, Tat) in HIV-integrated DNA positive and negative 
cells within uninfected, HIV-infected and HIV-encephalitis human brain sections. No viral 
proteins were detected in uninfected tissues. HIV-encephalitis human brain tissue sections 
indicated a good correlation for all the HIV proteins in HIV-integrated DNA positive and 
negative cells. On the contrary, HIV-infected human brain tissue sections showed a major 
localization of the viral protein in HIV-integrated DNA negative cells than the positive one 
(* p<0.0001).   
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Figure 2.6. Explanation of the quantification of HIV reservoirs in human brain 
tissues: rationale for approach. (A) H&E staining section used for calculating the volume 
of the tissue. (B) Quantification of the total brain volume analyzed of 8 human occipital 
cortex slides used to investigate HIV reservoirs, 0.005152 cm3. The number of 4-9x106-7 
cells corresponds to the total cells in one slide. (C) Representation of the analyzed area. 
For the large-scale quantification brain included all lobes of the cerebrum, the basal 
ganglia, the thalamus, the ventricles and the hippocampi. (D) Table showing the numbers 
of cells in the total volume of tissue analyzed, including the total volume of the brain in 
female and male, the average of the human brain volume that we used to quantify viral 
reservoirs in the total brain, and quantification of microglia/macrophages and astrocytes 
with HIV-integrated from the 8 tissue sections analyzed. 
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Table 3. Quantification of HIV reservoirs in the entire human brain.  
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Table 4. Quantification of HIV reservoirs in the total human lymph nodes.  
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Introduction  
As described in Chapter 2, our data generated in vivo demonstrated that 
microglia/macrophages and a small population of astrocytes are infected with HIV and 
survive infection for extended periods of time, even in the presence of cART. In agreement, 
our data in vitro using human primary astrocyte cultures demonstrated that only 5% of cells 
are infected with HIV (Eugenin and Berman, 2007). However, despite the low number, 
HIV-infected astrocytes can trigger bystander cellular dysfunction compromising 
neighboring uninfected endothelial cells, neurons and astrocytes by a gap junction-
dependent mechanism (Eugenin and Berman 2007, Eugenin et al. 2011, Malik et al. 2017). 
Also, our laboratory demonstrated that the bystander mechanism of toxicity was mediated 
by the Cytochrome C, inositol triphosphate, and calcium dependent mechanism (Eugenin 
and Berman 2013). Electron microscopy analysis of HIV-infected astrocytes indicated that 
mitochondria were enlarged and membrane contacts with other organelles were 
compromised (data in process of publication). This phenotype was similar to that data 
obtained in latently HIV macrophage reservoirs described by us (Castellano et al. 2019). 
Briefly, we demonstrated that latent HIV-infected macrophages have a specific metabolic 
signature characterized by the use of unusual sources of energy such as 
glutamine/glutamate (Castellano et al. 2019). Uninfected macrophages use fatty acid and 
glucose as a major source of energy and upon blocking a particular metabolic pathway they 
can switch to alternative sources of carbon. In contrast, HIV-infected macrophages use fatty 
acid and glucose but also glutamine/glutamate as a major source of energy. More 
importantly, they cannot shift between different carbon sources to produce energy 
(Castellano et al. 2019). However, whether this metabolic signature was present in HIV-
infected astrocytes is unknown.  
In contrast, the metabolism of latent HIV-infected T cells has been correlated with 
enhanced glycolysis and OXPHOS. Glucose metabolism rather than fatty acid oxidation 
characterized the primary sources of energy for the latent CD4+ T cells (Valle-Casuso et al. 
2019). Glucose transporter-1 (Glut1), which is a marker for glycolysis, is up-regulated in 
CD4+ T cells of HIV-infected patients compared with uninfected controls (Palmer et al. 
2014). Glut1 mediates the glucose metabolic pathways by the homeostatic cytokine IL-7 
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(Loisel-Meyer et al. 2012). However, it is unknown whether a similar pathway is present 
in HIV-infected astrocytes. 
Overall, the investigated latently HIV-infected cells have different metabolic signatures, 
but all of them have a common feature, they are not able to shift from one source of energy 
to another by shifting away from OXPHOS towards glycolysis that is useful to support the 
rapid cell progression and proliferation (as demonstrated in glioblastoma cells) (Guda et 
al. 2019). This finding is unique and enables us to target this “weak” mechanism present 
in HIV reservoirs. Therefore, we examined OXPHOS in HIV-infected astrocyte cultures 
using the Seahorse Biosystems platform (Agilent Technologies, Santa Clara, CA) by 
testing different sources of carbon related to the tricarboxylic acid cycle (TCA) as we 
previously described for macrophages (Castellano et al. 2019).  
 
Materials and Methods  
Cell Culture Methods 
Human primary astrocytes were cultured using high glucose Dulbecco's modified Eagle's 
medium (DMEM, 11995-065, Thermo Fisher Scientific, Waltham, MA) supplemented 
with 10% fetal bovine serum (FBS, S12450H, Atlanta Biologicals, Flowery Branch, GA), 
penicillin, and streptomycin (15070063, Thermo Fisher Scientific, Waltham, MA) and 
grown at 37 °C in a humidified atmosphere with 5% CO2.  
 
HIV-infection of astrocyte cultures 
Confluent cultures of human astrocytes were infected by incubation with HIVADA (20–50 
ng p24/ml), using a previously described protocol (Eugenin et al. 2011). Briefly, astrocytes 
were exposed to the HIVADA for 24 hours. Later HIV-infected astrocytes were washed 
extensively to eliminate the unbound virus before addition of fresh medium supplemented 
with 5% fetal bovine serum (FBS, S12450H, Atlanta Biologicals, Flowery Branch, GA) 
and leaved for 6 days. 
 
Metabolic assessment through extracellular flux analysis 
Analysis of the oxygen consumption rate (OCR) were measured using an XFp Analyzer 
(Agilent Seahorse Technologies, Santa Clara, CA). XFp Seahorse plates were seeded with 
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10,000 human primary astrocytes per well. Cells were infected with HIVADA for 7 days. 
Culture medium was replaced by XF base medium (102353-100, Agilent Seahorse 
Technologies, Santa Clara, CA) supplemented with 2 mM Glutamine (25030081, Thermo 
Fisher Scientific, Waltham, MA), 1 mM Pyruvate (P5280, Sigma-Aldrich, St. Luis, MO) 
and 10 mM Glucose (47829, Sigma-Aldrich, St. Luis, MO) according to the manufacturer’s 
instructions (https://www.agilent.com/cs/usermanuals/public/XFCellMitoStressTest). For 
testing single source of carbon for the TCA cycle, culture medium was replaced by XF 
base medium with Glutamine only, Pyruvate only, Glucose only, 2 mM Glutamate 
(1446600, Sigma-Aldrich, St. Luis, MO), or 50 µM Fumarate (242926, Sigma-Aldrich, St. 
Luis, MO) (Kornberg et al. 2018) with an adjusted pH of 7.4. Cells were then incubated at 
37°C without CO2 for 45 minutes. Four compounds from the XFp cell mito stress test kit 
(103010-100, Agilent Seahorse Technologies, Santa Clara, CA) were injected during the 
assay at the following final concentrations: oligomycin (2 µM), p-
trifluoremethoxyphenylhydrazone (FCCP, 0.8 µM), and a mixture of antimycin A (0.5 µM) 
and rotenone (0.5 µM). Agilent Seahorse software Wave 2.3 was used for data analysis. 
The mitochondrial basal respiration, the maximal respiration, the proton leak, the ATP 
production, the spare respiratory capacity and the non-mitochondrial respiration were used 
to compare metabolic activities of the HIV-infected astrocyte cultures with the uninfected 
controls. 
 
Statistical Analysis  
All data were expressed as mean ± standard error of the mean (SEM). Differences among 
groups were analyzed by t-test and one-way analyses of variance (ANOVA test), using 
Bonferroni’s multiple comparison test for post-hoc analysis. The level of significance was 
accepted at p<0.05. Prism8.0 software was used to perform statistical analyses. 
 
Results 
Analysis of the mitochondrial metabolic profile of human astrocytes by the Seahorse 
system.  The Seahorse systems enables us to measure electron transport chain (ETC) 
(Figure 3.2 A) and the OXPHOS function in the mitochondria. As indicated in the Figure 
3.2 A, the ETC mechanism occurs in the inner mitochondrial membrane and the five 
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protein complexes that compose it transfer electrons and pump protons into the inter 
membrane space. Protons in the mitochondrial inter membrane space generate a high 
proton gradient that enable the complex V to convert ADP into ATP and produce energy. 
Rotenone, Antimycin A and Oligomycin are used for the seahorse analysis to specifically 
inhibits complex I, IV and V, respectively and evaluate oxygen consumption rate (Figure 
3.2 A).  
OXPHOS is the main source of oxygen consumption in the mitochondria and OCR is used 
to assess mitochondrial integrity and performance (Figure 3.2 B). Through the Seahorse 
analysis, it is possible to evaluate the mitochondrial basal respiration, the ATP production, 
the proton leak, the maximal respiration, the spare respiratory capacity, the non-
mitochondrial respiration, and the coupling efficiency (Figures 3.2 B and 3.3). The 
mitochondrial basal respiration (Figure 3.2 A, blue box) represents the energetic demand 
of the cell under baseline conditions. The ATP production (Figure 3.2 B, pink box), 
evaluated after the inhibition of complex V by oligomycin, shows the ATP molecules 
produced by the mitochondria. The proton leak (Figure 3.2 A, violet box) characterizes the 
remaining basal respiration not coupled to ATP production. The maximal respiration 
(Figure 3.2 A, green box) calculated after the FCCP injection shows the maximum rate of 
respiration that the cells can accomplish. The spare respiratory capacity (Figure 3.2 B, dark 
green box) indicates the capability of the cell to respond to an energetic demand. The non-
mitochondrial respiration (Figure 3.2, red box) reveals the consume of oxygen after the 
addition of rotenone and antimycin A and it is driven by processes outside the 
mitochondria. The coupling efficiency represents the relationship between the ATP 
production rate and the basal respiration rate. Thus, we used this assay to provide insight 
about mitochondrial function to understand the metabolic profile of HIV-infected 
astrocytes compared to the uninfected astrocytes using different sources of carbons (Figure 
3.1), as we recently described for HIV-infected macrophages (Castellano et al. 2019).  
 
Human astrocytes can use different sources of carbon to produce energy. As indicated 
in the Figure 3.1, glucose, pyruvate, glutamine, glutamate, and fumarate can be metabolic 
sources for the TCA cycle in the mitochondria (Figure 3.1) and used by viral reservoirs to 
produce energy and survive (Castellano et al. 2019). Thus, we determined how these 
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alternative sources of carbon for the TCA cycle can affect mitochondria metabolism in 
uninfected and HIV-infected astrocytes cultures. We treated uninfected and HIV-infected 
astrocyte cultures with media supplemented with 10 mM Glucose, 1 mM Pyruvate and 2 
mM Glutamine as a mix reference media, with 10 mM Glucose, 1 mM Pyruvate, 2 mM 
Glutamine, 2 mM Glutamate, or 50 µM Fumarate containing media to perform the 
Seahorse analysis. As control, uninfected astrocytes were used and we showed that basal 
respiration (Figure 3.3 B), maximal respiration (Figure 3.3 C), proton leak (Figure 3.3 D), 
ATP production (Figure 3.3 E), spare respiratory capacity (Figure 3.3 F), coupling 
efficiency (Figure 3.3 G) and non-mitochondrial oxygen consumption (Figure 3.3 H) in 
mix control uninfected condition were induced by the ETC inhibitors using the same 
timecourse showed in Figure 3.3 A, as well as other cell types (Pence and Yarbro 2018, van 
der Windt et al. 2016). When we replaced the mix media with the media containing only 
glucose, we observed decrease in basal respiration (Figure 3.3 B, ! p=0.0215), maximal 
respiration (Figure 3.3 C, ! p=0.0069) and spare respiratory capacity (Figure 3.3 F, ! 
p=0.0068). In contrast to what we noticed for glucose, when the mix media was replaced 
with media containing only pyruvate or glutamine, we did not observed differences in basal 
respiration, maximal respiration, proton leak, ATP production, spare respiratory capacity, 
coupling efficiency and non-mitochondrial oxygen consumption. Remarkably, even that 
glutamate is a sub-product of glutamine, we observed a significant decrease in basal 
respiration (Figure 3.3 B, ^ p<0.0001), maximal respiration (Figure 3.3 C, ^ p<0.0001), 
proton leak (Figure 3.3 D, ^ p=0.0012), ATP production (Figure 3.3 E, ^ p=0.0067), spare 
respiratory capacity (Figure 3.3 F, ^ p<0.0001), and coupling efficiency (Figure 3.3 G, ^ 
p=0.0038) compared to the mix media condition, the media containing only glucose, 
glutamate or glutamate conditions. This may suggest impairment in glutamine synthetase 
or glutaminase enzymes in the HIV-infected cultures (Figure 3.1). Normally, the reaction 
between glutamine and glutamate is reservable. Thus, a gradient problem may be present 
and will be explored in future studies. When we replaced the media mix with the media 
containing only fumarate, the differences observed were for maximal respiration (Figure 
3.3 C, ~ p=0.0312) and spare respiratory capacity (Figure 3.3 F, ~ p=0.0212) that 
decreased, and for non-mitochondrial oxygen consumption (Figure 3.3 H, ~ p=0.0446) 
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which increased. These data suggest that OXPHOS is not compromised and that uninfected 
astrocytes can use different sources of carbon to produce energy. 
 
HIV-infected astrocytes can use different sources of carbon to produce energy in a 
similar manner to uninfected astrocytes.  Our Seahorse analysis comparing uninfected 
and HIV-infected astrocyte cultures treated with media supplemented with glucose, 
pyruvate and glutamine as a mix reference media, with glucose, pyruvate, glutamine, 
glutamate, or fumarate containing media did not show any significative changes in basal 
respiration (Figure 3.3 B), maximal respiration (Figure 3.3 C), proton leak (Figure 3.3 D), 
ATP production (Figure 3.3 E), spare respiratory capacity (Figure 3.3 F), coupling 
efficiency (Figure 3.3 G) and non-mitochondrial oxygen consumption (Figure 3.3 H). This 
may be explained by the low numbers of HIV-infected cells in cultures. Nevertheless, when 
we compared the HIV-infected astrocytes cultures treated with the mix media to HIV-
infected astrocytes cultures treated with glucose, pyruvate, glutamine, glutamate, or 
fumarate containing media, we detected differences. Replacing the mix media with glucose 
containing media, we only observed decreasing levels of maximal respiration (Figure 3.3 
C, !! p=0.0032) and spare respiratory capacity (Figure 3.3 F, !! p=0.0009), but no 
significant differences were detected between HIV-infected astrocytes and uninfected 
astrocytes treated with glucose. Moreover, when we replaced mix media in HIV-infected 
astrocytes with medium containing only pyruvate we did not detect any changes in basal 
respiration (Figure 3.3 B), maximal respiration (Figure 3.3 C), proton leak (Figure 3.3 D), 
ATP production (Figure 3.3 E), spare respiratory capacity (Figure 3.3 F), and coupling 
efficiency (Figure 3.3 G). Instead, the media containing only glutamine in HIV-infected 
astrocytes cultures induced decrease of spare respiratory capacity (Figure 3.3 F, ** 
p=0.0368) compared to the HIV-infected astrocyte cultures treated with media mix. In 
agreement with the control uninfected condition, media containing only glutamate also 
generated several changes compared to the mix media in HIV-conditions. In fact, the media 
containing only glutamate in HIV-infected astrocyte cultures decreased basal respiration 
(Figure 3.3 B, ^^p=0.0026), maximal respiration (Figure 3.3 C, ^^ p<0.0001), proton leak 
(Figure 3.3 D, ^^ p=0.0180), ATP production (Figure 3.3 E, ^^ p=0.0171), and spare 
respiratory capacity (Figure 3.3 F, ^^ p<0.0001) compared to HIV-infected astrocytes 
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treated with media mix, glucose, pyruvate, and glutamine containing media. Again, when 
we replaced the media mix with the media containing only fumarate in HIV-infected 
astrocyte cultures, the maximal respiration (Figure 3.3 C, ~~ p=0.0342) and the spare 
respiratory capacity (Figure 3.3 F, ~~ p=0.0368) decreased, but were maintained at the 
same levels as the uninfected astrocyte cultures treated with the media containing only 
fumarate. These results suggest that also in HIV conditions OXPHOS is not fully 
compromised, thus uninfected and HIV-infected astrocytes can use different sources of 
carbon to produce energy. 
 
HIV infection changes the non-mitochondrial oxygen consumption in astrocytes. As 
indicated above, Seahorse analysis comparing uninfected and HIV-infected astrocyte 
cultures treated with media supplemented with glucose, pyruvate and glutamine as a mix 
reference media, with glucose, pyruvate, glutamine, glutamate, or fumarate containing 
media did not show any significative changes in basal respiration (Figure 3.3 B), maximal 
respiration (Figure 3.3 C), proton leak (Figure 3.3 D), ATP production (Figure 3.3 E), spare 
respiratory capacity (Figure 3.3 F), coupling efficiency (Figure 3.3 G) and this was valid 
also for the non-mitochondrial oxygen consumption (Figure 3.3 H). In addition, when we 
replaced the media mix in HIV-infected astrocyte cultures with media containing only 
glucose or pyruvate, any differences were detected for the non-mitochondrial oxygen 
consumption. Noteworthy, only glutamine (Figure 3.3 H, ** p=0.0308) and glutamate 
(Figure 3.3 H, ^^ p=0.0449) treated HIV-infected astrocyte cultures showed decreased 
levels of non-mitochondrial oxygen consumption compared to the HIV-infected astrocytes 
treated with mix media and media containing only glucose, pyruvate or fumarate. This data 
suggests that HIV-infected astrocytes can use alternative sources of energy that are 
completely independent from mitochondria, such as the pentose phosphate pathway 
(Loreck et al. 1987).  
 
Discussion 
Measurement of cellular respiration can be used to assess cellular energy metabolism for 
the oxygen consumption during oxidative phosphorylation (Divakaruni et al. 2014). For 
our analysis, we used glucose, pyruvate, glutamine, glutamate and fumarate as respiratory 
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substrates from which electrons are transported through the electron transport chain to 
measure oxygen consumption and evaluate if HIV infection can alter mitochondrial 
metabolism in astrocytes. 
Metabolic analyses for latently HIV-infected macrophages and CD4+ T cells have shown 
that they use glutamine/glutamate and glucose, respectively, as primary sources of energy. 
Therefore, we demonstrated that HIV-infected astrocytes compared with uninfected 
astrocytes did not show compromised metabolic steps in the tricarboxylic acid cycle 
preceding oxidative phosphorylation, even in the presence of different carbon sources. This 
may be due to the culture’s composition of around 95% of uninfected astrocytes and only 
5% of HIV-infected astrocytes.  Nevertheless, the non-mitochondrial oxygen consumption 
rate decreased for glutamine and glutamate in HIV-infected astrocytes suggesting that 
glutaminase (GLS) and/or glutamine synthase (GS) enzymes do not work properly and that 
HIV-infected astrocytes need to be partially supported by a non-mitochondrial source of 
energy such as pentose phosphate pathway. The pentose phosphate pathway can metabolize 
glucose in the cytoplasm, parallelly to glycolysis (Loreck et al. 1987).  Its activity has been 
investigated in astrocytes (Brekke et al. 2012, Sickmann et al. 2005), where it covers 
approximately 5% of the glucose metabolism, but can be upregulated to in response to 
pathological conditions (Allaman et al. 2010, Dusick et al. 2007). Therefore, for future 
experiments we intend to investigate GLS and GS activity in HIV-infected astrocytes. In 
parallel, we plan to examine the glucose-6-phosphate dehydrogenase (G6PDH) activity 
because it catalyzes the conversion of glucose-6-phosphate to 6-phosphoglucono-δ-lactone 
that is the first and rate-limiting step of the pentose phosphate pathway (PPP) testing its 
role in HIV-infected astrocytes. 
Thus, if our analysis cannot draw a specific metabolic profile for HIV-infected astrocytes 
due to their low number in culture, we can assess that they use glucose as a major energy 
source as well as that they can be partially dependent on non-mitochondrial energy sources 
such as the pentose phosphate pathway.  
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Figure 3.1. Biochemical reactions driving the TCA cycle, adapted from (Anderson N. 
M. et al. 2018). Glucose represents the major source of energy for the cells. Glucose is 
transported into the cell by glucose transporters and delivered to the TCA cycle in the form 
of pyruvate. The starting metabolite for the TCA cycle is acetyl-CoA, deriving from 
pyruvate. Specifically, the pyruvate dehydrogenase (PDH) enzyme transforms pyruvate, 
nicotinamide adenine dinucleotide (NAD+), coenzyme A into acetyl-CoA, CO2, and 
NADH. Several redox reactions allow acetyl-CoA to produce high-energy electrons, which 
are carried to the electron transport chain by nicotinamide adenine dinucleotide (NAD+) 
and flavin adenine dinucleotide (FAD). Thus, oxidative phosphorylation produces 
adenosine triphosphate (ATP). Since NAD+ and FAD require oxygen, the TCA cycle 
works in aerobic environments. Eight steps characterize the TCA cycle. Three of them are 
irreversible: the generation of citrate from oxaloacetate and acetyl-CoA by citrate synthase 
(CS); the conversion of isocitrate to α-ketoglutarate (α-KG) by isocitrate dehydrogenase 
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(IDH2/3); and the formation of succinyl-CoA from α-KG by α-ketoglutarate 
dehydrogenase complex (KGDHC). The other steps include the conversion of citrate into 
isocitrate by aconitase (AH), the formation of the succinate from succinyl CoA by succinyl-
CoA synthase (SCS) generating guanosine triphosphate (GTP), the oxidization of succinate 
by succinate dehydrogenase (SDH) to have fumarate and transfer two hydrogen atoms to 
the FAD+ to obtain FADH2, the conversion of fumarate in malate by fumarate hydratase 
(FH), and the oxidation of malate in oxaloacetate by malate dehydrogenase (MDH) and 
generation to a molecule of NAD+.  
In addition to glucose, amino acids can also participate to the TCA cycle. Glutamine, which 
is the most abundant amino acid in the human body, enters the TCA cycle in the form of 
α-KG. Glutamine is first hydrolyzed by glutaminase (GLS) into glutamate (which can be 
converted into glutamine again by glutamine synthase, GS), which subsequently is 
dehydrogenated by glutamate dehydrogenase (GLUD) to form α-KG that continues the 
TCA cycle. The sources of carbon for the TCA cycle used in our experiment are highlighted 
in red. 
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Figure 3.2. Mitochondrial metabolic profile by Seahorse system: rationale for 
approach.  (A) Electron transport chain mechanism. Electron transport chain mechanism 
occurs in the inner mitochondrial membrane and is composed of five protein complexes 
that transfer electrons and pump protons from the matrix to the inter membrane space, 
generating a high proton gradient within the inter membrane space that is used to pump 
protons through complex V to convert ADP into ATP. Briefly, complex I receives two 
electrons from NADH and facilitates the transport of four hydrogen ions from the matrix 
to the inter membrane space. Complex II, which receives two electrons from complex I, 
converts succinate to fumarate to produce the hydrogen ions needed to convert FAD to 
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FADH2. FADH2 transfers electrons to the complex III, which gives them to the 
Cytochrome C (CytC) and pumps four hydrogens into the inter membrane space. CytC is 
a mobile electron carrier that shuttles electrons from complex II to complex IV, which 
transfers two protons to the intermembrane space. Complex IV also mediates the 
conversion of oxygen into water using two protons removed from the matrix. In conclusion, 
the transport of two electrons trough the ETC enables hydrogens to be pumped into the 
intermediate space generating a chemical potential gradient necessary for complex V to 
convert ADP into ATP. Rotenone, Antimycin A and Oligomycin are inhibitors of complex 
I, IV and V, respectively, used to evaluate oxygen consumption rate. (B) Oxygen 
consumption rate examined by Seahorse analyzer. After the measurement of basal OCR 
(blue box), oligomycin is injected to inhibit complex V and shut down ATP production. 
Therefore, oligomycin is used to indirectly assess the amount of ATP produced by 
OXPHOS (pink box) and the remaining basal respiration not coupled to ATP production 
generates proton leak (violet box). The second injection is characterized by FCCP that 
determines the maximal OCR (green box), which dissipates the membrane potential 
between the intermembrane space inducing an increase of electron transport chain to 
compensate the chemical gradient. The difference between maximal respiration and the 
basal respiration represents the spare respiratory capacity (dark green box) that is a measure 
of the ability of the cell to respond to increased energy demand or stress. The final injection 
with rotenone and antimycin A completely shuts down electron transport, inhibiting 
complex I and complex II. This combination collapses mitochondrial respiration and 
enables the calculation of non-mitochondrial respiration (red box) driven by processes 
outside the mitochondria.  
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Figure 3.3. HIV-infection of astrocytes decreases the non-mitochondrial oxygen 
consumption after treatment with media containing only glutamine and glutamate as 
major carbon sources. (A) Schematic representation of oxygen consumption rate by the 
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Seahorse analyzer. OCR measurements were performed in human primary astrocytes (both 
HIV-infected and uninfected) treated with media supplemented with 10 mM Glucose, 1 
mM Pyruvate and 2 mM Glutamine as mix, with 10 mM Glucose, 1 mM Pyruvate, 2 mM 
Glutamine, 50 µM Fumarate, and 2 mM Glutamate, separately. (B) Basal respiration 
measurement. Basal respiration did not change between control uninfected and HIV-
infected astrocytes treated with mix media, media containing only glucose, pyruvate, 
glutamine, glutamate media, or fumarate, as well as the other measurements. Decreased 
levels of basal respiration were detected in glucose control uninfected condition (! as 
compared to the mix control uninfected condition, p=0.0215, n=9), in glutamate control 
uninfected condition (^ as compared to the mix control uninfected condition, p<0.0001, 
n=9), in glutamate HIV-infected conditions (^^ as compared to the mix HIV-infected 
condition, p=0.0026, n=9), and was unchanged for the other conditions respectively 
compared with the control uninfected and the HIV-infected mix. (C) Maximal respiration 
measurement. The maximal respiration decreased only in glucose uninfected control 
condition (! as compared to the mix control  uninfected condition, p=0.0069, n=9), in 
glucose HIV-infected condition (!! as compared to the mix HIV-infected condition, 
p=0.0032, n=9), in fumarate control uninfected condition (~ as compared to the mix control 
uninfected condition, p=0.0312, n=9), in fumarate HIV-infected condition (~~ as compared 
to the mix HIV-infected condition, p=0.0342, n=9), in the glutamate uninfected control (^ 
as compared to the mix control uninfected condition, p<0.0001, n=9) and HIV-infected 
conditions (^^ as compared to the mix HIV-infected condition, p<0.0001, n=9). (D) Proton 
leak measurement. The proton leak was only reduced in the glutamate conditions (^as 
compared to the mix control uninfected condition, p=0.0012; ^^ as compared to the mix 
HIV-infected condition, p=0.0180, n=9).  (E) ATP production measurements. Consistent 
with D, ATP production was reduced in glutamate conditions (^ as compared to the mix 
control uninfected condition, p=0.0067; ^ ^ as compared to the mix HIV-infected condition, 
p=0.0171, n=9). (F) Spare respiratory capacity measurement. In agreement with the other 
measurements, the spare respiratory capacity was reduced in glutamate conditions (^ as 
compared to the mix uninfected control condition, p<0.0001; ^^ as compared to the mix 
HIV-infected condition, p<0.0001, n=9) but also in glucose conditions (! as compared to 
the mix control uninfected condition, p=0.0068; !! as compared to the mix HIV-infected 
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condition, p=0.0009, n=9), in glutamine HIV condition (** as compared to the mix HIV-
infected condition, p=0.0368, n=9), and in fumarate conditions (~ as compared to the mix 
control uninfected condition, p=0.0212; ~~ as compared to the mix HIV-infected condition, 
p=0.0368, n=9). (G) Coupling efficiency measurement. The coupling efficiency, ratio 
between ATP production rate basal respiration rate, was only reduced for glutamate 
uninfected control (^ as compared to the mix control uninfected condition, p=0.0038, n=9). 
(H) Non-mitochondrial oxygen measurement. The non-mitochondrial oxygen 
consumption was increased in fumarate uninfected control condition (~ as compared to the 
mix control uninfected condition, p=0.0446, n=9) and decreased in glutamine and 
glutamate HIV conditions (** as compared to the mix HIV-infected condition, p=0.0308; 
^^ as compared to the mix control HIV-infected condition, p=0.0449, n=9).  
Our results indicate that HIV-infected astrocytes compared with the uninfected astrocytes 
do not show compromised metabolic steps in the tricarboxylic acid cycle in the presence 
of glucose, pyruvate, glutamine, glutamate or fumarate as sources of carbon. In addition, 
glutamine and glutamate in HIV-infected astrocytes decrease non-mitochondrial oxygen 
indicating that HIV-infected astrocytes are partially supported by a non-mitochondrial 
source of energy. 
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Introduction 
Lipids are highly abundant in the brain (Hancock et al. 2017), where they perform 
several functions as vital components of membranes structure, metabolism, cell 
proliferation, survival, apoptosis, and signaling (Cermenati et al. 2015). Disruption or 
imbalance in lipid composition or metabolism has been associated with several 
neurodegenerative diseases (Mesa-Herrera et al. 2019). In Chapter 2, we demonstrated that 
the failure in eradicate HIV is due to the presence of latently viral reservoirs located in 
different anatomical compartments including the brain. Thus, we propose that HAND is 
dependent on the viral reservoirs present within the brain and one of the mechanisms of 
damage amplification is mediated by lipids.  
In a similar manner to other neurocognitive diseases (Adibhatla and Hatcher 2007, 
Xicota et al. 2019), HAND has been linked to lipid dysregulation including structural, 
signaling and circulating lipids (Bandaru et al. 2013, Kearns et al. 2017, Kelesidis and 
Currier 2014). Our interest in structural/signaling lipids was also supported by data from 
our laboratory showed peripheral lipid dysregulation in HIV-infected patients. The levels 
of PGE2 (a bioactive eicosanoid lipid) in the sera of HIV-infected individuals virally 
suppressed with cART were elevated compared to the uninfected individuals (Velasquez 
et al. 2019). In addition, PGE2 secretion in the media of the peripheral blood mononuclear 
cells (PBMCs) isolated from HIV-infected individuals or isolated from uninfected 
individuals and stimulated with Gp120 was higher compared to the secretion obtained in 
PBMCs isolated from uninfected individuals (Velasquez et al. 2019). PGE2 is an 
eicosanoid synthetized from arachidonic acid (AA) via cyclooxygenase 2 and 
prostaglandin E synthase. It is a potent inflammatory lipid mediator (Park J. Y. et al. 2006) 
that according to our laboratory data, can be secreted via pannexin 1 (Panx-1) channels into 
the extracellular space (Velasquez et al. 2019), where it binds to E-prostanoid (EP) 
receptors to trigger toxic signaling pathways into the neighboring cells (Andreasson 2010).  
Thus, we used MALDI-MSI with a high spatial resolution and high mass accuracy, 
to investigate altered structural/signaling lipid distribution in HIV-infected brain tissues 
compared to uninfected controls. We used an untargeted lipidomics approach to identify 
the major lipids spectral peaks corresponding to phospholipids highly abundant in the 
brain. Phospholipids are essential membrane lipids, they are comprised of a glycerol 
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molecule, two hydrophobic fatty acids chains, and a hydrophilic phosphate head group. 
They can be classified in several molecular species based on the fatty acid tail groups, who 
have a standard nomenclature constructed with the number of carbon atoms in the fatty 
acid chain and the number of double bonds, thereby providing information on the saturation 
of the chain. Phospholipids containing very long chain fatty acids (fatty acids with more 
than 22 carbons) are known to be predominantly located within the grey matter (Kihara 
2012). Additionally, phospholipids containing polyunsaturated fatty acids (PUFAs - fatty 
acids containing 2 or more double bonds) are mostly localized into the grey matter 
(Soderberg et al. 1991). Conversely, white matter is enriched in saturated and 
monounsaturated fatty acids (Lopez et al. 1995). Furthermore, monounsaturated fatty 
acids, particularly oleic acid, are known to be predominantly localized into myelin (Guest 
et al. 2013).  
Thus, we applied MALDI-MSI analysis to HIV-infected human brain tissue samples to 
identify potential lipid biomarkers of HAND and to verify the link between altered lipid 
distribution in the brains obtained from individuals with minimal to undetectable viral 
replication, few viral reservoirs, but with cognitive impairment. Our data demonstrate that 
despite all previous points, we identified a significant lipidic dysregulation in vast areas of 
the CNS, supporting our hypothesis that lipids “help” HIV reservoirs to spread damage 
within the CNS. 
 
Materials and Methods 
Human brain tissue sections 
Unfixed human brain tissue blocks of HIV-infected and uninfected patients were obtained 
from NNTC (Table 2 in Chapter 2). Unfixed human brain tissues were cut in 12 µm thick 
tissue serial sections using a Leica CM1850 cryostat (Buffalo Grove, IL) and thaw-
mounted onto stainless steel slides. After sectioning, tissues were placed in a dessicator for 
15 minutes and then transferred to a -80 °C freezer for storage and for preventing lipid 
degradation. All these tissues come from postmortem donations (2 hours after death), 
where blood was eliminated by PBS perfusion to prevent any lipid accumulation within 
the blood vessels.  
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Matrix application to tissue sections 
Prior to MALDI-MSI analysis, the thaw-mounted tissue sections were removed from the -
80 °C freezer and allowed to reach room temperature for 15 minutes. α-Cyano-4-
hydroxycinnamic acid (C2020, Sigma-Aldrich, St. Luis, MO) and 1,5-
Diaminonaphthalene (D21200, Sigma-Aldrich, St. Luis, MO) matrices were evaluated for 
positive and negative lipid imaging, respectively. 5 mg/ml of α-Cyano-4-hydroxycinnamic 
acid was dissolved in 70% Acetone (34850, Sigma-Aldrich, St. Luis, MO) and 5 mg/ml of 
α-Cyano-4-hydroxycinnamic acid was dissolved in 70% Acetonitrile (34851, Sigma-
Aldrich, St. Luis, MO) and 0.1% Trifluoroacetic acid (91707, Sigma-Aldrich, St. Luis, 
MO). All matrices were applied to the tissue by airspray deposition using the TM-sprayer 
(HTX Technologies LLC, Chapel Hill, NC).  The nozzle temperature was set to 60 °C, 
flow rate was 50 L/min and 20 passes over the tissue were performed.   
 
MALDI-MSI Analysis  
MALDI-MSI analysis was performed using Q Exactive HF Hybrid Quadrupole-Orbitrap 
Mass Spectrometer (Thermo Fisher Scientific, Waltham, MA) equipped with an Elevated 
Pressure Matrix Assisted Laser/Desorption Ionization (EP MALDI) source integrating an 
Nd:YAG laser (Spectroglyph LLC). Data were acquired at 40 µm2 lateral resolution in 
negative and positive ion mode. External mass calibration was performed using calibration 
solutions (A39239, Thermo Fisher Scientific, Waltham, MA).  Accurate mass measured 
lipid peaks were identified by matching to reference lipids in the LIPID MAPS and Human 
Metabolome Database within a ±0.002 Da mass tolerance window. Data visualization was 
performed using Thermo ImageQuest software. Ion images were plotted within a ±0.002 
m/z mass tolerance window and all lipid images were normalized to the total ion current 
(TIC) chromatogram. Extracted ion images were interpolated using the linear interpolate 
function. 
 
Results 
MALDI-MSI analysis for lipid markers of the grey and white matter. The workflow 
for lipidomic profiling of the human brain tissues by MALDI-MSI is shown in Figure 4.1.   
The human brain tissues were acquired from uninfected and HIV-infected individuals 
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undergoing cART, with a good CD4 count and with undetectable viral load as indicated in 
Table 2 of Chapter 2. Initially, the phospholipid profile of the frontal cortex from HIV-
infected individuals was compared to uninfected individuals to evaluate alterations in lipid 
distribution and relative intensity. To guide phospholipid localization in the grey matter 
and in the white matter, H&E staining (Figures 4.2 A, 4.3 A, and 4.4 A) was performed on 
adjacent tissue sections to the ones used for MALDI-MSI.  
Membrane phospholipids such as phosphatidylethanolamine (PE), 
phosphatidylinositol (PI), and phosphatidic acid (PA) have previously been demonstrated 
using MALDI-MSI to show altered abundance and distribution within the brain following 
damage caused by infection, inflammation, and/or trauma (Adibhatla and Hatcher 2008, 
Ojo et al. 2018). Our MALDI-MSI results indicated that membrane phospholipids of the 
grey matter (Figure 4.2 B, C, D) and the white matter (Figure 4.3 B, C, D) did not show 
significative changes in relative expression and localization in HIV-infected brain tissues 
when compared to the controls uninfected. In Figure 4.2, we show representative images 
for membrane phospholipids containing polysaturated fatty acids that are markers of the 
grey matter such as  phosphatidylethanolamine 40:6 (PE 40:6, Figure 4.2 B), 
phosphatidylinositol 18:0/20:4 (PI 18:0/20:4, Figure 4.2 C) and phosphatidic acid 40:6 (PA 
40:6, Figure 4.2 D). Note, the distribution and relative abundance of the lipids do not 
significantly change between HIV-infected brain tissue and uninfected control. As they are 
essential structural membrane glycolipids of the grey matter and unaltered in our analysis, 
we can assess that the grey matter in HIV-infected patients under cART and with 
undetectable viral load is structurally intact. Next, we repeated the same analysis for the 
white matter phospholipids, and we did not observe significant dysregulation of the 
membrane lipids. The short chain and monounsaturated fatty acid membrane 
phospholipids, phosphatidylethanolamine 36:2 (PE 36:2, Figure 4.3 B), phosphatidylserine 
36:1 (PS 36:1, Figure 4.3 C), and phosphatidic acid 36:1 (PA 36:1, Figure 4.3 D) were 
showed as representation. Even though PA 36:1 relative expression appeared increased in 
the cell bodies of HIV-infected tissues compared to controls, it is necessary to increase the 
numbers of the samples to better investigate this variation. Nevertheless, these markers 
maintained similar relative intensity and localization in the white matter of uninfected and 
HIV-infected brain tissues. Thus, these results indicated that also the structure of the white 
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matter is not compromised in HIV conditions even that most HIV-infected individuals had 
neurocognitive decline.  
 
MALDI-MSI showed sulfatide dysregulation in HIV-infected human brain tissues. 
Although the gross grey and white matter are not perturbed in HIV-infected brain, through 
our untargeted MSI analyses, we identified a specific lipid class, sulfatide, that showed a 
significative change in relative abundance between the uninfected and the HIV-infected 
brain tissues. Sulfatide, is a glycosphingolipid with a polar galactosyl-3-O-sulfate head 
group and a lipid core of ceramide made by a fatty acid and a long-chain base. Sulfatide is 
expressed in both grey and white matter (Takahashi and Suzuki 2012). Literature data 
indicate that the white matter mostly present long-chain sulfatides with structural roles in 
the plasma membrane, instead, the grey matter mainly shows short-chain sulfatides 
typically localized in intracellular vesicles (Isaac et al. 2006). As shown in Figure 4.4, 
sulfatide relative intensity was much higher in HIV-infected tissues than in uninfected 
controls, specifically in the white matter where sulfatide is known to be largely located 
(Han 2007). We analyzed several species of sulfatide, and we demonstrated that sulfatide 
containing short acid-chain 16:0 (labeled sulfatide 16:0 in Figure 4.4 B) did not show 
significative increase of relative expression between HIV-infected brain tissue as compared 
to uninfected control, but it still maintains its location in the white matter. On another hand, 
sulfatide containing short acid-chain 18:0 (labeled sulfatide 18:0 in Figure 4.4 C) and 
particularly sulfatide containing long acid-chains 24:1 (labeled sulfatide 24:1 in Figure 4.4 
D) and 25:1 (labeled sulfatide 25:1 in Figure 4.4 E) significantly increased their relative 
expression in the white matter of HIV-infected brain tissues. This result is highly important 
because it is the first data identifying and visualizing potential lipid markers in HIV-
infected patients with neurocognitive disorders.  
 
Discussion  
Lipidomics by MALDI-MSI is a young discipline with enabling high spatial 
resolution, highly specific imaging of lipids in tissue without the requirement for additional 
labeling steps (Luberto et al. 2019). Although, MALDI-MSI was previously applied to 
investigate cART distribution and efficacy in HIV-infected individuals or animal models 
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of HIV infection (Ntshangase et al. 2019, Seneviratne et al. 2018), this potent tool has not 
been used to explore lipids alteration in HIV-infected tissues, especially in the brain. 
Therefore, we proposed to investigate lipid alteration by MALDI-MSI in human brain 
tissues from HIV-infected individuals undergoing cART, with normal CD4 count and 
without detectable viral replication but developing asymptomatic or mild neurocognitive 
disorders.  
Although, HIV persists in the brain of HIV-infected individuals in few viral 
reservoirs and introduces changes in neuronal branching (Kovalevich and Langford 2012) 
generating a change in volume of the infected brain (Ances et al. 2012), the neurons do not 
die. Thus, our results showing no significative changes in relative expression and 
distribution for the essential membrane phospholipids in grey and white matter confirmed 
that the brain structures of the HIV-infected individuals undergoing cART and without 
viral replication are not compromised. 
Thereafter, analyzing ceramide related metabolites, we found that sulfatide 
increased in relative expression in the white matter of HIV-infected tissues, especially 
sulfatides containing long acid-chain. Sulfatide increase in intensity cannot be due to the 
diffusion or release from damaged brain structures because the grey and the white matter 
resulted structurally intact. Hence, we propose it is due to an increased synthesis in white 
matter or the inability of the arylsulfatase A enzyme to degrade sulfatide in the lysosome 
of the white matter.  Thus, our future experiments will focus on investigating sulfatide 
synthesis pathway in HIV-infected brain tissues.  
Sulfatide has been shown to be dysregulated in several neurodegenerative diseases. 
A substantial reduction in sulfatide levels has been observed in the brain and the CSF of 
Alzheimer’s disease subjects, in which the low levels of sulfatide is accompanied with a 
significant increase in ceramide, possibly caused by increased sulfatide degradation (Han 
et al. 2002). On the contrary, elevated levels of sulfatide was detected in the superior frontal 
and cerebellar grey matter of Parkinson’s disease subjects (Cheng et al. 2003). Thus, 
literature data and our results suggest that sulfatide has a strong potential for being 
considered a biomarker for neurocognitive impairment and a potential target for therapeutic 
molecules that can prevent or cure HAND.   
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  In addition, antiretroviral drugs, particularly protease inhibitor drugs, has been 
demonstrated to directly cause lipid dysregulation and all the HIV-infected tissues in our 
study came from patients on cART. However, current evidence supports that HAART-
induced lipid dysregulation primarily affects triglyceride and cholesterol metabolism (Lo 
2011). For HIV-infected individuals, white matter thinning with loss of volume and 
structural integrity of myelin were reported by immunohistochemical staining in 
postmortem tissues  (Langford et al. 2003) or by diffusion tensor imaging (Correa et al. 
2015) analyses suggesting a possible relation with the antiretroviral compounds used to 
treat HIV individuals (Jensen et al. 2019). Our analysis did not detect significant structural 
damage in the white matter of HIV-infected patients under cART but we intend to expand 
our analysis. Moreover, there are no current reports of direct drug-induced sulfatide 
dysregulation. Thus, the observed changes in sulfatide distribution are unlikely to be due 
to the drug therapy. 
In summary, the key points of this chapter are: 1)  grey and white matters of the 
brain of HIV-infected individuals under cART and with undetectable viral replication are 
not structurally compromised; 2) sulfatide is a potential biomarker for HAND that increase 
in the white matter of HIV-infected individuals. Thus, MALDI-MSI was essential for 
identifying sulfatide, whose role will be investigated in vitro in the following chapters.  
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Figure 4.1. Lipidomic profile by MALDI-MSI: rationale for approach. (A) Tissue 
collection and sectioning. Post-mortem frontal lobe brain tissues from uninfected and HIV-
infected individuals virally suppressed with cART, with a normal CD4 count and 
undetectable viral load were obtained from the NNTC and cryo-sectioned at 12 µm. (B) 
MALDI matrix application. Matrix was sprayed matrix using a TM-sprayer. (C) Data 
acquisition. MSI data were acquired at 40 µm
2
 lateral resolution in negative and positive 
ion mode using a Q Exactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo 
Scientific) equipped with an Elevated Pressure Matrix Assisted Laser/Desorption 
Ionization (EP MALDI) source integrating an Nd:YAG laser (Spectroglyph LLC). (D) Data 
visualization. It was performed using Thermo ImageQuest software by plotting ion 
intensity versus relative position of the data from the sample. (E) H&E staining. Adjacent 
brain tissue sections were stained with H&E to visualize brain morphology. 
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Figure 4.2. Representative distribution of phospholipids in the grey matter of 
uninfected and HIV-infected brain tissues. The top and the lower panels present brain 
sections of uninfected and HIV-infected individuals, respectively. (A) H&E-stained 
reference sections for the grey matter (indicated with grey arrows) and the white matter 
(indicated with white arrows). MALDI-MSI images for (B) phosphatidylethanolamine 
(PE) 40:6, (C) phosphatidylinositol (PI) 18:0/20:4, (D) phosphatidic acid (PA) 40:6. 
Intensity is expressed by the gradient intensity scale. Scale bar=5mm.  
Our results indicate that the relative intensity and the localization of the phospholipids 
characteristic for the grey matter do not significantly change under HIV condition. 
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Figure 4.3. Representative distribution of phospholipids in the white matter of 
uninfected and HIV-infected brain tissues. The top and the lower panels present brain 
sections of uninfected and HIV-infected individuals, respectively. (A) H&E-stained 
reference sections for the white matter (indicated with white arrows) and the grey matter 
(indicated with grey arrows). MALDI-MSI images for (B) phosphatidylethanolamine (PE) 
36:2, (C) phosphatidylserine (PS) 36:1, (D) phosphatidic acid (PA) 36:1. Intensity is 
expressed by the gradient intensity scale. Scale bar=5mm.  
Our results indicate that the relative intensity and the localization of the phospholipids 
characteristic for white matter do not significantly change under HIV condition. 
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Figure 4.4. Representative distribution of sulfatide in uninfected and HIV-infected 
brain tissues. The top and the lower panels present brain sections of uninfected and HIV-
infected individuals, respectively. (A) H&E-stained reference sections for the grey matter 
(indicated with grey arrows) and the white matter (indicated with white arrows). MALDI-
MSI images for (B) sulfatide 16:0, (C) sulfatide 18:0, (D) sulfatide 24:1, and (E) sulfatide 
25:1. Intensity is expressed by the gradient intensity scale. Scale bar=5mm.  
Our results indicate that sulfatide containing short acid-chain 18:0 and long acid-chains 
increase in relative expression in white matter under HIV condition. 
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Introduction  
As described in Chapter 4, we identified that sulfatide increases its relative expression in 
the white matter of HIV-infected individuals without any sign of structural membrane 
phospholipid dysregulation. Thus, sulfatide change in relative concentration was 
associated with HIV infection and cognitive disease. As described in Table 2, the brain 
tissue sections investigated were obtained from individuals with minimal to undetectable 
HIV replication, normal CD4 count, and asymptomatic neurocognitive impairment. 
Despite these minimal neurocognitive alterations, sulfatide changes were significant. Also, 
we described in Chapter 2 that the brain tissues analyzed only showed minimal numbers 
of viral reservoirs with perivascular localization comprised microglia/macrophages and a 
small population of astrocytes. Surprisingly, we detected that several proteins diffused to 
the neighboring areas of the brain from areas containing HIV-integrated DNA. Thus, we 
propose that HIV proteins dysregulate sulfatide release and we focused our investigation 
on Gp120, Tat1-72, Nef, Vif and Vpr. All the selected proteins have already been identified 
to have significant toxicity within the brain.  
For example, the soluble viral envelope protein Gp120 has neurotoxic effect that induces 
axonal degeneration via activation of several neurotoxic pathways including dysregulated 
calcium homeostasis, activation of oxidative stress, induction of the proapoptotic 
transcription factor p53, mitochondrial fission/fusion, and impaired mitochondrial 
dynamics (Avdoshina et al. 2016).  
The viral transactivator protein, Tat, induces neuronal apoptosis through the formation of 
a macromolecular complex composed by the low-density lipoprotein receptor-related 
protein (LRP), postsynaptic density protein-95 (PSD-95), N-methyl-d-aspartic acid 
(NMDA) receptors, and neuronal nitric oxide synthase (nNOS) in the neuronal plasma 
membrane (Eugenin et al. 2007). Moreover, Tat upregulates Cx43 gene and protein 
expression binding Cx43 promoter and supporting gap junctional communication in human 
primary astrocytes (Berman et al. 2016), which is the topic of the following chapter.  The 
viral transactivator is a 101-residue protein encoded by two exons. We decided to use Tat1-
72 that defines the first exon and that activates transcription with the same proficiency of 
the full-length protein. 
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The negative factor, Nef, is a small protein expressed abundantly in astrocytes of HIV-
infected brains. It induces axonal and neurite degeneration of neurons through oxidative 
stress (Sami Saribas et al. 2017). Nef also contributes to inflammation inducing the 
production of pro-inflammatory cytokines such as CCL5 by the Akt, p38MAPK, NF-κB, 
CEBP, and AP-1 pathways (Liu X. et al. 2014). 
The viral initial factor, Vif, shows its neurotoxic properties by inhibiting proteasomal 
degradation of ubiquitinated proteins (Royal et al. 2012).   
Instead, Vpr induces neuronal apoptosis altering the mitochondrial transition pore 
formation, inducing cytochrome c release, and  increasing the activation of caspase-8 
(Jacotot et al. 2000, Pomerantz 2004).  
In our analysis, we choose all these HIV proteins for their full blow neurotoxic effects and 
because some of them were directly detected as soluble proteins diffusing into the non-
HIV-associated DNA cells of the HIV-infected brain tissues. However, it was unknown 
whether HIV proteins compromised sulfatide release.  
 
Materials and Methods  
Cell Culture Methods 
Human primary astrocytes and SH-SY5Y human neuroblastoma cells were separately 
maintained in culture. High glucose Dulbecco's modified Eagle's medium (DMEM, 11995-
065, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum 
(FBS, S12450H, Atlanta Biologicals, Flowery Branch, GA), penicillin, and streptomycin 
(15070063, Thermo Fisher Scientific, Waltham, MA) was used to grow the human primary 
astrocytes at 37 °C in a humidified atmosphere with 5% CO2. SH-SY5Y human 
neuroblastoma cells were grown in gelatin coated coverslips using the same medium of 
astrocytes supplemented with 2 mM L-glutamine (25030081, Thermo Fisher Scientific, 
Waltham, MA), 2% B27 (17504044, Thermo Fisher Scientific, Waltham, MA) and 2 mM 
Glutamax (35050-061, Thermo Fisher Scientific, Waltham, MA). Before to obtain co-
cultures, SH-SY5Y human neuroblastoma cells were differentiated with 10 µM Retinoic 
Acid (R2625, Sigma-Aldrich, St. Luis, MO-Aldrich, St. Luis, MO) for 7 days. 
Differentiated SH-SY5Y human neuroblastoma cells were flipped on the human primary 
astrocytes to obtain co-cultures that were maintained for 12 hours in the media of 
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differentiated SH-SY5Y human neuroblastoma cells before to be treated with HIV 
proteins. This is a similar protocol described for hippocampal neurons to enable proper 
differentiation and synaptic development (Kaneko et al. 2014). 
 
ELISA for sulfatide and PGE2 
Co-cultures of human primary astrocytes and differentiated neurons were treated with HIV 
recombinant proteins Gp120 (HIV-1 BaL; 50 and 100 nM; 4961, NIH AIDS Reagent 
Program, Germantown, MD), Tat1-72 (HIV-1;100, and 300 nM), Nef (HIV-1 HXB2; 100 
and 250 nM; 13134, NIH AIDS Reagent Program, Germantown, MD), Vif (HIV-1 HXB2; 
100 and 300 nM; 11050, NIH AIDS Reagent Program, Germantown, MD) or Vrp (HIV-1; 
100 and 300 nM; 6447, NIH AIDS Reagent Program, Germantown, MD), for  6, 12, 24, 
and 48 hours. Sulfatide concentration was evaluated in the co-culture media using Human 
sulfatide ELISA kit (MBS7242142, MyoBioSource, San Diego, CA), and PGE2 
concentration with human PGE2 ELISA kit (ab133021, Abcam, Cambridge, UK) 
according to the manufacturer’s instructions. Human sulfatide ELISA kit had a sensitivity 
of 1 ng/ml, human PGE2 ELISA kit had a sensitivity of 13.4 pg/ml. Sulfatide and PGE2 
concentrations were quantified by bioluminescence (Optical Density 450/415 nm) using a 
Perkin Elmer envision system (2102 Multilabel Reader, Perkin Elmer, Waltham, MA). 
 
Statistical Analysis  
All data were expressed as mean ± standard error of the mean (SEM). Differences among 
groups were analyzed by a one-way analysis of variance (ANOVA test), using Bonferroni’s 
multiple comparison test for post-hoc analysis. The level of significance was accepted at 
p<0.05. Prism8.0 software was used for the statistical analyses performed. 
 
Results 
Evaluation of sulfatide secretion in mixed co-cultures of differentiated neurons and 
human primary astrocytes. Although, magnetic resonance spectroscopy and magnetic 
resonance imaging can provide elucidation about lipid distribution and characterization, 
they have never been applied to assess lipid alteration in HIV condition, especially for 
sulfatide, due to lack of specificity. Sulfatide, is a sulfoglycolipid synthetized by 
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oligodendrocytes, Schwan cells, astrocytes and neurons (Takahashi and Suzuki 2012). Our 
MALDI-MSI results for HIV-infected brain tissues showed higher sulfatide relative 
intensity in the white matter. On the contrary, elevated levels of sulfatide were detected in 
the grey matter of Parkinson’s disease subjects (Fabelo et al. 2011) and decreased level 
were identified in the grey and in white matters of Alzheimer’s disease subjects (Cheng et 
al. 2003). These pathologies show significant brain destruction and their progression is 
irreversible, critical difference with the milder forms of HAND. However, in HIV 
condition cognitive disorders can be reversible and even fluctuating. We detected that brain 
structural damage was minimal. Thus, we propose that sulfatide may be used as a marker 
of brain compromise and can provide signs of early CNS damage. 
In control untreated condition, analysis of our co-cultures of differentiated neurons and 
human primary astrocytes indicated that sulfatide was released into the media in a stable 
manner during the time course analyzed (6, 12, 24 and 48 hours) with a concentration of 
2.331 mg/ml.  
 
Gp120 increases sulfatide secretion in mixed co-cultures of differentiated neurons and 
human primary astrocytes. Treatment of mixed cultures of differentiated neurons and 
human primary astrocytes with Gp120 50 nM for 6, 12, 24 and 48 hours and subsequent 
ELISA for sulfatide demonstrated that Gp120 50 nM transiently increased sulfatide 
secretion. Specifically, sulfatide secretion was only increased after 24 hours (Figure 5.1 A, 
* p=0.0040) to be reduced at 48 hours (Figure 5.1 A, # p=0.0040). In addition, increasing 
Gp120 concentration at 100 nM did not change the transient increase in sulfatide secretion 
at 24 hours (Figure 5.1 B, * p=0.0257) that was again decreased at 48 hours (Figure 5.1 B, 
# p=0.0012). Thus, Gp120 data indicates that some HIV proteins at specific concentrations 
and time points can increase sulfatide secretion, even transiently.  
 
Tat prevents sulfatide secretion in mixed co-cultures of differentiated neurons and 
human primary astrocytes. In contrast to the Gp120 data upregulating sulfatide secretion 
at 24 hours at different concentrations, we identify that HIV-1 Tat1-72 100 ng/ml reduced 
sulfatide secretion at 48 hours (Figure 5.2 A, # p=0.0457). Although at 6 hours sulfatide 
secretion was also reduced, it was not statistically significant. On another hand, Tat1-72 at 
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increased concentration of 300 ng/ml did not reduce sulfatide secretion at 48 hours (Figure 
5.2 B) and any significative differences compared to control were detected at 6,12, and 24 
hours. Thus, Tat1-72 data indicate that some HIV proteins at specific concentrations can 
reduce sulfatide secretion.  
 
Nef and Vif increase sulfatide secretion in mixed co-cultures of differentiated neurons 
and human primary astrocytes. Treatment of mixed cultures of differentiated neurons 
and human primary astrocytes with Nef or Vif for 6, 12, 24 and 48 hours and subsequently 
analyzed by  ELISA for sulfatide demonstrated that Nef 100 ng/ml and Vif 100 ng/ml, in 
the same manner, increased sulfatide secretion at 48 hours (Figure 5.3 A, * p=0.0148; 
Figure 5.4 A, * p=0.0005). Increasing Nef concentration to 250 nM and Vif to 300 ng/ml 
did not further increase sulfatide secretion at 48 hours (Figure 5.3 B, * p=0.0002; Figure 
5.4 B,  p=0.0157) and any significative differences compared to control were detected at 
6, 12, and 24 hours, as observed at the lower concentration. Thus, Nef and Vif data indicate 
that several HIV proteins at specific time points can increase sulfatide secretion.  
 
Vpr increases sulfatide secretion in mixed co-cultures of differentiated neurons and 
human primary astrocytes. In agreement with Gp120 data showing upregulating 
sulfatide secretion, we identified that Vpr 100 ng/ml transiently increased sulfatide 
secretion at 24 hours (Figure 5.5 A, * p=0.0094).  Partially consistent with this observation, 
treatment with a higher concentration of Vpr (300 ng/ml) induced an earlier increase in 
sulfatide secretion at 12 hours (Figure 5.5 B, * p=0.0439) compared to control condition. 
Thus, Vpr data confirm that several HIV proteins at specific concentrations and time points 
can increase sulfatide secretion, even transiently.  
 
HIV proteins do not change PGE2 secretion in vitro. PGE2, an AA-related metabolite that 
stimulates inflammation, was used as control (Figures 5.6 to 5.10). Our previous laboratory 
data showed that it is altered in the sera of all the HIV individuals. Thus, we evaluated 
whether viral proteins can regulate PGE2 release in vitro. Analysis of our mixed co-culture 
of differentiated neurons and human primary astrocytes indicated that PGE2 was released 
into the media in a stable manner at 6, 12, 24 and 48 hours with a concentration of 30 pg/ml 
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(Figures 5.5 to 5.10). Treatment of the mixed cultures of differentiated neurons and human 
primary astrocytes with Gp120 (50 nM, Figure 5.6 A; 100 nM, Figure 5.6 B), Tat1-72 (100 
ng/ml, Figure 5.7 A; 300 ng/ml, Figure 5.7 B), Nef (100 ng/ml, Figure 5.8 A; 250 ng/ml, 
Figure 5.8 B), Vif (100 ng/ml, Figure 5.9 A; 300 ng/ml, Figure 5.9 B) or Vpr (100 ng/ml, 
Figure 5.10 A; 300 ng/ml, Figure 5.10 B) for 6, 12, 24 and 48 hours and subsequent ELISA 
for PGE2 did not demonstrate difference in PGE2 secretion compared to the control. These 
results indicate that PGE2 secretion is not dependent on HIV protein stimulations.  
 
Discussion 
In this chapter, we identified that Gp120, Tat, Nef, Vif and Vpr HIV proteins are 
able to dysregulate sulfatide secretion in the co-cultures of human primary astrocytes and 
SH-SY5Y neuroblastoma cells, but the mechanism of sulfatide release is still under 
investigation.  
As described in Chapter 2, HIV protein secretion or diffusion can compromise large 
regions of tissue in close contact with viral reservoirs. This is supported by the fact that 
HIV proteins have previously been shown to be a source of neuronal damage (Kaul and 
Lipton 2006, Nath 2002). Neuronal damage occurs in the absence of neuronal infection 
and exposure of the neurons to the HIV proteins is able to trigger neuronal damage 
cascades. However, neurons in HIV-infected individuals do not necessary die but can show 
dendritic simplification and synaptic pruning, decreasing the synaptodendritic connectivity 
(Kovalevich and Langford 2012, Ru and Tang 2017). However, it still controversial 
whether in vivo HIV proteins are released into the neurons and glia cells. We demonstrated 
that this mechanism occurs in HIV-infected individuals without sign of viral replication 
(see Table 2, Chapter 2) and our research prove that the current cART blocks peripheral 
viral replication but does not prevent HIV protein synthesis.  
As described in Figure 1.5, sulfatide is concentrated in the cellular membrane 
including Golgi apparatus and lysosome. Although we demonstrated that sulfatide 
secretion can be regulated by several HIV proteins, the source of sulfatide release in 
response to HIV proteins is unknown. We cannot discard that viral proteins induce sulfatide 
secretion via gap junctions, exoxomes or other extracellular vesicles.  
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Sulfatide was released in control conditions, however, Gp120, Nef, Vif and Vpr 
were shown to increase its secretion and potentially increase apoptosis too. The 
concentration of sulfatide released as described in the subsequent chapters was not 
associated with apoptosis but toxicity cannot be excluded.  
Sulfatide may also contribute to synaptic pruning and for this reason our future experiments 
aim to analyze synaptic proteins in SH-HY5Y neuroblastoma cells stimulated with viral 
proteins to investigate synaptic stability and signaling.  
Moreover, our results for PGE2 secretion in the human primary astrocyte-SH-SY5Y 
neuroblastoma cell co-cultures did not show any significant changes in the presence of all 
the viral proteins used in this study. PGE2 secretion has been detected in PBMC isolated 
from HIV-infected individuals using a Panx-1 dependent mechanism (Velasquez et al. 
2019). To further elucidate the role of sulfatide in neuroHIV, future studies will focus on 
assessing the mechanism of sulfatide release.  
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Figure 5.1. Gp120 treatment of mixed cultures of human primary astrocytes and 
differentiated neurons increases sulfatide secretion. Media collected from co-cultures 
of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells at 
different time points were assessed for sulfatide by ELISA. Sulfatide secretion did not 
significantly change in control cultures at different time points (control equal to 2.331 
mg/ml). Due to the minimal variations, we set the control sulfatide secretion at 1. (A) 
Quantification of extracellular release of sulfatide in the media of co-cultures of human 
primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells treated with 
HIV-1 BaL Gp120 50 nM for 6, 12, 24 and 48 hours. Sulfatide secretion increased at 24 
hours (* as compared to Control condition, p=0.0040, n=3) and decreased at 48 hours (# 
as compared to Gp120 50 nM 24h condition, p=0.0040, n=3), showing a transient 
secretion; (B) the same conditions used in A were repeated with a higher concentration of 
HIV-1 BaL Gp120 (100 nM). Consistent with A, the higher concentration resulted in 
increased sulfatide secretion at 24 hours (* as compared to Control condition, p=0.0257, 
n=3), which was then reduced at 48 hours (# as compared to Gp120 100 nM 24h condition, 
p=0.0012, n=3).  
Our results indicate that independently of the different concentrations of Gp120, sulfatide 
release increases transiently at 24 hours.  
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Figure 5.2. Tat treatment of mixed cultures of human primary astrocytes and 
differentiated neurons prevents sulfatide secretion. Media collected from co-cultures of 
human primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells at 
different time points were assessed for sulfatide by ELISA. Control cultures at different 
time points did not significantly change (control equal to 2.331 mg/ml) in sulfatide 
secretion. Due to the minimal variations, we set the control sulfatide secretion at 1.  (A) 
Quantification of the extracellular release of sulfatide in the media of co-cultures of human 
primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells treated with 
HIV-1 Tat1-72 100 ng/ml for 6, 12, 24 and 48 hours. Sulfatide secretion appeared to be 
reduced at 6 hours, however the change was not significant. In addition, sulfatide secretion 
did not change at 6, 12 and 24 hours compared to the control, except at 48 hours when it 
was reduced (# compared to Control condition, p=0.0457, n=3); (B) the same conditions 
used in A were repeated with HIV-1 Tat1-72 at 300 ng/ml showing that no significant 
changes in sulfatide secretion were observed during the time course analyzed compared to 
the control. 
Our results indicate that sulfatide secretion can be reduced after treatment with Tat1-72. 
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Figure 5.3. Nef treatment of mixed cultures of human primary astrocytes and 
differentiated neurons increases sulfatide secretion. Media collected from co-cultures 
of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells at 
different time points were assessed for sulfatide by ELISA. Control cultures at different 
time points did not significantly change (control equal to 2.331 mg/ml) in sulfatide 
secretion. Due to the minimal variations, we set the control sulfatide secretion at 1. (A) 
Quantification of the extracellular release of sulfatide in the media of co-cultures of co-
cultures of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma 
cells treated with HIV-1 HXB2 Nef 100 ng/ml for 6, 12, 24 and 48 hours. Sulfatide 
secretion increased at 48 hours (* as compared to Control condition, p=0.0148, n=3); (B) 
the same conditions used in A were repeated with HIV-1 HXB2 Nef 250 ng/ml. Consistent 
with A, sulfatide secretion was higher at 48 hours after administration of higher 
concentration of Nef (* as compared to Control condition, p=0.0002, n=3).  
Our results indicate that sulfatide release is increased 48 hours after treatment with Nef. 
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Figure 5.4. Vif treatment of mixed cultures of human primary astrocytes and 
differentiated neurons increases sulfatide secretion. Media collected from co-cultures 
of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells at 
different time points were assessed for sulfatide by ELISA. Control cultures at different 
time points did not significantly change (control equal to 2.331 mg/ml) in sulfatide 
secretion. Due to the minimal variations, we set the control sulfatide secretion at 1. (A) 
Quantification of the extracellular release of sulfatide in the media of co-cultures of co-
cultures of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma 
cells treated with HIV-1 HXB2 Vif 100 ng/ml for 6, 12, 24 and 48 hours. Sulfatide secretion 
increased at 48 hours (* as compared to Control condition, p=0.0005, n=3); (B) the same 
conditions used in A were repeated with HIV-1 HXB2 Vif 300 ng/ml. Consistent with A, 
sulfatide secretion was increased at 48 hours (* as compared to Control condition, 
p=0.0157, n=3).  
Our results indicate that Vif can increase sulfatide release at 48 hours.  
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Figure 5.5. Vpr treatment of mixed cultures of human primary astrocytes and 
differentiated neurons increases sulfatide secretion. Media collected from co-cultures 
of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells at 
different time points were assessed for sulfatide by ELISA. Control cultures at different 
time points did not significantly change (control equal to 2.331 mg/ml) in sulfatide 
secretion. Due to the minimal variations, we set the control sulfatide secretion at 1. (A) 
Quantification of the extracellular release of sulfatide in the media of co-cultures of co-
cultures of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma 
cells treated with HIV-1 Vpr 100 ng/ml for 6, 12, 24 and 48 hours. Sulfatide secretion 
increased at 24 hours (* as compared to Control condition, p=0.0094, n=3). The release of 
sulfatide returned to control levels at 48 hours, showing a transient secretion; (B) the same 
conditions used in A were repeated with HIV-1 Vpr 300 ng/ml. Consistent with A, also at 
higher concentration, sulfatide secretion resulted increased at 12 and 24 hours (* as 
compared to Control condition, p=0.0439, n=3). The release returned to control levels at 
48 hours, indicating a transient secretion similar to the time course observed in A.  
Our results indicate that sulfatide release is increased at 12 and 24 hours after treatment 
with Vpr. 
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Figure 5.6. Gp120 treatment of mixed cultures of human primary astrocytes and 
differentiated neurons does not change PGE2 secretion. Media collected from co-
cultures of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma 
cells at different time points were assessed for PGE2 by ELISA. Control cultures at 
different time points did not significantly change (control equal to 30 pg/ml) in PGE2 
secretion. Due to the minimal variations, we set the control PGE2 secretion at 1.  (A) 
Quantification of the extracellular release of PGE2 in the media of co-cultures of human 
primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells treated with 
HIV-1 Bal Gp120 50 nM for 6, 12, 24 and 48 hours. PGE2 secretion did not change during 
the analyzed time course; (B) the same conditions used in A were repeated with HIV-1 Bal 
Gp120 100 nM. Consistent with A, secretion of PGE2 did not change compared to the 
control. 
Our results indicate that independent of time points and concentrations, PGE2 secretion 
does not change after treatment with Gp120.  
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Figure 5.7. Tat treatment of mixed cultures of human primary astrocytes and 
differentiated neurons does not change PGE2 secretion. Media collected from co-
cultures of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma 
cells at different time points were assessed for PGE2 by ELISA. Control cultures at 
different time points did not significantly change (control equal to 30 pg/ml) in PGE2 
secretion. Due to the minimal variations, we set the control PGE2 secretion at 1. (A) 
Quantification of the extracellular release of PGE2 in the media of co-cultures of human 
primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells treated with 
HIV-1 Tat1-72 100 ng/ml for 6, 12, 24 and 48 hours. PGE2 secretion did not change during 
the time course analyzed; (B) the same conditions used in A were repeated with HIV-1 Tat1-
72 300 ng/ml. Consistent with A, secretion of PGE2 did not change compared to the control. 
Our results indicate that independently of time points and concentrations, PGE2 secretion 
does not change after treatment with Tat.  
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Figure 5.8. Nef treatment of mixed cultures of human primary astrocytes and 
differentiated neurons do not change PGE2 secretion. Media collected from co-cultures 
of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells at 
different time points were assessed for PGE2 by ELISA. Control cultures at different time 
points did not significantly change (control equal to 30 pg/ml) in PGE2 secretion. Due to 
the minimal variations, we set the control PGE2 secretion at 1. (A) Quantification of the 
extracellular release of PGE2 in the media of co-cultures of human primary astrocytes and 
differentiated SH-SY5Y human neuroblastoma cells treated with HIV-1 HXB2 Nef 100 
ng/ml for 6, 12, 24 and 48 hours. PGE2 secretion did not change during the time course 
analyzed; (B) the same conditions used in A were repeated with HIV-1 HXB2 Nef 250 
ng/ml. Consistent with A, secretion of PGE2 did not change compared to the control. 
Our results indicate that PGE2 secretion after treatment does not change with Nef.  
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Figure 5.9. Vif treatment of mixed cultures of human primary astrocytes and 
differentiated neurons does not change PGE2 secretion. Media collected from co-
cultures of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma 
cells at different time points were assessed for PGE2 by ELISA. Control cultures at 
different time points did not significantly change (control equal to 30 pg/ml) in PGE2 
secretion. Due to the minimal variations, we set the control PGE2 secretion at 1. (A) 
Quantification of the extracellular release of PGE2 in the media of co-cultures of human 
primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells treated with 
HIV-1 HXB2 Vif 100 ng/ml for 6, 12, 24 and 48 hours. PGE2 secretion did not change at 
all the time points; (B) the same conditions used in A were repeated with HIV-1 HXB2 Vif 
300 ng/ml. Consistent with A, secretion of PGE2 did not change compared to the control. 
Our results indicate that PGE2 secretion does not change after treatment with Vif.  
 
 
115 
 
 
 
Figure 5.10. Vpr treatment of mixed cultures of human primary astrocytes and 
differentiated neurons does not change PGE2 secretion. Media collected from co-
cultures of human primary astrocytes and differentiated SH-SY5Y human neuroblastoma 
cells at different time points were assessed for PGE2 by ELISA. Control cultures at 
different time points did not significantly change (control equal to 30 pg/ml) in PGE2 
secretion. Due to the minimal variations, we set the control PGE2 secretion at 1. (A) 
Quantification of the extracellular release of PGE2 in the media of co-cultures of human 
primary astrocytes and differentiated SH-SY5Y human neuroblastoma cells treated with 
HIV-1 Vpr 100 ng/ml for 6, 12, 24 and 48 hours. PGE2 secretion did not change at all the 
time points; (B) the same conditions used in A were repeated with HIV-1 Vpr 300 ng/ml. 
Consistent with A, secretion of PGE2 did not change compared to the control. 
Our results indicate that PGE2 secretion does not change after treatment with Vpr.  
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Introduction 
A critical mechanism discovered in our laboratory is that HIV, even in the absence of viral 
replication, uses gap junctional communication to spread toxicity and inflammation from 
HIV-infected into uninfected cells. We identified that Tat is a key viral protein to maintain 
Cx43 expression and functional gap junction channels (Berman et al. 2016). Our data 
described in Chapter 2 further reinforce our previous results. Thus, we examined whether 
extracellular sulfatide regulates Connexin 43 (Cx43), Zonula-Occludens 1 (ZO-1), and 
Connexin 36 (Cx36) expression using human primary astrocytes and SH-SY5Y 
neuroblastoma cells.  
We propose that sulfatide helps to maintain Cx43 expression in neurons and glia cells. We 
specifically analyzed whether sulfatide changes Cx43 mRNA and protein expression.  
Cx43 is the major expressed connexin in astrocytes and Cx36 is exclusively expressed in 
neurons (Rash et al. 2001). In addition, we investigated the tight-junction protein ZO-1. 
ZO-1 binds to both connexins, Cx43 and Cx36, in order to stabilize them on the plasma 
membrane (Thevenin et al. 2013). Although, ZO-1 binds to the extreme carboxyl terminus 
of Cx43 with the second PDZ domain (Giepmans and Moolenaar 1998), it interacts with 
the C-terminal tail of Cx36 using the first PDZ domain (Li X. et al. 2004) while performing 
a scaffold role for the GJs in the plasma membrane. Notably, ZO-1 interaction regulates 
GJs dynamic turnover maintaining GJ channels in an open and functional state. On the 
contrary, when ZO-1 separates from Cxs, it induces GJs closure and transitioning for 
endocytosis (Thevenin et al. 2017).  This dynamic turnover of GJs determines a relative 
short half-life (1–5 hours) of Cxs and GJs, regulating the physiological presence of GJs 
into the plasma membrane and resulting in GJs recycling or the triggering of apoptosis in 
pathological conditions. In particular, the dynamic turnover of Cx43 is mediated by an 
organized process of phosphorylation/dephosphorylation in specific serine (S) residues of 
the Cx43 C-term (Thevenin et al. 2017). When Cx43 is phosphorylated in the S373, Cx43 
does not interact with ZO-1, but forward trafficking towards the plasma membrane occurs. 
The S373 phosphorylation step explains the unphosphorylated isoform (NP) detected in 
our western blotting experiment that specifically indicates Cx43 non-phosphorylated in 
S365. Once S373 is dephosphorylated, ZO-1 can bind to Cx43 and S365 is phosphorylated 
(P1 isoform of our western blotting) allowing the GJs to be open and functional. Another 
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important step includes the phosphorylation of S262 by ERK1/2 that allows Cx43 inclusion 
into the plaque (Solan and Lampe 2007), it explains the P2 isoform detected in our western 
blotting. After that, S365 and S262 become dephosphorylated, and S368 can be 
phosphorylated causing the closure of GJs and release of ZO-1. The phosphorylation on 
S368, S255, S279, and S282 cause Cx43 GJs internalization by endocytosis via clathrin 
system. Overall, we evaluate whether extracellular sulfatide compromise cell-to-cell 
communication in vitro.  
 
Materials and Methods 
Cell Culture Methods 
Human primary astrocytes, SH-SY5Y human neuroblastoma cells, and Hela cells stably 
transfected with Cx43-CFP were used. High glucose Dulbecco's modified Eagle's medium 
(DMEM, 11995-065, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% 
fetal bovine serum (FBS, S12450H, Atlanta Biologicals, Flowery Branch, GA), penicillin, 
and streptomycin (15070063, Thermo Fisher Scientific, Waltham, MA) was used to grow 
all the cells at 37 °C in a humidified atmosphere with 5% CO2.  
SH-SY5Y human neuroblastoma cells were differentiated with 2 mM L-glutamine 
(25030081, Thermo Fisher Scientific, Waltham, MA), 2% B27 supplement (17504044, 
Thermo Fisher Scientific, Waltham, MA), 2 mM Glutamax (35050-061, Thermo Fisher 
Scientific, Waltham, MA) and 10 µM Retinoic Acid (R2625, Sigma-Aldrich, St. Luis, MO-
Aldrich, St. Luis, MO) for 7 days.  
Media for Hela cells stably transfected with Cx43-CFP was supplemented with 2 mM 
Geneticin (10131-027, Thermo Fisher Scientific, Waltham, MA). 
 
Total mRNA isolation 
Human primary astrocytes and SH-SY5Y cultures were treated with Sulfatide (10 ng/ml) 
for 6, 12 and 24 hours. Arachidonic acid (AA) (100 µM) was used as a control due to its 
effects in astrocytes (Martinez A. D. and Saez 1999). These concentrations were chosen 
according to lower pathological levels detected in non-myelinated areas (for sulfatide) and 
in the sera (for AA) of virologically suppressed HIV-infected individuals. Untreated and 
treated cells were harvested in TRI REAGENT (93289, Sigma-Aldrich, St. Luis, MO) 
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according to the manufacturer’s instructions. Cells were scratched in TRI REAGENT (1ml 
for 60 mm well plate) and 0.2 ml of chloroform (288306, Sigma-Aldrich, St. Luis, MO) 
were then added to the samples. After 3 minutes, the mixtures were transferred to 1 ml 
Eppendorf containing 0.5 ml pf phase lock gel (2302830, QuantaBio, Beverly, MA) and 
centrifuged at 12000 x g for 15 minutes at 4°C, to separate the RNA (aqueous phase) from 
proteins (red organic phase) and DNA (interphase). The aqueous phase was transferred to 
a fresh tube in which 0.5 ml of isopropanol (278475, Sigma-Aldrich, St. Luis, MO) was 
added. After 10 minutes, the samples were centrifuged at 12000 x g at 4°C for 15 minutes. 
The supernatant was removed and 1 ml of 75% ethanol (51976, Sigma-Aldrich, St. Luis, 
MO) was added to the RNA pellet at the bottom of the tube. The mixture was centrifuged 
at 7500 x g at 4°C for 5 minutes. The RNA was eluted from the filter in 100μl of DEPC-
treated water (AM9938, Invitrogen, Carlsbad, CA) and warmed for 10-15 minutes at 60 ºC 
to be fully dissolved. The RNA extract obtained was stored at -20 °C until use. The 
concentration of each sample was calculated by spectrophotometric analysis (OD 260/280) 
using NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA). 
 
Reverse Transcription PCR 
Reverse transcription for first-strand cDNA synthesis was performed using the SuperScript 
III First-Strand (18080-051, Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. 50 µM oligo (dT) was complexed with 300 ng of extracted RNA, in a final 
volume of 10 μl. Samples were incubated at 65 °C for 5 minutes and then placed on ice for 
at least 1 minute. 10 μl of cDNA synthesis mix (containing 10x RT buffer, 2 mM MgCl2, 
0.1 M DTT, 40 U/ μl RNaseOUT, 200 U/ μl  SuperScript III RT) was added prior to use of 
the Thermocycler (50°C for 50 minutes,  85°C 60’ for 5 minutes) (170-9703, BioRad, 
Hercules, CA). The cDNA obtained was stored at -20 °C until use. 
 
Quantitative real-time PCR (qRT-PCR) 
Human Cx43, ZO-1, Cx36 and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
expression in untreated and treated astrocytes and SH-SY5Y neuroblastoma cell line were 
analyzed by qRT-PCR using a StepOnePlus Real Time PCR system (4376600, Thermo 
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Fisher Scientific, Waltham, MA) (Table 5), absolute blue QPCR SYBR low Rox Mix 
(AB4323A, Thermo Fisher Scientific, Waltham, MA), and the primers in Table 6. Single 
product amplification was confirmed by melting curve analysis, and primer efficacy was 
near or close to 100% in all experiments.  
 
Table 5. qRT-PCR parameters. 
Temperature Time Process Number of Cycles 
95 ºC 15’ Enzyme Activation 1 cycle 
95 ºC 30’’ Denaturation  
 
40 cycles 
Tº annealing primers 
(~56 ºC) 
30’’ Annealing 
72 ºC 30’’ Extension 
95 ºC 15’’ Denaturation  
1 cycle 60 ºC 1’ Starting 
Temperature 
95 ºC 15’ Melting Step 
 
Table 6. Human reverse and forward primer sequences for Cx43, ZO-1, Cx36 and 
GAPDH. 
Gene Reverse Primer Forward Primer 
Cx43 5′-
GGGTTAAGGGAAAGAGCGAC
C -3′ 
5′-
CCCCATTCGATTTTGTTCTGC-
3’ 
ZO-1 5′-
CGCCTTTGGACAAAGAGAAG-
3′ 
5′-
TTTTAGGATCACCCGACGAC-3’ 
Cx36 5′-
TTCCTAGCCCTGGACAGAGA-
3′ 
5′-
GATGCAGTGCGTAGACCTGA-
3’ 
121 
 
GAPDH 5′-
AACGGATTTGGTCGTATTGGG
C-3′ 
5′-
CTTGACGGTGCCATGGAATTT
G-3’ 
 
Western blotting 
Human primary astrocytes and  SH-SY5Y neuroblastoma cultures were treated with 
sulfatide (10 ng/ml, 24323, Cayman Chemical, Ann Arbor, MI) and AA (100 µM, 2756, 
Tocris, Bristol, UK) for 6, 12 and 24 hours and harvested in RIPA buffer (9806, Cell 
Signaling, Danvers, MA) containing protease and phosphatase inhibitors (20 mM; 
pyrophosphate, 20 mM; NaF, 100 mM; NaVO3, 200 μM; leupeptin, 500 μg/ml; aprotinin, 
40 μg/ml; soybean trypsin inhibitor, 2 mg/ml; benzamidine, 1 mg/ml; ω-amino caproic 
acid, 1 mg/ml; PMSF, 3 mM; and EDTA, 20 mM). Untreated and treated cells were lysed, 
and the protein content of each cell lysate was determined using Bradford’s method (Bio-
Rad labs, Hercules, CA). Samples containing 50 μg of proteins were used to analyze Cx43, 
ZO-1, Cx36 and GAPDH. Proteins were separated in 7.5 % SDS-PAGE and 
electrophoretically transferred to nitrocellulose membrane, which was incubated 
sequentially with blocking solution (5 % non-fat milk in Tris-buffered saline); anti-Cx43 
(dilution 1:1000, anti-rabbit, C6219, Sigma-Aldrich, St. Luis, MO), anti-ZO-1 (dilution 
1:1000, anti-rabbit, 402200, Thermo Fisher Scientific, Waltham, MA), anti-Cx36 (dilution 
1:1000, anti-mouse, 37-4600, Thermo Fisher Scientific, Waltham, MA), and anti-GAPDH 
(dilution 1:1000, anti-rabbit, 14C10, Cell Signaling, Danvers, MA); and anti-rabbit/mouse 
IgG conjugated to HRP (dilution 1:1000, 7074S/7076S, Cell Signaling, Danvers, MA). 
Antigen-antibody complexes were detected by ECL (NEL103E001EA, Perkin Elmer, 
Boston, MA). The resulting immunoblot signals were scanned and densitometric analysis 
was performed using ImageJ NIH-image software. All results were normalized to the 
values obtained for control conditions. 
 
Immunofluorescence 
Human primary astrocytes and Hela cells stably transfected with Cx43-CFP were grown 
on coverslips and were treated with sulfatide and AA (resulting in a final concentration of 
10 ng/ml and 100 µM, respectively) for 6, 12 and 24 hours. Later, untreated and treated 
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cells were fixed with 4% PFA (15710-S, Electron Microscopy Science, Hatfield, PA) and 
permeabilized in 0.1% Triton (X-100, Sigma-Aldrich, St. Luis, MO) for 2 min at room 
temperature. Cells were incubated in blocking solution (0.5 M EDTA pH 8.0 (15575-038, 
Thermo Fisher Scientific, Waltham, MA), 1% Fish gelatin from cold water (G7765, Sigma-
Aldrich, St. Luis, MO), 0.1 g Albumine from bovine serum fraction V (BP1605, Thermo 
Fisher Scientific, Waltham, MA), 1% Horse serum (H1138, Sigma-Aldrich, St. Luis, MO), 
5% human serum (31876, Thermo Fisher Scientific, Waltham, MA), 9 ml ddH20) overnight 
at 4 °C and then in diluted primary antibodies (anti-Cx43, dilution 1:1000, anti-rabbit, 
C6219, Sigma-Aldrich, St. Luis, MO;  anti-ZO-1, dilution 1:200, anti-mouse, MABT339, 
Millipore, Burlington, MA) overnight at 4 °C. Cells were washed several times with PBS 
(BP665-1, Thermo Fisher Scientific, Waltham, MA) at room temperature and incubated 
with the appropriate secondary antibodies (plus Phalloidin 680 or Texas Red, dilution 
1:250, A22286/T7471, Thermo Fisher Scientific, Waltham, MA) for at least 2 hours at 
room temperature followed by several washes in PBS. Cells were then mounted using 
Prolong Gold anti-fade reagent (P36930, Thermo Fisher Scientific, Waltham, MA) and 
examined using an A1 confocal microscope (Nikon, Japan). Specificity was confirmed by 
replacing the primary antibodies with the appropriate isotype matched control reagent, anti-
IgG2A, or the IgG fraction of normal mouse/rabbit serum (A-2179/A-0418, Sigma-Aldrich, 
St. Luis, MO). 
 
Statistical Analysis  
All data were expressed as mean ± standard error of the mean (SEM). Differences among 
groups were analyzed by a one-way analysis of variance (ANOVA test), using Bonferroni’s 
multiple comparison test for post-hoc analysis. The level of significance was accepted at 
p<0.05. Prism8.0 software was used for the statistical analyses performed. 
 
Results 
Extracellular sulfatide increases cell-to-cell communication in human primary 
astrocytes. Considering that HIV-infected astrocytes use GJs and uHCs to spread 
inflammatory and pro-apoptotic molecules into the neighboring uninfected cells (Eugenin 
and Berman 2007) and that HIV proteins induce the secretion of sulfatide (see Chapter 5), 
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we mimicked these pathological conditions in vitro. We evaluated mRNA and protein 
expression by carrying out qRT-PCR, western blotting, and immunofluorescence in human 
primary astrocytes treated with 10 ng/ml sulfatide for 6, 12 and 24 hours. We showed that 
sulfatide upregulates Cx43 mRNA expression at 24 hours (Figure 6.1 A, * p=0.0425). 
Furthermore, sulfatide increased Cx43 P1 and P2 isoforms after 24 hours (Figure 6.2 C, * 
p<0.0001; Figure 6.2 D, * p=0.0092). This means that sulfatide induced S365 and S262 
phosphorylation in the C-term of Cx43 to make GJs open, functional, and well incorporated 
in the plaque between the cells. In addition, immunofluorescence analysis for Cx43, ZO-
1, actin and DAPI in human primary astrocytes treated with sulfatide showed an increase 
in Cx43 intensity (Figure 6.3 B, * p=0.0099), and Cx43-ZO-1 colocalization (Figure 6.3 
D, * p=0.0117; Figure 6.2 E, * p=0.0006), based on the maximum peak from all the groups 
treated. Thus, it suggests that Cx43 can be regulated by sulfatide in the forward trafficking 
towards the plasma membrane and in the stabilization into the plasma membrane.  
Although, sulfatide did not change ZO-1 mRNA compared to the control conditions 
(Figure 6.1 B), it increased ZO-1 protein level after 12 (Figure 6.2 F, * p=0.0006) and 24 
hours (Figure 6.2 F, * p=0.0006). Any significative changes were detected for ZO-1 
maximal peak intensity compared to the controls in the immunofluorescence analysis 
(Figure 6.3 C). This indicates that sulfatide upregulates astrocyte cell communication 
systems, especially working on the protagonist of the channels, Cx43.  
Likewise, we performed the same experiments in human astrocytes using AA, because 
several previous unpublished data in our laboratory and data from the literature (Martinez 
A. D. and Saez 1999, Puebla et al. 2017) showed that AA either decreased or did not change 
junctional communication. We showed that AA, as well as other inflammatory molecules, 
decreased cell-to-cell communication systems in human primary astrocytes. Specifically, 
AA transiently reduced Cx43 mRNA expression after 12 hours (Figure 6.4 A, * p=0.0414), 
as well as decreased all the protein isoforms of Cx43 after 24 hours compared to the control 
conditions (Figure 6.5 B, * p=0.0007; C, * p=0.0074; D * p=0.0034), suggesting that AA 
supports the close status of GJs. On another hand, AA did not change ZO-1 mRNA (Figure 
6.4 B) but drastically decreased ZO-1 proteins at all timepoints compared to the control 
conditions (Figure 6.5 F, * p<0.0001), confirming that AA destabilizes Cx43 in the plaque 
and obstructed cellular communication. In addition, immunofluorescence for Cx43, ZO-1, 
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actin and DAPI in human primary astrocytes treated with AA demonstrated that Cx43 
trafficking was not affected due to any significative changes in Cx43 and ZO-1 intensities 
(Figure 6.6 B and C) and colocalization (Figure 6.6 D and E), considering the maximum 
peak from all the treated groups. So, AA perfectly reproduced inflammatory conditions 
enhancing GJ closure. 
 
Extracellular sulfatide downregulates mRNA and proteins involved in cell-to-cell 
communication in differentiated SH-SY5Y neuroblastoma cell line. Neurons are not 
directly infected by HIV, but they are targets of HIV proteins. As sulfatide secretion is 
regulated by HIV proteins, we assessed sulfatide effect on cell-to-ell communication using 
qRT-PCR and western blotting on SH-SY5Y neuroblastoma cells differentiated for 1 week 
with retinoic acid and treated with sulfatide for 6, 12 and 24 hours. We analyzed the level 
of Cx43, ZO-1 and Cx36 (which allow neuron cellular communication and maintain 
electrical connectivity between different populations of neurons). Our results showed that 
sulfatide downregulated Cx43 mRNA expression after 24 hours compared to the control 
conditions (Figure 6.7 A, * p=0.002), downregulated ZO-1 mRNA expression at all the 
time points compared to control conditions (Figure 6.7 B, * p<0.0001), but did not affect 
Cx36 mRNA expression (Figure 6.7 C). Nevertheless, only ZO-1 protein underwent a 
significant reduction after sulfatide treatment all the time points (Figure 6.8 E, * p<0.0001), 
suggesting that sulfatide decrease expression of mRNA and proteins involved in cellular 
communication in neurons by reducing ZO-1, whose interaction with Cxs is necessary to 
establish cellular communication. Although, sulfatide decreased Cx43 mRNA, the two 
isoforms of proteins detected in neurons were repristinated. Moreover, Cx36 protein, as 
well as Cx36 mRNA, did not undergo significantly changes.  
Using the same approach as applied to astrocytes, SH-SY5Y cells were treated with AA as 
a positive control. In differentiated neurons, AA transiently decreased Cx43 mRNA after 
6 hours (Figure 6.9 A, * p<0.0001) and 24 hours (Figure 6.9 A, * p<0.0001), but did not 
change Cx43 protein expressions (Figure 6.10 B and C). Moreover, AA increased ZO-1 
mRNA level after 12 (Figure 6.9 B, * p<0.0001) and 24 hours (Figure 6.9 B, * p<0.0001), 
but any change was detected at the protein level (Figure 6.10 E).  In addition, neither Cx36 
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mRNA (Figure 6.9 C) or Cx36 protein (Figure 6.10 G) significantly changed. Thus, we can 
assess that AA does not change the cellular communication system between neurons. 
 
Extracellular sulfatide induces Cx43 internalization in Hela cells. Although, sulfatide 
can differentially regulate cellular communication in astrocytes and neurons, we 
investigated Cx43 trafficking using Hela cells stably transfected with Cx43-CFP. We also 
treated these cells with 10 ng/ml sulfatide for 6, 12 and 24 hours and we stained them for 
phalloidin Texas Red to visualize the cellular membrane (Figure 6.11 A). Thus, we 
identified that in all the control conditions and at 0 hour sulfatide, Cx43 was mostly 
localized in the plasma membrane to generate plaques (Figures 6.11 A as indicated by the 
yellow arrows). On the contrary, in sulfatide conditions Cx43 had a cytoplasmatic 
localization (Figures 6.11 A, as indicated by the white arrows), suggesting that sulfatide 
induces Cx43 internalization, moving Cx43 from the plaques (Figures 6.11 A, as indicated 
by the yellow arrows, and Figure 6.11 B, ** p<0.0001) in the cellular membrane to the 
intracellular vesicles (Figures 6.11 A, as indicated by the white arrows, and Figure 6.11 B, 
** p<0.0001) into the cytoplasm. This demonstrates that, sulfatide can modulate Cx43 
trafficking towards the cytoplasm.  
Hela cells stably transfected with Cx43-CFP were treated with AA for 6, 12 and 24 hours. 
Our results showed that AA did not induce Cx43 internalization. Internalized vesicles were 
also present in 6, 12 and 24 hours control conditions (Figure 6.12 A, as indicated by white 
arrows, and Figure 6.12 B, ** p<0.0001). This Cx43 internalization may be due to the soya 
oil/water solvent (Tocrisolve) used to dissolve AA and that we also used to treat 6, 12 and 
24 hours control conditions. This consideration is supported by Cx43 localization in the 
plaques at no treatment (0 hour control and 0 hour sulfatide) conditions (meaning no 
treatment with Tocrisolve and AA, respectively) (Figure 6.12 A, as indicated by yellow 
arrows, and Figure 6.12 B), when the cells never came in contact with Tocrisolve. Thus, 
we cannot assess that AA regulates Cx43 trafficking.  
 
Discussion  
As we explained in the general introduction and in this chapter’s introduction, cell-to-cell 
communication is a common physiological and pathological system used by cells to share 
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signaling as well as toxic molecules. Although, several pathological conditions showed a 
decreased level of GJs and uHC (Rouach et al. 2002), HIV is the only case that showed the 
opposite. In fact, HIV-infected astrocytes use GJs and uHCs to communicate with and 
induce apoptosis to the neighboring neurons, the other nearby astrocytes and the adjacent 
endothelial cells. Therefore, we investigated whether our potential lipid biomarker of the 
HIV CNS disease, sulfatide, could be involved in the regulation of cellular communication. 
Our data from human primary astrocytes showed that sulfatide upregulated Cx43. These 
results support our proposed mechanism of bystander damage and can be related to the 
common feature of GJs and uHCs being opened and functional in HIV-infected astrocytes.  
On the contrary, in differentiated SH-SY5Y neuroblastoma cells, sulfatide downregulates 
ZO-1, but it did not regulate Cx43 and Cx36. Thus, in neurons sulfatide displayed a 
different effect decreasing cell-to-cell communication. Sulfatide decreased ZO-1 
destabilizing Cxs in the plaques.  
In addition, in Hela cells stably transfected with Cx43-CFP, we demonstrated that sulfatide 
induced internalization of the plaques, regulating Cx43 trafficking from the plasma 
membrane to the cytoplasm. Although, this result seems to show an opposite mechanism 
from that one proposed for astrocytes, it is necessary to consider that the systems used are 
different. However, both in astrocytes and in Hela cells transfected with Cx43-CFP, 
sulfatide modulated Cx43 trafficking. Future experiments will further evaluate changes in 
cell-to-cell communication by using die coupling or electrophysiology. 
In conclusion, sulfatide may directly and indirectly contributes to the expansion of neuronal 
damage and neurocognitive disorders observed in the numerous cases of HIV-infected 
individuals under cART and with undetectable viral replication.  
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Figure 6.1. Extracellular sulfatide upregulates Cx43 mRNA in human primary 
astrocytes. Treatment of human primary astrocytes with sulfatide resulted in increased 
level of Cx43 mRNA. mRNA was isolated from human primary astrocytes and were 
assessed for Cx43 and ZO-1 using RT-PCR. (A) Quantification of Cx43 mRNA in human 
primary astrocytes treated with 10 ng/ml sulfatide for 6, 12 and 24 hours. Controls at 
different time points did not significantly change (controls equal to 1.8 2-ΔΔCt, was set to 
1). Cx43 mRNA increased at 24 hours (* as compared to controls and 0h Sulfatide 
conditions, p=0.0425, n=3). (B) The same conditions used in A were repeated for ZO-1 
mRNA level (controls equal to 2.9 2-ΔΔCt, was set to 1). In contrast with A, sulfatide did 
not significantly upregulate ZO-1 mRNA. 
Our results indicate that sulfatide treatment upregulates Cx43 mRNA level after 24 hours.  
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Figure 6.2. Extracellular sulfatide upregulates Cx43 and ZO-1 proteins in human 
primary astrocytes. Treatment of human primary astrocytes with sulfatide resulted in 
increased level of Cx43 and ZO-1 proteins. Proteins were extracted from human primary 
astrocytes and were assessed for Cx43 and ZO-1 using wester blotting. (A) Detection of 
Cx43 resulted in several bands representing different isoforms of around 43 kDa, according 
to the literature (Thevenin et al. 2017). GAPDH was used as control loading. (B) 
Quantification of Cx43 non-phosphorylated (NP) isoform in human primary astrocytes 
treated with 10 ng/ml sulfatide for 6, 12 and 24 hours. Controls at different time points did 
not significantly change (controls equal to 0.5 arbitrary units, was set to 1). (C) The same 
conditions used in A were repeated for Cx43 phosphorylated isoform (P1) (controls equal 
to 0.3 arbitrary units, was set to 1). Sulfatide increased Cx43 P1 protein level after 24 hours 
(* as compared to controls and 0h Sulfatide conditions, p<0.0001, n=3). (D) The same 
conditions used in A and in B were repeated for Cx43 phosphorylated isoform (P2) 
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(controls equal to 0.4 arbitrary units, was set to 1). Sulfatide increased Cx43 P2 protein 
level after 24 hours (* as compared to controls and 0h Sulfatide conditions, p=0.0092, n=3). 
(E) Detection of ZO-1 resulted in a single band of 220 kDa, GAPDH was used as loading 
control. (F) Quantification of ZO-1 protein in human primary astrocytes treated with 10 
ng/ml sulfatide for 6, 12 and 24 hours. Controls at different time points did not significantly 
change (controls equal to 0.5 arbitrary units, was set to 1).  Sulfatide increased ZO-1 protein 
level after 12 hours (* as compared to controls and 0h Sulfatide conditions, p=0.0006, n=3), 
suggesting a transient increase that came back to the control levels at 24 hours.  
Our results indicate that sulfatide treatment upregulates Cx43 P1 and P2 isoforms protein 
level at 24 hours and transiently ZO-1 protein level at 12 hours.  
 
 
 
 
 
 
 
 
130 
 
 
131 
 
Figure 6.3. Extracellular sulfatide upregulates Cx43-ZO-1 colocalization in human 
primary astrocytes. Treatment of human primary astrocytes with sulfatide resulted in 
increased Cx43 and ZO-1 colocalization as well as stabilizing Cx43 plaques at the plasma 
membrane. Immunofluorescence staining for Cx43, ZO-1, actin and DAPI was performed 
in human primary astrocytes in control and sulfatide treated conditions after 6, 12 and 24 
hours. (A) Representative staining for Cx43 in green, ZO-1 in white, actin in red and DAPI 
in blue (20X). Quantification for 5 pictures per condition representing the total number of 
the pixels was performed considering the relative staining intensity from the maximal peak 
of all the treated groups (B) for Cx43 that was upregulated in sulfatide conditions (* as 
compared to control conditions, p=0.0099, n=3) and (C) for ZO-1 that did not show any 
difference in intensity for the controls and the treated groups (n=3). Co-localization for 
Cx43 and ZO-1 was measured by (D) correlation coefficient between Cx43 and ZO-1 (* 
as compared to control condition p=0.0117, n=3) and (E) overlap coefficient between Cx43 
and ZO-1 (* as compared to control conditions, p=0.0006, n=3;) considering the  maximal 
peak of all the control and treated groups. Both analyses used to calculate Cx43 and ZO-1 
colocalization showed upregulation for the sulfatide treated groups. 
Our results indicate that sulfatide treatment upregulates Cx43 intensity and Cx43-ZO-1 
colocalization in human primary astrocytes.  
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Figure 6.4. Arachidonic acid (AA) downregulates Cx43 mRNA in human primary 
astrocytes. Treatment of human primary astrocytes with AA resulted in decreased level of 
Cx43 mRNA. mRNA was isolated from human primary astrocytes were assessed for Cx43 
and ZO-1 using RT-PCR. (A) Quantification of Cx43 mRNA in human primary astrocytes 
treated with 100 µM AA for 6, 12 and 24 hours. Controls at different time points did not 
significantly change (controls equal to 2.7 2-ΔΔCt, was set to 1). Cx43 mRNA decreased at 
12 hours (* as compared to controls and 0h Sulfatide conditions, p=0.0414, n=3), 
supporting a transient downregulation. (B) The same conditions used in A were repeated 
for ZO-1 mRNA level (controls equal to 2.5 2-ΔΔCt, was set to 1). In contrast with A, 
sulfatide did not change ZO-1 mRNA. 
Our results indicate that sulfatide treatment transiently downregulates Cx43 mRNA level 
at 12 hours.  
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Figure 6.5. Arachidonic acid (AA) downregulates Cx43 and ZO-1 proteins in human 
primary astrocytes. Treatment of human primary astrocytes with AA resulted in 
decreased level of Cx43 and ZO-1 proteins. Proteins were extracted from human primary 
astrocytes and were assessed for Cx43 and ZO-1 using wester blotting. (A) Detection of 
Cx43 resulted in several bands representing different isoforms of around 43 kDa, according 
to the literature (Thevenin et al. 2017). GAPDH was used as control loading. (B) 
Quantification of Cx43 non-phosphorylated (NP) isoform in human primary astrocytes 
treated with 100 µM AA for 6, 12 and 24 hours. Controls at different time points did not 
significantly change (controls equal to 0.5 arbitrary units, was set to 1). AA decreased Cx43 
NP protein level after 24 hours (* as compared to controls and 0h AA conditions, p=0.0007, 
n=3). (C) The same conditions used in B were repeated for Cx43 phosphorylated isoform 
(P1) (controls equal to 0.7 arbitrary units, was set to 1). Consistent with A, AA decreased 
Cx43 P1 protein level after 24 hours (* as compared to controls and 0 hour AA conditions, 
p=0.0074, n=3). (D) The same conditions used in B and C were repeated for Cx43 
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phosphorylated isoform (P2) (controls equal to 0.5 arbitrary units, was set to 1). AA 
decreased Cx43 P2 protein level after 12 and 24 hours (* as compared to controls and 0h 
AA conditions, p=0.0034 and p=0.0067, n=3). (E) Detection of ZO-1 resulted in a single 
band of 220 kDa, GAPDH was used as loading control. (F) Quantification of ZO-1 protein 
in human primary astrocytes treated with 100 µM AA for 6, 12 and 24 hours. Controls at 
different time points did not significantly change (controls equal to 3.5 arbitrary units, was 
set to 1).  AA decreased ZO-1 protein level after 6, 12 and 24 hours (* as compared to 
controls and 0h AA conditions, p<0.0001, n=3).  
Our results indicate that AA treatment downregulates Cx43 and ZO-1 protein levels.  
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Figure 6.6. Arachidonic acid (AA) does not change Cx43-ZO-1 colocalization in 
human primary astrocytes. Treatment of human primary astrocytes with AA does not 
upregulate Cx43 and ZO-1 colocalization. Immunofluorescence staining for Cx43, ZO-1, 
actin and DAPI was performed in human primary astrocytes in control and AA treated 
conditions after 6, 12 and 24 hours. (A) Representative staining for Cx43 in green, ZO-1 
in white, actin in red and DAPI in blue (20X). Quantification for 5 pictures per condition 
representing the total number of the pixels was performed considering the relative staining 
intensity from the maximal peak of all the treated groups (B) for Cx43 that did not show 
any difference in intensity (n=3) and (C) for ZO-1, that consistent with B did not show any 
difference in intensity for the controls and the treated groups (n=3). Co-localization for 
Cx43 and ZO-1 was measured by (D) correlation coefficient between Cx43 and ZO-1 (n=3) 
and (E) overlap coefficient between Cx43 and ZO-1 (n=3) considering the maximal peak 
of all the control and treated groups. Both analyses used to calculate Cx43 and ZO-1 
colocalization do not show significant changes for the AA treated groups compared to 
controls. 
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Figure 6.7. Extracellular sulfatide downregulates Cx43 and ZO-1 but not Cx36 
mRNA in SH-SY5Y neuroblastoma cells. Treatment of in SH-SY5Y neuroblastoma cells 
with sulfatide resulted in decreased level of Cx43 and ZO-1 mRNA. mRNA was isolated 
from SH-SY5Y neuroblastoma cells and was assessed for Cx43, ZO-1, Cx36 using RT-
PCR. (A) Quantification of Cx43 mRNA in SH-SY5Y neuroblastoma cells treated with 10 
ng/ml sulfatide for 6, 12 and 24 hours. Controls at different time points did not significantly 
change (controls equal to 5 2-ΔΔCt, was set to 1). Cx43 mRNA decreased at 24 hours (* as 
compared to controls and 0h Sulfatide conditions, p=0.0002, n=3). (B) The same conditions 
used in A were repeated for ZO-1 mRNA level (controls equal to 1.2 2-ΔΔCt, was set to 1). 
ZO-1 mRNA decreased at 6, 12 and 24 hours (* as compared to controls and 0h Sulfatide 
conditions, p<0.0001, n=3). (C) The same conditions used in A and B were repeated for 
Cx36 mRNA level (controls equal to 1 2-ΔΔCt, was set to 1). Sulfatide treatment did not 
change Cx36 mRNA level.  
Our results indicate that sulfatide treatment downregulates Cx43 mRNA level at 24 hours 
and ZO-1 at all the time points considered.   
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Figure 6.8. Extracellular sulfatide downregulates ZO-1 protein in SH-SY5Y 
neuroblastoma cells. Treatment of in SH-SY5Y neuroblastoma cells with sulfatide 
resulted in decreased level ZO-1 protein. Proteins were extracted from in SH-SY5Y 
neuroblastoma cells and were assessed for Cx43, ZO-1 and Cx36 using wester blotting. 
(A) Detection of Cx43 resulted in two bands representing different isoforms of around 43 
kDa, according to the literature (Thevenin et al. 2017). Tubulin was used as control loading. 
(B) Quantification of Cx43 non-phosphorylated (NP) isoform in SH-SY5Y neuroblastoma 
cells treated with 10 ng/ml sulfatide for 6, 12 and 24 hours. Cx43 at different time points 
did not significantly change (controls equal to 0.3 arbitrary units, was set to 1). (C) The 
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same conditions used in B were repeated for Cx43 phosphorylated isoform (P1) (controls 
equal to 0.3 arbitrary units, was set to 1). Consistent with B, Cx43 at different time points 
did not significantly change (D) Detection of ZO-1 resulted in two bands of around 220 
kDa that were analyzed as sum. GAPDH was used as loading control. (E) Quantification 
of ZO-1 protein in SH-SY5Y neuroblastoma cells treated with 10 ng/ml sulfatide for 6, 12 
and 24 hours. Controls at different time points did not significantly change (controls equal 
to 1.1 arbitrary units, was set to 1).  In contrast with B and C, Sulfatide decreased ZO-1 
protein level after 6,12 and 24 hours (* as compared to controls and 0h Sulfatide condition, 
p<0.0001, n=3). (F) Detection of Cx36 resulted in two bands of around 36 kDa that were 
analyzed as sum. GAPDH was used as loading control. (G) Quantification of Cx36 protein 
in SH-SY5Y neuroblastoma cells treated with 10 ng/ml sulfatide for 6, 12 and 24 hours. 
Consistent with B and C, sulfatide did not significantly change Cx36 protein level (controls 
equal to 1 arbitrary unit, was set to 1).   
Our results indicate that sulfatide treatment downregulates ZO-1 protein level at all the 
time points considered. 
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Figure 6.9. Arachidonic acid (AA) downregulates Cx43 but not Cx36 mRNA and 
upregulates ZO-1 mRNA in SH-SY5Y neuroblastoma cells. Treatment of SH-SY5Y 
neuroblastoma cells with AA resulted in transient decreased level of Cx43 mRNA. mRNA 
was isolated from SH-SY5Y neuroblastoma cells and was assessed for Cx43, ZO-1 and 
Cx36 using RT-PCR. (A) Quantification of Cx43 mRNA in SH-SY5Y neuroblastoma cells 
treated with 100 µM AA for 6, 12 and 24 hours. Controls at different time points did not 
significantly change (controls equal to 1.7 2-ΔΔCt, was set to 1). Cx43 mRNA decreased 
transiently at 6 hours (* as compared to controls and 0h AA conditions, p<0.0001, n=3) 
and again at 24 hours (* as compared to controls and 0h AA conditions, p<0.0001, n=3), 
supporting transient downregulation. (B) The same conditions used in A were repeated for 
ZO-1 mRNA level (controls equal to 1.7 2-ΔΔCt, was set to 1). In contrast with A, AA 
upregulated ZO-1 mRNA at 12 and 24 hours (* as compared to controls and 0h AA 
conditions, p<0.0001, n=3). (C) The same conditions used in A and B were repeated for 
Cx36 mRNA level (controls equal to 1 2-ΔΔCt, was set to 1).  
Our results indicate that AA treatment transiently downregulates Cx43 mRNA level at 6 
and 24 hours, in contrast to ZO-1 that is upregulated.  
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Figure 6.10. Arachidonic acid (AA) does not change Cx43, ZO-1 and Cx36 proteins in 
SH-SY5Y neuroblastoma cells. Treatment of SH-SY5Y neuroblastoma cells with AA 
resulted in any changes. Proteins were extracted from SH-SY5Y neuroblastoma cells and 
were assessed for Cx43, ZO-1 and Cx36 using wester blotting. (A) Detection of Cx43 
resulted in two bands representing different isoforms of around 43 kDa, according to the 
literature, Tubulin was used as control loading. (B) Quantification of Cx43 non-
phosphorylated (NP) isoform in human primary astrocytes treated with 100 µM AA for 6, 
12 and 24 hours. AA did not significantly change Cx43 NP (controls equal to 0.4 arbitrary 
units, was set to 1). (C) The same conditions used in B were repeated for Cx43 
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phosphorylated isoform (P1) (controls equal to 0.3 arbitrary units, was set to 1). Consistent 
with B, AA did not significantly change Cx43 P1. (D) Detection of ZO-1 resulted in two 
bands of around 220 kDa that were calculated as sum. GAPDH was used as loading control. 
(E) Quantification of ZO-1 protein in SH-SY5Y neuroblastoma cells treated with 100 µM 
AA for 6, 12 and 24 hours (controls equal to 1.1 arbitrary units, was set to 1). Again, AA 
did not significantly change ZO-1 expression. (F) Detection of Cx36 resulted in two bands 
of around 36 kDa that were calculated as sum. GAPDH was used as loading control. (G) 
Quantification of Cx36 protein in SH-SY5Y neuroblastoma cells treated with 100 µM AA 
for 6, 12 and 24 hours. Consistent with Cx43 and ZO-1 results, AA did not significantly 
change Cx36 expression. (controls equal to 0.8 arbitrary units, was set to 1).   
Our results indicate that AA, independently of the time points, does not change cellular 
communication system in neurons. 
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Figure 6.11. Extracellular sulfatide induces internalization of Cx43-CFP in Hela cells. 
Treatment with sulfatide of Hela cells stably transfected with Cx43-CFP resulted in 
internalization of Cx43-CFP. (A) Representative staining for actin (red) in Hela cells stably 
transfected with Cx43-CFP (green) for controls and sulfatide groups at 6, 12 and 24 hours 
(40X). Plaques and internalized vesicles are indicated by yellow and white arrows, 
respectively. (B) Quantification for 5 pictures per condition representing the total number 
of the pixels was performed considering the percentage of Cx43 positive cells. Cx43 in the 
control conditions is mostly localized in the plasma membrane creating the plaques (yellow 
arrows, ** as compared to controls and 0h Sulfatide conditions, p<0.0001), instead, in 
sulfatide conditions Cx43 localized in the cytoplasm (white arrows, ** as compared to 
controls and 0h Sulfatide conditions, p<0.0001). 
Our results indicate that sulfatide increases the trafficking of Cx43 in Hela cells stably 
transfected with Cx43-CFP.  
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Figure 6.12. Internalization of Cx43-CFP is not observed in AA treated Hela cells 
versus controls Hela cells. Treatment with AA of Hela cells stably transfected with Cx43-
CFP did not affect Cx43-CFP trafficking. (A) Representative staining for actin (red) in Hela 
cells stably transfected with Cx43-CFP (green) for controls and AA groups at 6, 12 and 24 
hours (40X). Plaques and internalized vesicles are indicated by yellow and white arrows, 
respectively. (B) Quantification for 5 images per condition representing the total number 
of the pixels was performed considering the percentage of Cx43 positive cells. Cx43 in 
control and AA conditions at 6, 12, 24 hours were localized in intracellular vesicles (** as 
compared to 0h control and 0h AA conditions, p<0.0001). The 6, 12 and 24 hours control 
conditions were treated with the vehicle (Tocrisolve) which may induce the observed 
changes. 
Results suggest that AA does not change Cx43 trafficking in Hela cells stably transfected 
with Cx43-CFP, Cx43 internalization is due to the soya oil/water solvent used to dissolve 
AA, and that was used to treat 6, 12 and 24 hours control conditions.  
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Introduction  
Proteomics is defined as a large-scale study for the identification and the 
quantification of proteomes, which includes a set of proteins synthetized in a specific 
biological context. Proteomics can expand genomic and transcriptomics data to directly 
identify the proteins that are up- or down-regulated in specific conditions, and to 
investigate the related pathways  (Aslam et al. 2017).  
Previous transcriptomics and proteomics results from our laboratory (data not 
shown) supported lipid alteration in HIV-infected astrocytes, mostly related to the up-
regulation of ceramide related enzymes. In particular, transcriptomic analysis of 7 days 
HIV-infected astrocytes showed that HIV infection increased levels of glucosylceramidase, 
galactosyltransferase, and ceramide synthase that are enzymes critically involved in 
ceramide and sulfatide synthesis. In addition, proteomics data from 21 days HIV-infected 
astrocytes confirmed glucosylceramidase and galactosyltransferase up-regulation, 
suggesting sulfatide accumulation. This result correlates with our MSI data presented in 
Chapter 4 showing higher sulfatide relative abundance in the brain, specifically in the white 
matter of HIV-infected individuals under cART and without viral replication (see Table 2, 
Chapter 2).  
Since we have proposed sulfatide as a potential biomarker of neurocognitive 
disorders in HIV-infected individuals virally suppressed with cART and without detectable 
viral load, our interest was to investigate whether sulfatide altered cell-to-cell 
communication (see Chapter 6). Moreover, we demonstrated that sulfatide secretion can be 
regulated by several HIV proteins and it can modulate cell-to-cell communication, 
especially Cx43 trafficking in Hela cells stably transfected with Cx43-CFP.  
Although, we have not yet determined the molecular pathways that connect sulfatide with 
Cx43, we decided to identify the Cx43 partners in Hela cells stably transfected with Cx43-
CFP under sulfatide and AA conditions. Thus, coimmunoprecipitation for Cx43 was 
performed to identify potential Cx43 binding proteins.  
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Materials and Methods   
Cell Culture Methods 
Hela cells stably transfected with Cx43-CFP were grown with high glucose Dulbecco's 
modified Eagle's medium (DMEM, 11995-065, Thermo Fisher Scientific, Waltham, MA) 
supplemented with 10% fetal bovine serum (FBS, S12450H, Atlanta Biologicals, Flowery 
Branch, GA), 2 mM Geneticin (10131-027, Thermo Fisher Scientific, Waltham, MA), 
penicillin, and streptomycin (15070063, Thermo Fisher Scientific, Waltham, MA) at 37 °C 
in a humidified atmosphere with 5% CO2.  
 
Cx43 immunoprecipitation 
Immunoprecipitation analysis was performed for Cx43 as described in Figure 7.1.  Hela 
cells stably transfected with Cx43-CFP were treated with sulfatide (10 ng/ml) or with AA 
(100 µM) for 24 hours. Cells were homogenized with RIPA buffer containing protease and 
phosphatase inhibitors and sonicated using 5 pulses of 30 seconds on and 30 seconds off 
in a Microtip (Misonix, Inc, Microson XL-2000). Samples were pre-cleared with protein 
G plus agarose (sc-2002, Santa Cruz Biotechnology, Dallas, TX) and immunoprecipitated 
using Cx43 antibody (C6219, Sigma-Aldrich, St. Luis, MO). These samples were sent to 
Creative Proteomics (Shirley, NY) to be analyzed and quantified on a high-resolution mass 
spectrometry platform coupled with nanoflow UPLC to select proteins with a fold-change 
cutoff above 1.5 or below 1/1.5. 
 
Proteomics for proteins associated with Cx43 
The beads samples from untreated and sulfatide/AA treated cultures of Hela cells stably 
transfected with Cx43-CFP were resuspended in 40 μL of 1× electrophoresis sample buffer, 
boiled for 15 minutes and run on 12% separating gel for 20 minutes at 80 kV and for 30 
minutes at 120 kV. The SDS-PAGE gel was stained with Coomassie Brilliant Blue and 
each gel band was cut to be subjected to protein precipitation using cold acetone and 
centrifuged at 12000 rpm. Later, 50 mM ammonium bicarbonate was added, and the 
protein solution was transferred into Microcon devices YM-10 (Millipore). The device was 
centrifuged at 12000 rpm at 4°C for 10 min. Subsequently, 200 μL of 50 mM ammonium 
bicarbonate was added to the concentrate followed by centrifugation and repeated once. 
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After being reduced by 10 mM DL-dithiothreitol at 56°C for 1 hour and alkylated by 20 
mM odoacetamide at room temperature in dark for 1hour, the device was centrifuged at 
12000 rpm at 4°C for 10 minutes and washed once with 50 mM ammonium bicarbonate. 
100 μL of 50 mM ammonium bicarbonate and free trypsin were added into the protein 
solution at a ratio of 1:50, and the obtained solution was incubated at 37°C overnight. 
Finally, the device was centrifuged at 12000 rpm at 4°C for 10 minutes. 100 μL of 50 mM 
ammonium bicarbonate was added into the device and centrifuged, and then repeated once. 
The extracted peptides were lyophilized to near dryness and resuspended in 2-20 μL of 
0.1% formic acid before LC-MS/MS analysis. These samples were analyzed and quantified 
on Obitrap Q Exactive HF mass spectrometer coupled with Ultimate 3000 nano UHPLC 
system. The detected peptides were analyzed and searched against human protein database 
using Maxquant. The parameters were set as follows: the protein modifications were 
carbamidomethylation (fixed) and oxidation (variable); the enzyme specificity was set to 
trypsin; the maximum missed cleavages were set to 2; the precursor ion mass tolerance was 
set to 10 ppm, and MS/MS tolerance was 0.6 Da.  
 
Pathways analysis 
Creative Proteomics identified 455 proteins, 263 and 188 were proteins that bind to Cx43 
after sulfatide and AA treatments, respectively. These proteins were classified in 13 
families (Tables 7 to 15, Figures 7.2 and 7.3) according to their function and to their 
location described in GeneCards human gene database. Only the up-regulated recycling-
transport (Table 7, in green), mitochondrial (Table 8, in green) and membrane (Table 9, in 
green) related proteins after sulfatide and AA stimulations were run for the Ingenuity 
Pathway Analysis (IPA) to build molecular networks of each experimental system (Figures 
7.4 and 7.5).  
 
Results 
Extracellular sulfatide changes the molecular interactions of Cx43. Although, sulfatide 
can regulate mRNA and protein expression, we used Hela cells stably transfected with 
Cx43-CFP treated with 10 ng/ml sulfatide for 24 hours to pull-down Cx43 using G PLUS 
Agarose beads (Figure 7.1). We repeated the same experiment with Hela cells stably 
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transfected with Cx43-CFP but treated with AA as control condition, where cell-to-cell 
communication is not upregulated and Cx43 trafficking does not change. Thus, we 
confirmed the presence of Cx43 into the beads by SDS-page for both treatments (Figure 
7.1). These beads were processed and analyzed by Nano LC-MS/MS for proteomics. 
Proteomics analysis revealed 455 proteins. Comparing the control sample obtained from 
the coimmunoprecipitation of Cx43 in Hela cells stably transfected with Cx43-CFP and 
the sulfatide sample obtained from the same cells treated with sulfatide for 24 hours, 263 
proteins that bind to Cx43 were highlighted, 95 were upregulated and 168 downregulated. 
Comparing the control sample with the AA sample, 188 proteins were identified, 139 were 
up-regulated and 49 down-regulated. We classified the highlighted proteins of each 
experimental system into 13 families (nuclear, nuclear membrane, mRNA, ribosomal, 
metabolic, secreted, Golgi apparatus, endoplasmic reticulum, mitochondrial, recycling-
transport, ubiquitin, and membrane related proteins, plus unknown proteins) according to 
their role and physiological compartments provided by GeneCards information and 
literature data. We show an illustration that integrates all of them in Figures 7.2 and 7.3. 
Nuclear, membrane nuclear and mRNA related proteins (in the frame of Figures 7.2 and 
7.3) were excluded for the following analysis because they do not bind to Cx43, their 
detection was an experimental artefact due to the mechanical disruption of the nuclear 
membrane during processing of the samples. Thus, we focused on plasma membrane, 
mitochondria (Rodriguez-Sinovas et al. 2018) and transport compartments (Thomas et al. 
2005), where Cx43 is predominantly located.   
Focusing our analysis in the transport proteins that directly or indirectly bind to 
Cx43, sulfatide upregulated proteins related to myosin such as Myosin Light Chain 1 
(MYOFTA, MYO1B, MYO1C) and proteins involved in vesicular fusion and trafficking 
like the Rabs membrane-bound proteins (RAB2A, RAB1A) and the N-Ethylmaleimide 
Sensitive Factor (NSF). Parallelly, tubulin (Tubulin Alpha 1c TUBA1C, Tubulin Beta Class 
I TUBB, Tubulin Beta 4B Class IVb TUBB4B, Tubulin Folding Cofactor A TFCA) and 
cytoskeletal organized proteins such as Leucine Rich Pentatricopeptide Repeat Containing 
(LRPPRC) and Dynein Cytoplasmic 1 Heavy Chain 1 (DYNC1H1) were downregulated 
(Table 7).  
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On another hand, AA induced upregulation of actin related proteins (ACTα/ACTβ, 
ARPC4) and membrane adaptors such as Flotillin 1 (FLOT1) and VAMP Associated 
Protein B and C (VAPBC), and downregulated Bone Marrow Stromal Cell Antigen 2 
(BST2), which blocks the release of nascent virions to the membranes of infected cells 
(Table 7).  
After that, we analyzed the mitochondrial proteins. Coimmunoprecipitation of 
Cx43 after sulfatide treatment highlighted upregulated proteins related to apoptosis (such 
as Apoptosis Inducing Factor Mitochondria Associated 1 (AIFM1)), to chaperon (such as 
Heat Shock Protein Family A Member 9 (HSPA9)), and to the mitochondrial 
transmembrane electron transport (such as Voltage Dependent Anion Channel 1/2 
(VDAC1/2)) (Table 8). At the same time,  ATP synthesis (ATP Synthase F1 Subunit Alpha 
ATP5A, ATP Synthase F1 Subunit Beta ATP5B, ATP Synthase Membrane Subunit G 
ATP5L, ATP Synthase Subunit O ATP5PO, Carbamoyl-Phosphate Synthase 1 CPS1) and 
fatty acid metabolism (Hydroxyacyl-CoA Dehydrogenase Trifunctional Multienzyme 
Complex Subunit Alpha HADHA and Hydroxyacyl-CoA Dehydrogenase Trifunctional 
Multienzyme Complex Subunit Beta HADHB) related proteins were downregulated in the 
mitochondria, suggesting that several sources of energy can be used by these cells (Table 
8). In contrast, when we analyzed the mitochondrial proteins binding to Cx43 after 
treatment with AA, the ATP synthase enzymes (ATP Synthase F1 Subunit Alpha ATP5A1, 
ATP Synthase F1 Subunit Gamma ATP5C1) were upregulated with associated TCA 
(GOT2) and glycolysis (Lactate Dehydrogenase B LDB) enzymes,  suggesting a crucial 
role of the mitochondrial metabolic pathways for AA (Table 8). 
Finally, we analyzed the plasma membrane proteins. In this case, we found a 
significative difference in proteins that interact with Cx43 following sulfatide and AA 
treatments. Specifically, sulfatide induced upregulation of proteins that regulate the cellular 
membrane organization and stability such as actin (ACTN1/4), annexin (ANXA1/5) and 
spectrin (SPTAN1, SPTBN) (Table 9). In addition, sulfatide upregulated Peptidylprolyl 
Isomerase A (PPIA), which is necessary for the formation of infectious HIV virions and 
Protein Phosphatase 1 Catalytic Subunit Alpha (PPP1CA) that is involved in HIV viral 
transcription, suggesting a mechanistic link between Cx43, sulfatide and HIV-infection. 
Furthermore, the observed upregulation of thioredoxin (TXN), which plays a key role in 
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the reversible S-nitrosylation of cysteine residues in target proteins, suggests that TXN may 
S-nitrosylate Cx43 to maintain open Cx43 hemichannels. Cytoskeleton related proteins 
(Cytoskeleton Associated Protein 4 CKAP4, Ezrin EZR) were observed to be 
downregulated in sulfatide condition (Table 9). 
AA downregulated Scavenger Receptor Class B Member 2 (SCARB2) and the adhesion 
molecule Metadherin (MTDH) discouraging cellular communication but upregulated 
several adaptors and actin related proteins that stabilize the plasma membrane (Table 9).  
Subsequently, only the up-regulated recycling-transport (Table 7, in green), 
mitochondrial (Table 8, in green), and membrane (Table 9, in green) related proteins after 
sulfatide and AA stimulation were run for the Ingenuity Pathway Analysis (IPA) to build 
molecular networks of each experimental system (Figures 7.4 and 7.5). Ingenuity pathway 
analysis for sulfatide provided 4 top canonical pathways including integrin-linked kinase 
signaling, actin cytoskeleton signaling, remodeling of epithelial adherens junctions and 
EIF2 signaling. They were represented as network overlapping in the Figure 7.4.  
The same analysis was repeated for proteomics data coming from the 
coimmunoprecipitation of Hela cells stably transfected with Cx43-CFP treated with AA 
and 5 top canonical pathways were identified including cell cycle G2/M DNA damage 
checkpoint regulator, Myc mediated apoptotic signaling, extracellular regulated kinase 5 
(ERK5) signaling, EIF2 signaling, and remodeling of epithelial adherent junctions (Figure 
7.5). Only the EIF2 signaling and remodeling of epithelial adherent junctions’ pathways 
were in common between the two experimental systems. 
 
Discussion  
Although, sulfatide can enhance Cx43 expression, we decided to pull-down Cx43 
in Hela cells stably transfected with Cx43-CFP treated with sulfatide and perform 
proteomics analysis to investigate proteins that directly or indirectly bind to Cx43 and 
related pathways. We also used AA as a control because it reduces Cx43 expression and 
mediates the rapid channel closure (Martinez A. D. and Saez 1999).  
Proteomics analysis provided a contained number of proteins that we divided in 13 
families. We focused our attention in the recycling-transport, mitochondria and plasma 
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membrane compartments to find specific correlations between sulfatide and cell-to-cell 
communication or sulfatide and mitochondrial metabolism.  
Analysis for the transport proteins induced by sulfatide and binding to Cx43 revealed an 
active vesicular transport that was also observed in the AA experimental condition but 
triggered by different proteins of the same pathways.  Analyzing the mitochondrial 
proteins, we discovered that sulfatide induces the upregulation of Cx43 binding proteins 
related to fatty acid, glucose, and glutamate/glutamine synthesis.  It is noteworthy that these 
results correlated to the metabolism of the HIV-infected astrocytes investigated in Chapter 
3. In addition, within the plasma membrane proteins that interact with Cx43 in the sulfatide 
treated cells PPIA and PPP1CA were identified. These proteins  play a crucial role in the 
formation of infectious HIV virions and in the viral transcription, supporting our 
association between viral reservoirs, bystander damage and lipid dysregulation 
investigated in Chapter 2 and 4. Sulfatide also upregulated TXN, which may induce S-
nitrosylation of Cx43 on cysteine 271 to maintain open and functional Cx43 hemichannels 
(Retamal et al. 2006, Straub et al. 2011). This result may explain the connection between 
sulfatide secretion, cellular communication and HIV infection. Thus, future experiments 
will be performed to confirm this hypothesis.  Moreover, the ingenuity pathway analysis 
for sulfatide highlighted pathways involved in cellular morphology, assembly, 
organization, and movement that further justify sulfatide contribution to cell-to-cell 
communication. Although, the same proteomics analysis is required to be repeated in 
human primary astrocytes treated with sulfatide or in HIV-infected astrocytes, this analysis 
still identifies proteins that are known in the literature to directly or indirectly bind to Cx43. 
These proteins include actinin (ACTN1, ACTN4) (Sorgen et al. 2018, Wall et al. 2007), 
debrin (DBN) (Ambrosi et al. 2016, Butkevich et al. 2004), or ezrin (EZR) (Pidoux et al. 
2014) and other new potential partners of Cx43. In summary, the work conducted 
demonstrates that sulfatide plays an important role in cell metabolism and communication 
and these findings will form the basis for further studies. 
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Figure 7.1. Summary of the immunoprecipitation protocol used to pull-down Cx43 
for proteomics analysis.  (A) Hela cells stably transfected with Cx43-CFP were plated 
and treated with 10 ng/ml sulfatide or with 100 µM AA for 24 hours. (B) Untreated and 
treated cells were scratched with RIPA buffer to obtain the total cell lysates. A small 
amount of total cell lysate was isolated to be analyzed by SDS-page. (C) The total lysates 
were complemented with IgG and Protein G PLUS-Agarose beads to prevent non-specific 
binding. (D) Antibody against Cx43 was added to pull-down Cx43 and the related binding 
proteins. (E) The beads binding Cx43 and related interacting proteins were collected and 
dissolved in PBS.  (F) Total lysate, supernatant and beads were analyzed by SDS-page for 
Cx43. The band at 43 kDa representing Cx43 was strongly detected in the beads sample 
(3). (G) Beads were analyzed for proteomics. 
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Cx43 associated proteins involved in Recycling-
Transport  
Down-Regulated Up-Regulated 
Sulfatide AA Sulfatide AA 
ACTA 1  AHNAK  B2M ACTα/ACTβ 
ACTB  BST2  CAPZA1 ANXA4  
ACTR2B                                              CKAP4 MYH10 ARPC4  
ACTR3 DYNC1H1  MYL12A CLTC  
ANXA2  FABP5  MYO1B FLOT1  
ANXA4 GDI2  MYO1C HSPB1  
ARPC2                                                 NPEPPS NSF  IghG1  
ATP6V1A RAF1  PPIA MAP4  
CAPZB             SCARB2  RAB1A MYH9  
CKAP4      TPM4  RAB2A RAB7A  
CLTC  TUBA1C  S100A11 RAF  
DYNC1H1 TUBB4B SERPINB1 S100A11  
FLNA             VAT1  TXN  SERPINB6  
FLOT1  YWHAG  YWHAB  STATHMIN  
GDI2 YWHAH  YWHAZ VAPB 
ITGB1     YWHAZ 
LRPPRC     YWHAE 
MYH9             YWHAQ 
PLIN3        
RAB6        
SERPINH1        
SLC3A2        
TBCA       
TPM4        
TFRC        
TUBA1C        
TUBB        
TUBB4B         
VAT1       
YWHAG        
YWHAQ       
YWHAZ       
 
Table 7. Summary of the recycling-transport related proteins that bind to Cx43 
detected after coimmunoprecipitation and subsequent proteomics. List of proteins 
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involved in the recycling and transport pathways after treatment with sulfatide and AA. 
Downregulated proteins are shown in red; upregulated proteins are shown in green. The 
common proteins between sulfatide and AA treatments are marked in bold type. 
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Cx43 associated proteins involved in 
Mitochondrial functions 
Down-Regulated Up-Regulated 
Sulfatide AA Sulfatide AA 
ATAD3B  ATAD3B  AIFM1  AIFM1  
ATP5PO  HADHB  HSPA9 ATP5A1 
ATP5A  TUFM  VDAC1 ATP5C1   
ATP5B    VDAC2 DDX5  
ATP5L      EIF4A1 
CPS1      FH  
HADHA      GOT2  
HADHB      HMGCL 
HMGCL      HSP90 
TUFM      LDHB  
      MDH2  
      PRDX3  
      SLC25A5  
      VDAC1  
 
Table 8. Summary of the mitochondrial related proteins that bind to Cx43 detected 
after coimmunoprecipitation and subsequent proteomics. List of proteins involved in 
the mitochondrial pathways after treatment with sulfatide and AA. Downregulated proteins 
are shown in red; upregulated proteins are shown in green. The common proteins between 
sulfatide and AA treatments are marked in bold type. 
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Cx43 associated proteins involved in 
Plasma Membrane functions 
Down-Regulated Up-Regulated 
Sulfatide AA Sulfatide AA 
BASP1  AHNAK  ACTN1  ACTA1  
CKAP4    MTDH  ACTN4  ACTB 
CTTN                                     NPEPPS  ANXA1  ANXA4  
EZR                           SCARB2  ANXA5 ATP1A1 
IQGAP1                         TLN1  CFL1  CALM1A  
GNB2L1              VAT-1  DBN 1 DBN1  
LMNB2   DSG1 DDX5  
LMO7   DSP EZR 
MSN   ESYT1  FLNB  
PHB2   FLNB HSPA1B  
SLC3A2   FSCN1 LMO7  
STOM   PLEC  MSN  
TLN1   PPIA  PLEC  
VCL   PPP1CA  PPM1G 
    SPTAN1  SLC3A2  
    SPTBN 1 SPTAN1 
    TXN  SPTBN1  
      VAPB  
      VCL  
 
Table 9. Summary of the membrane related proteins that bind to Cx43 detected after 
coimmunoprecipitation and subsequent proteomics. List of proteins involved in the 
membrane pathways after treatment with sulfatide and AA. Downregulated proteins are 
shown in red; upregulated proteins are shown in green. The common proteins between 
sulfatide and AA treatments are marked in bold type. 
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Cx43 associated proteins involved in 
Ribosomal functions 
Down-Regulated Up-Regulated 
Sulfatide AA Sulfatide AA 
EEF16  LARS  NACA FBL  
EEF2  RPS 15   KARS 
LARS RPS 18    MARS 
NCL  RPS 18A   NACA 
NPMI  RPS 34   NCL  
RPL 13 RPS 5     
RPL 15 RPS 7A     
RPL 18 A RPS11A     
RPL 26 RPS7     
RPL 3       
RPL 34       
RPL 5       
RPS 11       
RPS 13       
RPS 14       
RPS 18       
RPS 19       
RPS 2       
RPS 20       
RPS 23       
RPS 7       
RPS 8       
RPS A       
 
Table 10. Summary of the ribosomal related proteins that bind to Cx43 detected after 
coimmunoprecipitation and subsequent proteomics. List of proteins involved in the 
ribosomal pathways after treatment with sulfatide and AA. Downregulated proteins are 
shown in red; upregulated proteins are shown in green. The common proteins between 
sulfatide and AA treatments are marked in bold type. 
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Cx43 associated proteins induced in 
Endoplasmic Reticulum  
Down-Regulated Up-Regulated 
Sulfatide AA Sulfatide AA 
CALR  CCT3  HS7A9 CCT5  
CANX  FKBP4  HSPB1 CCT6A  
CCT3 HSP90 B1  PDIAG  DDOST  
CCT5 HSPA1B RPN1  GANAB  
CCT8 SERPINH1  STIP1  HSP90 
Ddast      PLIN3 
GANAB      PLOD3  
HSD90 
AB1     
POR  
HSP90 
AA1     
PRKCSH  
HSP90 B1     RPNI 
HSPAB     TCP1  
HSPD1       
HSPH1       
PRKCSH        
RPN2       
SRP14       
 
Table 11. Summary of the endoplasmic reticulum related proteins that bind to Cx43 
detected after coimmunoprecipitation and subsequent proteomics. List of proteins 
involved in the endoplasmic reticulum pathways after treatment with sulfatide and AA. 
Downregulated proteins are shown in red; upregulated proteins are shown in green. The 
common proteins between sulfatide and AA treatments are marked in bold type. 
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Cx43 associated proteins induced in 
Golgi Apparatus  
Down-Regulated Up-Regulated 
Sulfatide AA Sulfatide AA 
  CCT3    CCT5  
  FKBP4    CCT6A  
  
HSP90 
B1    
PLIN3 
  HSPA1B   TCP1  
 
Table 12. Summary of the Golgi apparatus related proteins that bind to Cx43 detected 
after coimmunoprecipitation and subsequent proteomics. List of proteins involved in 
the Golgi apparatus pathways after treatment with sulfatide and AA. Downregulated 
proteins are shown in red; upregulated proteins are shown in green. The common proteins 
between sulfatide and AA treatments are marked in bold type. 
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Cx43 associated proteins induced 
in Secretion System 
Down-Regulated Up-Regulated 
Sulfatide AA Sulfatide AA 
EXOSC4     GRN 
PGK1       
 
Table 13. Summary of the secreted proteins that bind to Cx43 detected after 
coimmunoprecipitation and subsequent proteomics. List of proteins involved in the 
pathways of secretion after treatment with sulfatide and AA. Downregulated proteins are 
shown in red; upregulated proteins are shown in green. The common proteins between 
sulfatide and AA treatments are marked in bold type. 
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Cx43 associated proteins induced in 
Metabolism 
Down-Regulated Up-Regulated 
Sulfatide AA Sulfatide AA 
ALPI    ACLY  AKR1B1  
APOA1    AHCY   APOA1  
CAD    BSG APRT  
ENO1    GAPDH CAD  
ESYT2    MAT2A  CBR1  
Fasn    PGAM2  ENO1  
GARTS    PGM1  FASN  
GOT2     PPP1CA  FH  
GPT    SLC25A13  GOT2  
IDH1      MAT2A  
IMPDH2      MDH2  
LDHA        
LDHB        
MTHFD1       
PAICS        
PGK1       
PHGDH        
PKM        
UGDH        
 
Table 14. Summary of the metabolic related proteins that bind to Cx43 detected after 
coimmunoprecipitation and subsequent proteomics. List of proteins involved in the 
metabolic pathways after treatment with sulfatide and AA. Downregulated proteins are 
shown in red; upregulated proteins are shown in green. The common proteins between 
sulfatide and AA treatments are marked in bold type. 
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Cx43 associated proteins involved in Ubiquitin-
related system 
Down-Regulated Up-Regulated 
Sulfatide AA Sulfatide AA 
UBE2N    UBE2N    PSMA1 PSMA4  
PSMBG   PSMA5 PSMB1  
    PSMA6 PSMB5  
    PSMD2 PSMD3  
    RPL11 RDL3 
    RPL13A RDL4 
    RPL14 RDLP2 
    RPL23 RPL13A 
    RPL31 RPL14 
    RPL4 RPL22 
    RPL7 RPL7 
    RPL8   RPL9 
    RPS10 RPNI  
    RPS12 RPS14 
    RPS16      RPS16 
    RPS25 RPS2 
    UBA-1 RPS23 
      RPS3 
      RPS8 
 
Table 15. Summary of the ubiquitin related proteins that bind to Cx43 detected after 
coimmunoprecipitation and subsequent proteomics. List of proteins involved in the 
ubiquitin related pathways after treatment with sulfatide and AA. Downregulated proteins 
are shown in red; upregulated proteins are shown in green. The common proteins between 
sulfatide and AA treatments are marked in bold type. 
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Figure 7.2. Schematic representation of all the Cx43 binding proteins detected after 
sulfatide treatment, coimmunoprecipitation and subsequent proteomics. Proteins 
binding to Cx43 were immunoprecipitated from Hela stably transfected Cx43-CFP cells 
treated with sulfatide for 24 hours. Proteins were classified in 13 families (nuclear, nuclear 
membrane, mRNA, ribosomal, metabolic, secreted, Golgi apparatus, endoplasmic 
reticulum, mitochondrial, recycling-transport, ubiquitin, and membrane related proteins, 
plus unknown proteins), according to their functional role and to their location described 
in GeneCards human gene database and literature data. Nuclear, membrane nuclear and 
mRNA related proteins (in the frame) were excluded because they do not physiologically 
bind to Cx43. Their detection was due to the mechanical disruption of the nuclear 
membrane during the procced of the samples. Downregulated proteins are indicated in red, 
upregulated in green.  
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Figure 7.3. Schematic representation of all the Cx43 binding proteins detected after 
AA treatment, coimmunoprecipitation and subsequent proteomics. Proteins binding 
to Cx43 were immunoprecipitated from Hela stably transfected Cx43-CFP cells treated 
with AA for 24 hours. Proteins were classified in 13 families (nuclear, nuclear membrane, 
mRNA, ribosomal, metabolic, secreted, Golgi apparatus, endoplasmic reticulum, 
mitochondrial, recycling-transport, ubiquitin, and membrane related proteins, plus 
unknown proteins), according to their functional role and to their location described in 
GeneCards human gene database and literature data. Nuclear, membrane nuclear and 
mRNA related proteins (in the frame) were excluded because they do not physiologically 
bind to Cx43. Their detection was due to the mechanical disruption of the nuclear 
membrane during the procced of the samples. Downregulated proteins are indicated in red, 
upregulated in green.  
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Figure 7.4. Network overlapping of the canonical pathways triggered by the up-
regulated recycling-transport, mitochondrial and membrane related proteins after 
sulfatide treatment. Proteins binding to Cx43 were immunoprecipitated from Hela stably 
transfected Cx43-CFP cells treated with sulfatide for 24 hours and analyzed by proteomics. 
The up-regulated proteins related to the recycling-transport, the mitochondrial and the 
membrane pathways were selected to build a specific molecular network using the 
Ingenuity Pathway Analysis software. The network overlapping showed the canonical 
pathways identified in our experimental system. Each pathway was indicated as a single 
“node” colored proportionally to the Fisher’s Exact Test p-value, where brighter red meant 
more significant. A line connected two pathways when at least one data set molecule was 
common between them.   
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Results suggest that the top canonical pathways include integrin-linked kinase (ILK) 
signaling, actin cytoskeleton signaling, remodeling of epithelial adherens junctions and 
EIF2 signaling. These pathways are involved in cellular morphology, assembly, 
organization, and movement.  
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Figure 7.5. Network overlapping of the canonical pathways triggered by the up-
regulated recycling-transport, the mitochondrial and the membrane related proteins 
after AA treatment. Proteins binding to Cx43 were immunoprecipitated from Hela stably 
transfected Cx43-CFP cells treated with AA for 24 hours and analyzed by proteomics. The 
up-regulated proteins related to the recycling-transport, the mitochondrial and the 
membrane pathways were selected to build a specific molecular network using the 
Ingenuity Pathway Analysis software. The network of overlapping showed the canonical 
pathways identified in our experimental system. Each pathway was indicated as a single 
“node” colored proportionally to the Fisher’s Exact Test p-value, where brighter red meant 
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more significant. A line connected two pathways when at least one data set molecule was 
common between them.   
Results suggest that the top canonical pathways are: EIF2 signaling, cell cycle G2/M DNA 
damage checkpoint regulator, Myc mediated apoptotic signaling, remodeling of epithelial 
adherent junctions, ERK5 signaling. These pathways are involved in protein synthesis, 
RNA damage and repair, cellular assembly and organization, protein trafficking, and cell 
death and survival.  
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Chapter 8: General discussion and future directions 
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HIV infection is a major public health concern, affecting around 40 million people 
in the world (https://www.who.int/news-room/fact-sheets/detail/hiv-aids). Current drugs to 
treat HIV-infected people are not a cure even they induce immune reconstitution (Perelson 
et al. 1997). Although, most HIV-infected patients under cART show a normal CD4 count, 
a low to undetectable viral load and an increased life-expectancy, they develop symptoms 
of accelerated aging including HIV-associated neurocognitive disorders (HAND) (Saylor 
et al. 2016). Neurological disorders affect more that the half of HIV-infected individuals 
and the mechanisms by which HIV induces HAND in the current cART era is unknown.  
HIV persists due to the presence of viral reservoirs in different anatomical compartments 
(Svicher et al. 2014). Moreover, upon cART interruption, the virus rebounds from all the 
anatomical compartments in which viral reservoirs are resident (De Scheerder et al. 2019).  
Currently, there is not a reliable method to detect viral reservoirs, as well as it is 
unknown in which cells HIV genome is integrated and the size of these cells. In addition, 
it is unclear the mechanism related to neuroHIV. Thus, this thesis tried to address these 
two major problems.  
As we describe in the general introduction, there are not reliable methods to detect 
viral reservoirs in the tissues. In this thesis, we outlined a microscopy strategy that can be 
used for the reliable identification, localization, and quantification of viral reservoirs in the 
tissues and blood of HIV-infected individuals. This methodology is based on a multi probe 
and antigen detection system using a DNA probe targeting the HIV-Nef sequence, an 
mRNA probe targeting HIV Nef mRNA, and detecting HIV proteins and cellular markers 
using the traditional antibody-based technology. For this analysis, we used human brain 
tissues provided by NNTC collected from uninfected and HIV-infected patients after 2 
hours of death to avoid molecular and tissue disruption. Infected patients were under cART 
for long time showing normal CD4 count and low to undetectable viral load (see Table 2, 
Chapter 2). Lymph nodes from the same patients were used as a control for the presence 
of the viral reservoirs. Through our strategy, we confirmed that the brain is an anatomical 
compartment for viral reservoirs (Balcom et al. 2019) and that a small population 
microglia/macrophages and a smaller population of astrocytes are the major reservoirs 
within the brain (Clayton et al. 2017, Li G. H. et al. 2016) in the current cART era. 
Nevertheless, not all microglia/macrophages and astrocytes were infected with HIV, 
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suggesting that an unknown mechanism of selection is used for specific niches within the 
brain that have a higher susceptibility to HIV infection. Moreover, literature data of the 
pre-cART era indicated that the percentage of macrophages and astrocytes with HIV-
integrated DNA is higher compared to our analysis (Castellano et al. 2017, Churchill et al. 
2009). Through our system, we identified that around 0.014% and 0.0035% cells in human 
brain tissue sections of HIV-infected individuals, showing HIV-integrated DNA, were 
macrophages/microglia and astrocytes, respectively. As expected, not all of these cells 
expressed HIV mRNA and few of them synthetized viral proteins. Despite effective cART, 
we demonstrated that HIV replication persists in particular areas of the brain. Interestingly, 
the low numbers of viral reservoirs into the brain cannot explain the damage detected in 
HIV-infected patients. But we demonstrated that viral reservoirs can synthetize HIV 
proteins that can diffuse or be secreted and be taken up by neighboring uninfected cells.  
This is the first scientific data demonstrating a local synthesis of viral proteins in the brain 
of HIV-infected individuals under cART. Several laboratories using animal models such 
as humanized mouse models and non-human primates (Hanna et al. 1998, Hansen et al. 
2009, Nesbit and Schwartz 2002, Yamada et al. 2015) have shown a consistent synthesis 
of HIV proteins that is not representative of what we observed in human brain tissues, 
where HIV proteins synthesis is not systemic but localized. Nevertheless, the basal 
synthesis of HIV proteins can validate the theory of HIV protein neurotoxicity that has 
discussed for many years and that implicates HIV proteins in the progression of neuroHIV 
(Kovalevich and Langford 2012, Mocchetti et al. 2012, Wallace 2006). Thus, we 
demonstrated that viral reservoirs contribute to the bystander damage by secretion of HIV 
proteins.  
To characterize viral reservoirs, we measured the metabolism of these cells based 
on our recent paper (Castellano et al. 2019). We identified that HIV-infected astrocytes do 
not behave as latently HIV-infected microglia/macrophages. This, it may be due to the low 
percentage (~5%) of HIV-infected astrocytes in cultures or because they really have a 
different metabolic profile. Nevertheless, we demonstrated that microglia/macrophages 
and astrocytes have a common link with glutamine/glutamate metabolism. Even though, 
HIV-infected microglia/macrophages use glutamine/glutamate as a major source of energy 
(Castellano et al. 2019), HIV-infected astrocytes released a large amount of 
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glutamine/glutamate in the media (Eugenin and Berman 2007). Future studies will 
elucidate whether HIV-infected astrocytes are the real glutamine/glutamate donors. 
Considering that our results for viral reservoirs identification and reservoirs 
metabolism indicate minimal changes, this do not correlate with the significant 
neurocognitive impairment that affect HIV-infected individuals.  Our recent data indicates 
that HIV-infected individuals under cART display circulating lipid altered metabolism 
(Velasquez et al. 2019). In addition, existing literature data revealed that HIV dysregulates 
lipids causing fat accumulation in the body (Bernasconi et al. 2002, Martinez E. et al. 2001) 
and dyslipidemia in the blood (Finkelstein et al. 2015, Souza et al. 2013). Importantly, 
HAND, as well as other neurodegenerative diseases, has been linked to lipid dysregulation 
(Bandaru et al. 2013), but a real examination of structural and signaling lipids in the brain 
of HIV-infected individuals under cART and developing neurocognitive impairment is 
missing. In this thesis, we analyzed lipid distribution in the brain of HIV-infected 
individuals by MALDI-MSI and we demonstrated the structural lipids of the grey and the 
white matters did not change in HIV condition, proving that the grey and white matter are 
not compromised in the cART era. Other neurodegenerative diseases showed significant 
changes in lipid distribution and an important structural damage (Hussain et al. 2019). For 
our analysis, we used the same tissue sections where we identified few viral reservoirs with 
HIV-integrated DNA, minimal expression of viral mRNA and viral proteins but with HIV 
proteins bystander release. We identified a significant dysregulation of sulfatide in large 
areas of the brain. Although, sulfatide is the major component of the myelin sheet (Schmitt 
et al. 2015), so it is relatively abundant in the white matter, its relative intensity was 
elevated in HIV condition. Our analysis needs to be expanded in order to show if sulfatide 
increase is due to an over production in the white matter or to a lysosomal storage disorder. 
Even though we do not know the mechanism of release of sulfatide, we showed that lipid 
dysregulation involves several subclasses of sulfatide and large areas of the brain, despite 
the virus is minimally replicated and the number of viral reservoirs is low. If HAND is 
compared with Alzheimer’s (AD) and Parkinson’s diseases (PD) several differences 
appear. First, sulfatide increases in the white matter of HIV-infected patients rather than in 
the grey matter as observed in PD’s patients (Cheng et al. 2003) or being reduced in both 
grey and white matter as observed in AD condition (Han et al. 2002). Second, in HAND 
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we did not detect significative alterations for structural membrane phospholipids, whereas 
in AD and PD conditions cholesterol and phospholipid alterations determine a significant 
CNS structural compromise (Hussain et al. 2019). These results may correlate with MRI 
data for HIV-infected brain showing reduction in brain volume but not structural disruption 
of the brain regions (Alakkas et al. 2019, Ances et al. 2012). This suggest that in the current 
cART era neuronal apoptosis is not the major mechanism triggered by HIV, but neuronal 
pruning (Ru and Tang 2017) can be a reasonable explanation for the reversible and flexible 
symptoms of the common milder forms of HAND. For all these reasons, we proposed 
sulfatide as a potential biomarker of HAND. For future directions, we intend to expand our 
research to a larger number of human brain tissues from cART suppressed HIV-infected 
individuals with different kind of cognitive impairment, we need to analyze different areas 
of the brain and isolate specific areas by Laser Capture Microdissection (LCM) to quantify 
the amount of sulfatide.  
Tissue reservoirs are not entirely silent, we identified a bystander release of HIV 
proteins that compromise a bigger area of the brain and we demonstrated that several viral 
proteins participate in sulfatide secretion in vitro. Evaluating sulfatide secretion in the 
media of human primary astrocytes and differentiated SH-SY5Y neuroblastoma cell co-
cultures, we showed that Gp120, Nef, Vif or Vpr increased its secretion. Even though the 
mechanism of release of sulfatide is unknown, a minimal amount of viral proteins can 
amply toxicity by sulfatide release. Then, we plan to reproduce the same experiment using 
connexin43 (Cx43) or pannexin-1 (Panx-1) blockers. This is because other bioactive lipids 
such as PGE2 can be released by these channels (Velasquez et al. 2019). Or we can consider 
potentially other sources of secretion such as exoxomes (Fruhbeis et al. 2012).  
One of the key finding of our laboratory is that HIV Tat, that is express in the brain 
of HIV-infected patients under cART, upregulates Cx43 expression in astrocytes (Berman 
et al. 2016). Hence, we have investigated extracellular sulfatide effects on human primary 
astrocytes, differentiated neurons, and Hela cells stably transfected with Cx43-CFP. We 
used astrocytes because they highly express Cx43, and our previous publication 
demonstrated that HIV-infected astrocytes induced bystander apoptosis of uninfected cells. 
Cx43 GJs are maintained between HIV-infected cells and uninfected cells in order to 
transfer toxic signals such as IP3 and calcium and extend survival of HIV-infected cells 
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(Eugenin and Berman 2007, 2013, Eugenin et al. 2011). Recently, unpublished data from 
our laboratory demonstrated that Nef can bind to IP3 receptors and amply the damage 
induced from the few HIV-infected astrocytes. On another hand, neurons were used to 
mimic the bystander effect mediated by the HIV-infected astrocytes for other residential 
cells in CNS (Eugenin et al. 2011, Ton and Xiong 2013). Hela cells were used as a stable 
system for Cx43 expression to study Cx43 trafficking. In these experiments, we 
demonstrated that sulfatide increased Cx43 mRNA and protein expression, especially in 
human primary astrocytes, and regulates the trafficking of Cx43 in Hela cells. This suggests 
that one of the potential mechanisms used by Tat to induce Cx43 expression is related to 
sulfatide release in HIV condition. 
Moreover, we investigated Cx43 binding proteins after sulfatide stimulation by 
coimmunoprecipitation and subsequent proteomics in Hela cells stably transfected with 
Cx43-CFP. Proteomics data revealed that sulfatide regulated three important families of 
proteins related to recycling-transport, mitochondria and cellular membrane, where Cx43 
is mostly localized. Between the recycling-transport proteins, we identify proteins binding 
to Cx43 involved in an active vesicular transport such as myosin and rab proteins. On 
another hand, mitochondrial proteins binding Cx43 and upregulated by sulfatide were 
related to glucose and glutamate/glutamine synthesis, that we analyzed in Chapter 3 and 
future experiments aim to demonstrate the direct interaction of Cx43 with these specific 
enzymes in the mitochondria. In addition, we found a particular proteomics profile for 
Cx43 in the plasma membrane that may result in stabilization of Cx43 by Tat and sulfatide. 
Although, we choose the Hela cells to perform this analysis because they represent a simple 
model, future studies intend to characterize Cx43 binding proteins in HIV-infected 
astrocytes. 
Overall, there are major contributions to the HIV field presented in this thesis. First, 
we have optimized a high throughput technique to identify, localize, and quantify viral 
reservoirs in blood and in the tissues. We characterized that localized populations of 
microglia/macrophages and astrocytes create clusters of infected cells. Second, we 
analyzed that viral reservoirs relay glutamine/glutamate to survive. Third, we identified 
that HIV-infected patients under cART do not have significative structural changes in grey 
and white matter, and we presented sulfatide as a potential lipid biomarker of HAND, that 
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is highly expressed in the white matter. Fourth, we showed that sulfatide secretion is 
regulated by low concentration of HIV proteins, suggesting that amplification of the 
damage is controlled by viral proteins through a lipid mediated mechanism. Fifth, we 
identified a potential mechanism used by Tat to increase Cx43 that is mediated by sulfatide, 
which increased the expression of Cx43 mRNA and protein. In conclusion, we enlightened 
new Cx43 partners showing a direct or indirect protein:protein interaction with Cx43 in the 
recycling-trafficking, membrane and mitochondria compartments.   
Although, CNS damage in HIV-positive individuals under cART is multifactorial 
we provided specific tools and unique data that describe a mechanism of neuronal 
bystander damage in HAND.  Therefore, we proposed sulfatide as a potential biomarker or 
as a molecular target for preventing or curing HAND in the HIV aviremic population. 
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